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Foreword 
 
This Ph.D. thesis is based on the results published or being published in international scientific 
journals. It is presented in four chapters corresponding to the papers in as much an unchanged 
form of the respective manuscripts as possible. Therefore, compounds and references are 
numbered independently in each chapter. An overview of the entire work is given in the 
following summary. 
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SUMMARY 
 
This work describes the use of the “direct amide cyclization” (DAC) of β-, γ-, and δ-hydroxy acid 
containing dipeptides, obtained by the reaction of the corresponding hydroxy acids with 3-amino-
2H-azirines, the so-called “azirine/oxazolone” method. The goal of this work was to synthesize 
cyclic depsipeptides with potential biological activities and to establish the limits of the DAC. 
In a short introduction the role of peptides and depsipeptides in nature is described, as well as a 
few of the most popular ways for their synthesis. Details about the azirine/oxazolone method and 
the direct amide cyclization, used throughout this work, are also given.  
In chapter one, several attempts to prepare a 7-membered cyclodepsipeptide via DAC are 
described, based on analogies with syntheses of 6- and 9-membered depsipeptides. Treating 
amide 1, prepared by the azirine/oxazolone method, under the DAC reaction conditions yielded, 
instead of the desired 7-membered ring, only its dimer 2 (Scheme 1). Variation of the 
concentration, temperature, reaction time and solvents led to an optimized yield of 73% for the 
dimeric product, whereas no monomeric product was found in any of the reaction mixtures. In 
order to clarify whether the twinning was a result of the chosen DAC reaction conditions, a 
number of classical lactonization procedures, among others the Corey-Nikolaou and  Mukayama 
methods, were applied, but none of them led to the 7-membered depsipeptides. If a cyclic product 
was formed at all, it was in all cases the dimer 2. Treatment of hydroxy acid 3 with DCC yielded 
oxazolone 4 in good yield, which upon subjection to DAC conditions formed 2 in excellent yield, 
suggesting, just as expected, that 4 is an intermediate in the DAC reaction. Thus five different 
methods for the synthesis of dimer 2 were elaborated, with yields varying from 26 to 86% 
(Scheme 1). The structures of amide 1, cyclodepsipeptide 2, hydroxy acid 3, and oxazolone 4 
were confirmed by X-ray crystallography. 
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Scheme 1 
 
In the second chapter of this work we tried to elucidate the reason for the twinning process, 
described in the first chapter. The substituents  in the hydroxy acid as well as  in the amino acid 
moieties were largely varied (1a-1h), and the attempted cyclization led in almost all cases to the 
14-membered depsipeptides of type 2 (Scheme 2).  
The twinning is most probably a result of the greater thermodynamic stability of the 14-
membered ring compared to the 7-membered one. Another factor, which might contribute to the 
twinning, as suggested in the literature, is H-bond formation, which would be much weaker in a 
7-membered ring. 
Molecular modeling using simple AM1 calculations shows that the formation of the dimeric 
depsipeptide is indeed favored over the formation of the monomer, but it does not explain why 
the 14-membered ring is the only product formed. A mixture between the monomeric and dimeric 
forms is to be expected. 
 
Synthesis of Cyclic Depsipeptides under Direct Amide Cyclization Conditions 
 13
O
N
H
R3 R4
N
O
R5R
1 R2
OH
O
NR
2
R1
OH O
R3
R4
 
R4
R4
R3
R1 R
2
R1 R2
O NH
NH O
O
O
O
O
R3
DAC
1a-h 4
 2a,b,d,f,g
 
 
 
 a b c d e f g h 
R1 Me Me H Me H Me Me Me 
R2 Me Me Me Me Ph Ph Me Me 
R3 Me Me Me Me Me Me H 
R4 Me Me Me 
CH2 CH2
CH2 CH2
 
Me Me Bn Bn 
R5 Me Ph Ph Me Ph Ph Ph Ph 
 
Scheme 2 
From the experiments carried out, it may be concluded that if neither of R1-R4 is a proton, i.e. 
both centers are disubstituted, the twinning occurs with good yields and no side products are 
formed. If the amino acid moiety is monosubstituted (i.e.  R3 = H or R4 = H), twinning also takes 
place, although not via DAC. Treating racemic 3h with I2 in MeCN gives the trans-dibenzyl 
dimer, trans-2h, while (S)-3h –yields the cis-diastereomeric 14-membered depsipeptide cis-2h in 
moderate yields (Scheme 3). The structure of both cyclodepsipeptides was established by X-ray 
crystallography. 
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Scheme 3 
 
If, on the other hand, the hydroxy acid moiety is monosubstituted (i.e. R1 = H or R2 = H), the 
formation of the intermediate oxazolone under DAC conditions could be monitored by IR 
spectroscopy, but then elimination of water occurs and no cyclic depsipeptides could be isolated.  
The third chapter is a direct follow-up of the first two, extending the use of the DAC on 
depsipeptides containing γ-hydroxy acids, which could potentially yield 8-membered cyclic 
depsipeptides or their cyclic dimers. The starting materials for the cyclization were again 
synthesized by using the azirine/oxazolone method and γ-hydroxy acids. But the DAC of amide 6 
did not lead to the desired products (e.g. 7), but instead to the 5-membered imino lactones 8 or the 
chlorinated acids 9, (Scheme 4).  
The formation of these unexpected products can be explained as follows. The initially formed 
oxazolone 10 possesses two electrophilic centers – the carbonyl and the imino C-atom, and the 
OH group can attack either one of them. Attack on the CO-group (path b) would lead to the 
desired 8-membered cyclodepsipeptide 7, whereas the  attack on the imino group (path a) leads to 
the isolated imino lactone 8. Apparently, the formation of a 5-memberd ring is preferred to the 
formation of the 8-membered one.  
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Scheme 4 
 
In polar solvents and/or in the presence of silica gel, the hydrochloride 8 of the imino lactone 
isomerizes to the chlorinated acids 9, presumably via SN2 attack of the chloride ion. Stabilization 
of imino lactones  8 was achieved by introducing additional substituents into the ring, which 
prevent ring opening to give 9, but still no cyclic depsipeptides could be isolated. The structures 
of both 8 and 9 were confirmed by X-ray crystallography. 
In the last chapter, the ‘direct amide cyclization’ conditions were applied to the linear precursor 
10, which contains a δ-hydroxy acid. The expected product in the case was either the 6-
membered imino lactone 12, analogous to 8, or a 9-membered cyclodepsipeptide. As a 9-
membered cyclodepsipeptide has already been synthesized via DAC from an α-hydroxy acid 
containing linear precursor, the formation of chloro acid 13 as the sole product was a surprise 
(Scheme 5).  
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The formation of 13 proceeds most probably via the intermediate 1,3-oxazololone derivative 11 
and the 6-membered imino lactone 12, which obviously is unstable under those conditions and, in 
analogy with 8, isomerizes spontaneously to the chloro acid 13. Thus, the dependence of the 
result of the DAC reaction on whether an α-, β-, γ-, or δ-hydroxy acid diamide is used has been 
confirmed. 
It may be concluded that the direct amide cyclization is an appropriate method for the synthesis 
of cyclic depsipeptides only if the terminal OH group is in  α- or β-position of the hydroxy acid. 
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ZUSAMMENFASSUNG 
 
Diese Arbeit beschreibt die Anwendung der "Direkten Amidzyklisierung" (DAC) von β-, γ- und 
δ-Hydroxysäure enthaltenden Dipeptiden zur Synthese von zyklischen Depsipeptiden. Die 
verwendeten Dipeptide wurden durch die Reaktion der entsprechenden Hydroxysäuren mit 3-
Amino-2H-azirinen, der so genannten "Azirin/Oxazolon Methode", hergestellt. Das Ziel dieser 
Arbeit war die Synthese zyklischer Depsipeptide mit potentieller biologischer Aktivität. Im 
weitern wurden auch die Grenzen der Reaktion untersucht. 
In einer kurzen Einleitung wird die Bedeutung der Peptide und der Depsipeptide in der Natur, 
sowie einige der populärsten Methoden für ihre Synthese beschrieben. Es folgt eine Übersicht 
über die in dieser Arbeit verwendete "Azirin/Oxazolon Methode", und  die "Direkte 
Amidzyklisierung". 
Im ersten Kapitel werden, in Anlehnung an vorherige Synthesen von 6- und 9-gliedrigen 
Depsipeptiden, einige Versuche beschrieben, die zu einem 7-gliedrigen Zyklodepsipeptiden 
führen sollten. Das durch die "Azirin/Oxazolon Methode" hergestellte Amid 1 lieferte jedoch bei 
der  Reaktion unter DAC Bedingungen  anstelle des gewünschten 7-gliedrigen Ringes 
ausschliesslich  den 14-gliedrigen Ring 2 (Schema 1). 
Änderungen der Konzentration, der Temperatur, der Reaktionszeit und des Lösungsmittels 
führten zu einer optimierten Ausbeute von 73% für das Zyklodimer. Dabei wurden keine 
Hinweise für die Bildung  eines monomeren zyklischen Produktes gefunden. Zur Klärung der 
Frage, ob diese Dimerisierung ein Resultat der gewählten Reaktionsbedingunen war, wurden eine 
Anzahl von klassischen Lactonisierungsverfahren, unter anderem die Corey-Nikolaou und 
Mukayama Methoden, angewendet. Keine dieser Methoden führte aber zu den gewünschten 7-
gliedrigen Depsipeptiden. Wenn überhaupt ein zyklisches Produkt gebildet wurde, war es immer 
das Dimer 2.  
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Schema 1 
 
Behandlung der Hydroxysäure 3 mit Dicyclohexylcarbodiimid (DCC) ergab das Oxazolon 4 in 
guten Ausbeuten, welches nach Reaktion unter den DAC Bedingungen das Dimer 2 in 
ausgezeichneter Ausbeute bildete. Dies deutet, wie erwartet, darauf hin, dass 4 ein Intermediat  in 
der DAC Reaktion ist. Insgesamt wurden fünf unterschiedliche Methoden zur Synthese des 
Zyklodimers 2 entwickelt, deren Ausbeuten von 26% bis 86%  reichen (Schema 1). Die 
Strukturen von Amid 1, Zyklodepsipeptid 2, Hydroxysäure 3 und Oxazolon 4 wurden mittels  
Röntgen Kristallographie bestätigt.  
Im zweiten Kapitel dieser Arbeit versuchen wir, die Hintergründe der im ersten Kapitel 
beschriebenen Zyklodimerisierung ("Twinning") aufzuklären. Die Substituenten in den 
Hydroxysäure- sowie in den Aminosäureeinheiten wurden variiert (1a-1h), und die 
Zyklisierungsversuche führten in fast allen Fällen zu Bildung der 14-gliedrigen Depsipeptide vom 
Typ 2 (Schema 2). 
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Das "Twinning" ist vermutlich eine Konsequenz der grösseren thermodynamischen Stabilität des 
14-gliedrigen Ringes im Vergleich mit dem 7-gliedrigen. Ein weiterer Faktor, der wie in der 
Literatur erwähnt, ursächlich mit der Dimerisierung in Zusammenhang stehen könnte, ist die 
Bildung unterschiedlich-stabiler H-Brücken in 7- und 14-gliedrigen Ringen. 
Mit einfachen AM1 Berechnungen konnte gezeigt werden, dass die Bildung des zyklischen 
Dimers in der Tat gegenüber der Bildung des zyklischen  Monomers bevorzugt wird, aber sie 
erklären nicht, warum der 14-gliedrige Ring das einzige Produkt der Reaktion ist. Eine Mischung 
zwischen dem Monomeren und dem Dimeren wäre zu erwarten. 
Aus den durchgeführten Experimenten kann man schliessen, dass, wenn sowohl die α-Stelle der 
Amino- als auch der Hydroxysäure disubstituiert ist, d.h., wenn keiner der Reste R1 bis R4 ein 
Proton ist, die Zyklodimerisierung  mit guten Ausbeuten verläuft und es keine Nebenprodukte 
gebildet werden. Wenn dagegen die Aminosäureeinheit monosubstituiert ist (d.h. entweder R3 = 
H oder R4 = H), findet die Zyklodimerisierung immer noch statt, jedoch nicht unter den DAC 
Bedingungen. Das Behandeln von  racemischem 3h mit I2 in MeCN gibt das trans-Dibenzyl 
Dimer, nämlich trans-2h, während (S)-3h  unter den gleichen Bedingungen das 14-gliedrige cis-
Zusammenfassung 
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2h in mässigen Ausbeuten ergibt (Schema 3). Die Strukturen beider Cyclodepsipeptide wurden 
durch Röntgen Kristallographie bestätigt. 
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Schema 3 
 
Wenn aber die Hydroxysäureeinheit monosubstituiert ist (d.h. entweder R1 = H oder R2 = H), 
kann zwar die Bildung des Zwischenproduktes 4 unter DAC Bedingungen mittels IR 
Spektroskopie verfolgt werden, leider findet dann in diesem Fall eine Wasserabspaltung statt und 
es kann kein zyklisches Depsipeptid isoliert werden.  
 
Das dritte Kapitel schliesst direkt an die ersten zwei an und untersucht die Anwendung der DAC-
Methode auf γ-Hydroxysäure-enthaltende Depsipeptide, welche zu 8-gliedrigen 
Zyklodepsipeptiden oder ihren zyklischen Dimeren führen könnten. Die Ausgangsmaterialien für 
die Zyklisierung wurden wieder unter Verwendung der "Azirin/Oxazolon Methode" aus  γ-
Hydroxysäuren synthetisiert. Die DAC von Amiden des Types 6 führte nicht zu den gewünschten 
Produkten (z.B. 7), sondern zu den 5-glidrigen Iminolaktonen 8 oder zu den chlorierten Säuren 9 
(Schema 4). 
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Schema 4 
 
Die Bildung dieser unerwarteten Produkte kann wie folgt erklärt werden: Das zuerst gebildete 
Oxazolon 10 besitzt zwei elektrophile Stellen, nämlich  das Carbonyl- und das Imino C-Atom. 
Folglich kann die OH-Gruppe eines dieser beiden Zentren angreifen. Der Angriff auf die CO-
Gruppe (Weg b, Schema 4) würde zum gewünschten 8-gliedrigen Zyklodepsipeptid 7 führen, 
während der Angriff auf die Imino-Gruppe (Weg a, Schema 4) zum Iminolacton 8 führt. In 
Übereinstimmung mit den bekannten Rinngschluss-Tendenzen  wird die Bildung eines 5-
gliedrigen Ringes gegenüber der jenigen des 8-gliedrigen bevorzugt. In polaren Lösungsmitteln 
und/oder in Anwesenheit von Kieselgel isomerisiert das Hydrochlorid  des Iminolaktons 8 zur 
chlorierten Säure 9, vermutlich über einen SN2 Angriff  des Chloridions. Eine Stabilisierung des 
Iminolaktons 8 und damit dessen Isolierung wurde erreicht, indem man zusätzliche Substituenten 
in den Ring einführte, welche die Ringöffnung verhindern. Es konnten aber keine zyklischen 
Depsipeptide isoliert werden. Die Strukturen von 8 und 9 wurden wiederum mittels Röntgen 
Kristallographie bestätigt. 
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Die Behandlung des linearen δ-Hydroxysäure-enthaltenden Dipeptids 10 mit der „Direkten 
Amidzyklizierung“ wurde im letzten Kapitel beschrieben. Das erwartete Produkt war in diesem 
Fall entweder das 6-gliedrige Iminolacton 12, das in Analogie zu 8 entstehen könnte, oder ein 9-
gliedriges Zyklodepsipeptid. Ein solches α-Hydroxysäure-enthaltende Zyklodepsipeptid wurde 
bereits mittels DAC hergestellt, deswegen war die Bildung der Chlorsäure 13 als einziges 
Produkt der Reaktion überraschend. 
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Die Bildung von 13 erfolgt sehr wahrscheinlich via Oxazolon 11 und Iminolakton 12, welches 
unter diesen Bediengungen nicht stabil ist und zu 13 isomerisiert. Hiermit haben wir bestätigt, 
dass die Produkte der DAC von der Stelle der OH Gruppe in den linearen Vorläufern direkt 
abhängig sind. Daraus kann man schliessen, dass α- und β-Hydroxysäure-enthaltende Vorläufer 
die einzigen sind, die sich für die Synthese zyklischer Depsipetide via DAC eignen. 
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General Introduction 
 
1. Peptides and Cyclic Peptides 
1.1. Peptides 
Peptides are naturally occurring oligo- and polymers of amino acids, connected by amide bonds 
(peptide bonds) between the carboxylic group of one building block and the amino group of the 
following block. This bond has an important property that has a marked effect on the rigidity of a 
polypeptide chain and consequently on the folding of the peptide as a whole. It has, namely, 
partial double bond character, which is caused by the resonance of the lone-pair electrons on the 
N-atom between the O- and N-atom. The consequence of this interaction is that the peptide bond 
is very rigid because of the higher rotation barrier along the N-CO axis. The net result is that the 
six atoms that are involved in the peptide bond all lie in a flat plane, i.e. the peptide bond freezes 
six atoms in a planar arrangement (Scheme 1). 
C NH
O
C
C N
O
C
..
Ψ Φ Ψ ΦH
+
α
α'
α
α'
 
Scheme 1 
 
This means that the only possible free rotation in the structure is around the bonds Cα’−NH 
(characterized by angle Φ ) and Cα−CO (characterized by angle Ψ). This rigidity is very 
important with respect to the biological activity of peptides, whose biological importance 
cannot be overstated, for they occur in all living tissues and are fundamental to life. Enzymes, 
which control metabolism, γ-globulin, from which antibodies are formed and oxygen-
transporting hemoglobin, are among the many peptides, on which our lives depend. Some 
hormones, e.g. insulin (controls sugar concentration in blood), oxytocin (responsible for 
contraction of the uterus in labour and ejection of milk from mammary glands during breast 
feeding) also belong to this group of biologically active substances. Further examples include 
opioid peptides such as endorphins and dynorphins (it is believed that they act as neutral 
General Introduction 
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transmitters at nerve junctions to block pain nerve transmissions), antibiotics like bleomycin 
and peplomycin or toxins, like α-bungarotoxin, the main component of the cobra venom.  
The formation of a peptide bond from a carboxylic group of one and the amine group of another 
amino acid requires, in the general case, activation of the former, as a reaction between the two 
does not occur at room temperature. The simplest method for the activation would be the use of 
acid chlorides, but their use has been limited, mainly because of “overactivation” leading to 
side products and epimerization. In 1955, Sheehan and Hess1 used for the first time 
dicyclohexylcarbodiimide (DCC) to couple two amino acid rests together. This was the 
beginning of the development of the so called coupling reagents. The idea is that the acid 
terminus is transferred into an activated intermediate, which is not isolated, thus making it not 
only more susceptible to a nucleophilic attack, but also presenting a good leaving group. Some 
of the most commonly used coupling reagents, leading to high yields and practically no side 
products are shown on Fig. 1. 
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Fig.1. Examples of coupling reagents 
 
 Every one of these has its advantages2, but the advantage of DEPBT is that, in contrast to some 
other coupling reagents, it can be used for the coupling of hydroxy acids with amino acids 
without the need of protecting the hydroxy group of the former3, something which is usually 
recommended when using other coupling reagents. In the following example, the OH-group of 
tyrosine methyl ester (Tyr-OMe, 2) may be left unprotected while coupling with isoleucine (Ile, 
1) and the dipeptide NH2-Ile-Tyr-OMe (3) is formed in excellent yield, as shown in Scheme 2. 
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1.2. Cyclic Peptides 
Cyclic peptides are formed upon formation of a peptide bond between the amino and the 
carboxylic termini of a linear peptide. If we take the above example, the reaction shown in 
Scheme 3 would lead to the cyclic dipeptide cyclo(Ile-Tyr) 5. 
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The conversion of linear peptides to cyclic peptides has been much facilitated nowadays, because 
the reagents for standard amide bond formation mentioned above could also be used as 
cyclization promoters.  
Recently reported examples involving head-to-tail cyclization (like the one between tyrosin and 
isoleucin) include a comparative study of the merits of various activation reagents for the 
synthesis of cyclosporin O4, the DPPA-mediated cyclisation of a precursor to eurystatin A5, 
various bradykinin analogues6, the marine natural product phakellistatin 57, and the didemnin-like 
depsipeptide (-)-tamandarin A8. 
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Such cyclic peptides and their derivatives continue to hold the attention of synthetic chemists and 
biologists alike. Apart from the occurrence in a variety of naturally occurring bioactive 
metabolites that possess strongly expressed and useful biological activity, cyclic peptides are 
often more stable in vivo than their linear counterparts and therefore often represent promising 
drug candidates. Another feature that contributes to the appeal of cyclic peptides is their reduced 
conformational mobility, which allows them to be used in the study and mimicry of protein 
folding and to present diverse functionalities in a well-defined and predictable manner.  
Even the smallest cyclopeptides -  the cyclodipeptides - possess biological activity.  Cyclic 
dipeptides, also known as 2,5-dioxopiperazines, 2,5-diketopiperazines, cyclo(dipeptides), or 
dipeptide anhydrides, are relatively simple compounds and therefore are among the most 
common peptide derivatives found in nature. Curtius and Gloebel synthesized the first cyclic 
dipeptide, cyclo(Gly-Gly), in 18889; however, their existence as a special group of compounds in 
nature was not recognized until early in the 20th century10. Between the late 1800s and early 
1900s, many simple diketopiperazines were synthesized for the sole purpose of examining their 
interesting physicochemical properties.  
Most cyclic dipeptides found to date appear to have emerged as by-products of fermentation and 
food processing and many are endogenous to members of animal and plant kingdoms and exhibit 
interesting physiological and/or pharmacological activities in mammals, but only one of these, 
cyclo(His-Pro), has been conclusively shown to be endogenous to mammals, and more 
specifically to the mammalian brain11. 
 
2. Depsipeptides and Cyclic Depsipeptides 
2.1. Depsipeptides  
Depsipeptides or depsides, i.e., heterodetic peptides which contain not only an amide bond but 
also other types of bonds (usually an ester, i.e. depside bond or a disulphide bridge) as part of 
their backbone, are another group of peptide derivatives with interesting biological properties. 
Although their occurrence and pharmacological value is incomparable with that of peptides, they 
still represent an interesting target for drug research and development.  To this class of 
compounds belong the obtusatic acid derivatives, isolated from lichens, that have antiastmatic 
properties,12 as well as salicylihalamides, possessing a wide range of properties, which could be 
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useful to the pharmaceutical industry.13 These include anti-cancer (e.g. apicularen A14), anabolic 
and antibacterial properties (e.g. zearalenone15). 
2.2. Cyclic Depsipeptides 
The cyclic analogues of depsipeptides have been found in many natural products and show a wide 
spectrum of biological activity.16 They are therefore sought after as promising lead compounds 
for drug design and discovery. Nature is a rich source of the most fascinating cyclodepsipeptides, 
and although the significance of incorporating a depside bond is not clear, it appears to be 
essential for biological activity, since all-amide analogues are often inactive.17 The depside bond 
is recognized as being more difficult to be incorporated into the backbone than the amide bond, 
so it is usually pre-formed in the linear precursor prior to cyclization at an amide bond to form the 
cyclic depsipeptides. 
2.2.1. Biologically active Cyclic Depsipeptides 
The best known structures in this category belong to the ion-selective antibiotics, valinomycin18, 
the closely related enniatin family19 and the actinomycins20. The common feature among them is 
that they all bind metal ions (as a rule of the alkali or alkaline earth group) in solution or on 
membrane surfaces. The resultant lipophilic complexes can freely penetrate the lipid layers of 
biomembranes, effecting thereby passive cation transport (along the electrical field gradient or the 
cation concentration gradient) across the membrane.  
Probably the most important of the antibiotic-ionophores is valinomycin (Fig. 2). At rather low 
concentrations (<10-8M) it selectively induces the potassium permeability of a wide variety of 
biological membranes21. The ionophoric properties of valinomycin are apparently responsible for 
its bacteriostatic action. Valinomycin is known to form more or less stable equimolar complexes 
with K+, Rb+, and Cs+ in neutral solvents, the stability of such complexes decreasing with 
increase in solvent polarity. The K+ complex is 104-103 times more stable than the corresponding 
Na+ complex, the K/Na complexing selectivity of valinomycin being the highest among the 
known alkali metal complexones. 
Valinomycin with its 36-membered ring possesses a wealth of possible conformations and 
elucidation of its three-dimensional structure has required considerable effort. It was the first 
peptide molecule of biological importance whose spatial structure was established without 
recourse to X-ray analysis.  3D structure elucidation was also helpful in shedding light on the 
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structure-function relation of valinomycin, which in turn has led to the synthesis of certain of its 
membrane-affecting analogs with unique properties.  
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Fig. 2. Structures of Valinomycin, Enniatin B and Actinomycin D 
 
Enniatins (Fig. 2) form complexes in organic solvents not only with alkali metals, but also with 
alkaline earth metals and some d-metals, (e.g. Ag+, Mn2+, Zn2+, Cd2+)22. Beside the typical 1:1 
complexes for valinomycin, they also form 2:1 (possibly 2:3) complexes, with a notable K over 
Na selectivity. Such 2:1 macrocycle/cation complexes are believed to form “sandwiches”, in 
which the most probable ligands are the amide carbonyl groups. In 3:2 complexes not only the 
amide carbonyls, but also the ester carbonyls interact with the complexing cation. It is believed 
that although enniatin complexes are less stable than those of valinomycin, this formation of non-
equimolar complexes protects the cation better from the medium and anion, and makes a major 
contribution to the cation permeability of artificial membranes23. 
Actinomycins, the third best studies class of cyclic depsipeptides are a group of rather toxic 
chromopeptides manifesting both antimicrobial and antitumor properties. All of them contain the 
same phenoxazone chromophore group (3-amino-4,5-dicarboxy-1,8-dimethyl-2-phenoxazone) 
and various cyclopeptidic moieties, some of which may have very similar structures. 
Actinomycins with two identical cyclopeptide groups are referred to as the  iso-series, and those 
with differing groups—as the aniso-series. Actinomycin C (Fig. 2) (frequently referred to as 
actinomycin D) is the most readily available member of this group. It belongs to the iso-series 
and has two pentapeptide chains, containing threonine-valine-proline-N-Me-glycine-N-Me-
valine.  The mode of action of actinomycins involves formation of highly stable complexes with 
DNA, which precludes the latter from performing its biological function.24,25 
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Another interesting example represent antamanide, cyclo(Val-Pro-Pro-Ala-Phe-Phe-Pro-Pro-Phe-
Phe) and several of its synthetic analogs, which also belong to the group of ionophoric antibiotics 
and as such are capable of complexing alkali and alkaline earth metal ions, the most stable 
complexes being with Na+ and Ca2+. The sodium complexing ability of the decapeptide 
determines its potential value as a tool for selectively inducing Na+ permeability in 
biomembranes. However, in comparison with valinomycin and the enniatins it displays lower 
lipophilic properties and penetrates with difficulty phospholipid monolayers. This may account 
for the very poor ionophoric activity of antamanide. A comparison of the complexing and 
antitoxic properties of antamanide and its analogs has led to the conclusion that the ability to 
complex Na+ (or Ca2+) ions is a necessary, but insufficient condition for the manifestation of 
biological activity in this series of compounds26. 
Unlike all of the examples mentioned so far, phallotoxins possess a heptapeptidic ring, bridged by 
the side chains of the tryptophan and cysteine residues (i.e. they contain sulphide bridges). Their 
close relatives, amatoxins have a larger ring (eight amino acid residues) with two additional 
oxygen functions in the bridge. Both of these toxin groups are found in the poisonous Amantia 
mushrooms and they primarily affect the liver cells. Phalloidin, the best known representative of 
the phallotoxins, localizes in this organ immediately after administration and displays prolonged 
resistance to enzymatic degradation, leading to problems with its neutralization in the body. 
Despite the quite similar structures, phallotoxins and amatoxins have different modes of action, a 
good illustration of the caution required in inferences by analogy. Phalloidin impairs the 
membranes of the liver cells, apparently binding to the (as yet hypothetic) actin-like protein 
constituent, and thereby causing their aggregation into (experimentally found) filamentous 
structures, so that potassium ions and enzymes are released from the cell27. The amatoxins, whose 
best studied representatives are the amanitins, have a much more specific action, becoming 
strongly bound to one of the DNA-dependent RNA-polymerases in the eukaryotes and thus 
suppressing its activity. For this reason the amanitins are being widely used as a powerful tool in 
biochemical research28. 
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2.2.2. Synthesis of Cyclic Depsipeptides 
Cyclic depsipeptides are particularly well represented in the form of marine natural products. 
Because of their marine origins, many cyclic depsipeptides bear unusual amino acid side chains 
which add to their interest and synthetic complexity. Methods for the synthesis of cyclic 
depsipeptides vary, but for the present purpose of describing the synthesis of cyclic peptides, they 
can be classified into either one of two categories: those where the critical cyclization step 
involves formation of an ester bond (macrolactonisation) and those where ring closure involves 
formation of an amide bond (macrolactamisation). Until recently, the preferred cyclization step 
was the latter, mainly because of the multiple coupling reagents, available for peptide bond 
formation and widely used in normal peptide synthesis. However, there have been cases (e.g. 
Jaspamide, possessing cytotoxic, antifungal and insecticidal  properties), where ester bond 
formation gave better results29 (Scheme 4). 
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Scheme 4 
In recent reports, where macrolactamisation is the key step en route to the cyclic depsipeptide, the 
ionophoric fungal metabolite valinomycin30 and the marine natural product (-)-tamandarin A9 
have been prepared. In these examples, cyclization was performed in solution using HATU as the 
activation reagent. As examples of macrolactonisation ring closures, the work of Ranganathan31 
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provides an interesting example of both appropriate methodology and the use of organic 
frameworks as conformational constraints. In these cases, linear precursors are generally reacted 
with appropriate dicarbonyl dichlorides to produce cyclic depsipeptides in reasonable yields. In 
these extensive studies,32,33 cyclic depsipeptides containing a variety of metal-coordination sites 
have now been prepared. Also of interest is the production of a peptide catenane (albeit in 5% 
yield) using this methodology34. 
The reduction in conformational freedom brought about by cyclization often results in higher 
receptor binding affinity. Frequently in these cyclic compounds, extra conformational restrictions 
are also built in, such as D-amino acids, N-alkylated-amino acids or α,α-disubstituted amino 
acids. One of the methods for the insertion of such residues in cyclic depsipeptides is the direct 
amide cyclization. 
 
3. Direct Amide Cyclization  
A useful method for the ring closure of depsipeptides which contain α,α-disubstituted α-amino 
acids is the so-called ‘direct amide cyclization’ method (DAC), developed in our laboratory (Ref. 
35 and references cited therein). The basic concept is that an amide of type 6 in a toluene solution 
or suspension is treated with dry HCl gas. Cyclization by elimination of the corresponding 
ammonium chloride leads to the intermediate 1,3-oxazol-5(4H)-one of type 7. In the absence of 
other nucleophiles, the oxazolone undergoes a ring enlargement via intramolecular nucleophilic 
attack of the hydroxy group at the carbonyl C-atom of the neighboring lactone group, leading to 
the depsipeptide 8 (Scheme 5). 
This method has been used efficiently for the synthesis of morpholine-2,5-diones (i.e. 6-
membered cyclic depsipeptides) as well as for some 9-, 12-, 15-36, 16-37 and 19-38 membered 
rings. For the preparation of the 6-, 9-, 12- and 15- membered rings of type 8, the linear 
precursors 6 have been prepared by coupling α-hydroxy acids with 2H-azirin-3-amines, whereas 
β-hydroxy acids and 2H-azirin-3-amines led to the precursors of the 16- and 19-membered 
cyclodepsipeptides . 
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4. Azirine/Oxazolone Method 
A very useful method for incorporating α,α-disubstituted α-amino acid residues into peptides is 
the so called azirine/oxazolone method. The problem with the incorporation of these residues by 
normal coupling methods is their steric hindrance around the NH2 group, caused by the α,α-
disubstitution. Although coupling with normal coupling reagents has been proved successful, the 
yields are usually low and the work up is tedious. All these troubles could be avoided by the use 
of the azirine/oxazolone method, in which 3-amino-2H-azirines are used as synthons for the 
corresponding amino acids. When an acidic compound with a pKa below 8 is mixed with such an 
azirine (9), the first step is the protonation of the latter. In the case of carboxylic acids (10), the 
carboxylate anion attacks in the following step the amidinium C-atom, thus activating the 
carboxylic group, which can be attacked by the aziridine N-atom. Opening of the three membered 
ring yields the zwitterionic oxazolidine intermediate 11. Reconstitution of the carbonyl group 
leads to the opening of the oxazolidine, yielding the desired dipeptide (6). In contrast to other 
methods, no side products or coupling reagents have to be separated from the target molecule 
(Scheme 6). 
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Scheme 6 
This method has been used for the incorporation  of isobutyric acid, isovaline, methylvaline, 
methylleucine and methylphenylalanine into peptide chains (cf. Refs. 39 and 40 and refrences 
cited therein) using the following 3-amino-2H-azirines (Fig. 3): 
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Fig. 3. 3-Amino-2H-azirines as synthons for α,α-disubstituted α-amino acids 
 
The synthesis of the corresponding  3-amino-2H-azirines could be achieved in a few steps, 
starting from the corresponding amides (Scheme 7). The first of the two major synthetic methods 
was developed in the 1970s by Rens and Ghosez41. It starts with N,N-disubstituted amides (12), 
with at least one α-H atom, which are treated with phosgene to yield the corresponding 
chloriminium chlorides 13, which upon treatment with base loose HCl and are converted into the 
chloroenamines 14. These are treated with NaN3, leading to α-azidoenamines 15 (formed via the 
keteniminium salt), which eliminate nitrogen and give the desired 3-amino-2H-azirines (9) in 
good yields. If the amides are not reactive enough, the thioamides could be used instead, because 
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of higher nucleophility of the thioamide group. Another method is to treat the amide enolate 16 
subsequently with diphenyl phosphorochloridate (DPPCl) to form the α-chloroenamine 14 and 
NaN3, yielding the α-azidoenamines (15) and finally the azirine42. This method has proven to be 
efficient only with N-phenyl amides. 
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Scheme 7 
 
5. Aim of this work 
Earlier experience showed that when α-hydroxy acids are reacted with azirines, and the formed 
α,α-disubstituted α-hydroxy acid amides 17 are subjected to the DAC conditions, the products 
formed are 6-membered depsipeptides 1836,43. Prolongation of the peptide chain with one more 
aminoisobutyric acid (Aib) unit leads to tripeptides 19, the cyclization of which gives the 9-
membered depsipeptide 20 (Scheme 8).  
Therefore, we were interested in reacting β- and γ-hydroxy acids with azirines and cyclizing the 
obtained α,α-disubstituted β-hydroxy and α,α-disubstituted γ-hydroxy acid amides. Such a 
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cyclization should hopefully yield 7-membered depsipeptides (in the case of the β-hydroxy acid 
amide) and 8-membered depsipeptides (in the case of the β-hydroxy acid amide) with potential 
biological activity. 
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Chapter 1 
 
An Unexpected Formation of a 14-Membered Cyclodepsipeptide1) 
 
 
 
 
The treatment of diluted solutions of the hydroxydiamides 6a and 6b in toluene with HCl gas at 
100o gave the dimeric, 14-membered cyclodepsipeptide 10 in up to 72% yield (Scheme 3). The 
same product was formed from the linear dimer of 6b, the depsipeptide 11, under the same 
conditions (Scheme 4). All attempts to prepare the cyclic 7-membered monomer 9, starting with 
different precursors and using different lactonization methods failed, and 10 was the only product 
which was formed (Scheme 6). For example, the reaction of the ester 20 with NaH in toluene at 
80o led exclusively to the cyclodimer 10. On the other hand, the base catalyzed cyclization of the 
hydroxydiester 22, which is the ‘O-analogue’ of 20, yielded neither the 7-membered dilactone, 
nor the 14-membered tetralactone, but only the known trimer  23 and tetramer 24 of 2,2-
dimethylpropiolactone (Scheme 7). 
 
                                                  
1) B. Iliev, A. Linden, H. Heimgartner, Helv. Chim. Acta 2003, 86, 3215. 
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1. Introduction  
 
The continuous and current interest in cyclic depsipeptides is a result of their well known  
biological activity. A large number of them have been isolated from natural sources, mainly from 
marine or surface cultures of the corresponding microorganisms (cf. [1-8]). Typical examples are 
the antibiotics valinomycin [9-11] and the enniatins [12], which act as ionophores [13]. The most 
demanding step in the synthesis of such compounds is the cyclization. As they contain amide 
groups and at least one ester group in the core, the cyclic depsipeptides could be prepared by the 
formation of either the amide or ester bonds as the ring closure step.  
 
The cyclization via amide-bond formation (lactamization; e.g. [14-16]) is usually carried out by 
following protocols for the synthesis of cyclopeptides using coupling reagents. On the other hand, 
successful cyclizations via ester-bond formation (lactonization; e.g. [17-19]) have also been 
described. In the last few years, the number of reports on the use of macrolactonizations in the 
preparation of cyclodepsipeptides has increased remarkably [6-8][20][21]. A useful method for 
the ring closure of depsipeptides which contain α,α−disubstituted α−amino acids is the so-called 
‘direct amide cyclization’ method, developed in our laboratory [22-28]. The basic concept is that 
an amide of type 1 in a toluene solution or suspension is treated with dry HCl gas. Cyclization by 
elimination of the corresponding  ammonium chloride leads to the intermediate 1,3-oxazol-
5(4H)-one of type 2. In the absence of other nucleophiles, the oxazolone undergoes a ring 
enlargement via intramolecular nucleophilic attack of the hydroxyl group at the carbonyl C-atom 
of the neighboring lactone group, leading to the depsipeptide 3 (Scheme 1). 
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As was reported earlier, this method has been used efficiently for the synthesis of morpholine-
2,5-diones (i.e. 6-membered cyclic depsipeptides) [23][29] as well as for some 9-, 12-, 15-[23], 
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16-[27] and 19-membered rings [30]. For the preparation of the 6-, 9-, 12- and 15- membered 
rings of type 3, the linear precursors 1 have been prepared by coupling α−hydroxy acids with 2H-
azirin-3-amines, whereas β−hydroxy acids and 2H-azirin-3-amines led to the precursors of the 
16- and 19-membered cyclodepsipeptides. The azirines themselves have been a target of our 
studies for some years [31-36], mainly because they proved to be useful synthons for α,α-
disubstituted α-amino acids in peptide synthesis [31][33][34][37-40]. 
Because the reaction of  α−hydroxy acids with 2H-azirin-3-amines followed by the ‘direct amide 
cyclization’ proved to be a convenient access to morpholine-2,5-diones, we intended to 
generalize this reaction sequence. Therefore, we carried out the reaction under similar conditions 
with some β−hydroxy acids in order to obtain 7-membered cyclic depsipeptides. In the present 
paper, we report the results of the reaction of  2H-azirin-3-amines with 3-hydroxy-2,2-
dimethylpropanoic acid (4). 
 
2. Results and Discussion 
 
2.1. Direct Amid Cyclization. As a model β−hydroxy acid we chose 3-hydroxy-2,2-
dimethylpropanoic acid (4), mainly due to its commercial availability and its previous use in this 
type of reactions [26][27]. The linear dipeptides 6 were prepared by the standard procedure [26] 
of coupling 4 with the corresponding 2H-azirin-3-amine (5a or 5b; cf. [31] and refs. cit. therein), 
to yield 6a and 6b, respectively, in excellent yields and without side products (Scheme 2). 
 
HO OH
O
N
N
R
Me
HO N
H
O
O
N
Me
R
THF
+
r.t., 18-24 h
4 5a R = Me
  b R = Ph
6a R = Me    73%
  b R = Ph    97%
 
Scheme 2 
 
Although the general protocol proposed MeCN as a solvent [26], THF turned out to be a better 
solvent in this particular case. In addition to the spectroscopic characterization of 6a and 6b (cf. 
[27] ), their structures were established by X-ray crystallography (Fig. 1). 
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a) 
 
 
b) 
 
Fig. 1. ORTEP-Plots [41] of the molecular structures of a) 6a  and b) one of the two symmetry-
independent molecules of  6b (arbitrary  numbering of the atoms; 50% probability ellipsoids). 
 
The conformations of the backbones of 6a and 6b are very similar, with the exception of the 
orientation of the OH group. In 6a, the NH group forms an intermolecular H-bond with its 
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adjacent amide O-atom from a neighboring molecule (N(4)…O(6”) 2.885(1) Å; N(4)-H…O(6”) 
161(1)o). This interaction links the molecules into extended chains which run parallel to the y-axis 
and have a graph set motif [42] of C(5). The OH group forms an intermolecular H-bond with its 
adjacent amide O-atom from a different neighboring molecule (O(1)…O(3’) 2.770(2) Å; O(1)-
H…O(3’) 169(2)o) and thereby also links the molecules into infinite chains which run parallel to 
the y-axis and have a graph set motif of C(6). The combination of the intermolecular interactions 
links the molecules into a two-dimensional network which runs parallel to the xy-plane. 
 
In the case of 6b, there are two symmetry-independent molecules in the asymmetric unit and they 
have almost identical conformations. The NH group in each molecule forms an intramolecular H-
bond with the OH group (e.g. N(4)…O(7) 2.728(2) Å; N(4)-H…O(7) 142(1)o in molecule A) to 
yield a six-membered loop with a graph set motif of S(6). The OH group of molecule A forms an 
intermolecular H-bond with the primary amide O-atom of molecule B (O(7)···O(25’) 2.684(1) Å; 
O(7)-H···O(25’) 173(2)o), while the OH group of molecule B has a similar interaction with a 
different molecule A (O(27)···O(5”) 2.692(1) Å; O(27)-H···O(5”) 174(2)o). These interactions 
link the molecules into infinite chains in which both symmetry-independent molecules are 
incorporated in an alternating ···A···B···A···B··· sequence. These chains run parallel to the y-axis 
and have a binary graph set motif of C 22(12). 
 
The dipeptide 6b, was subjected to the reaction conditions of the ‘direct amide cycliszation’, i.e. 
dry HCl gas was bubbled through a toluene suspension of 6b at 100o.  It was expected that 6b 
would react in an analogous manner to the amide 7, which gave 3,3,6,6-tetramethylmorpholine-
2,5-dione  (8) in up to 60% yield [43] (Scheme 3). Surprisingly, only the dimer of the expected 7-
membered ring 9, namely the 14-membered 3,3,6,6,10,10,13,13-octamethyl-1,8-dioxa-4,11-
diazacyclotetradecane-2,5,9,12-tetraone (10), was formed in 72% yield (Scheme 3). 
 
The 1H-NMR spectrum of 10 showed no signal for OH groups and confirmed the presence of NH 
groups. Two singlets for Me groups and a singlet for CH2 were also clearly distinguished. The 
13C-NMR spectra showed the presence of two C=O groups (174.3 and 178.2 ppm in (D6)DMSO), 
which was further confirmed by the IR spectrum (KBr; 1723 and 1673 cm-1). 
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Scheme 3 
 
Furthermore, the 13C-NMR spectrum indicated two different types of Me2C groups, in addition to 
a OCH2 group. With this set of data, the distinction between the monomeric lactone 9 and the 
dimer 10 was not possible. But the mass spectra (CI and ESI mode) indicated a molecular weight 
of 370, which corresponds to the 14-membered depsipeptide 10. Finally its structure was 
confirmed by X-ray crystallography (Fig. 2). 
 
The molecule sits across a crystallographic center of inversion. The symmetry-unique NH group 
forms a very weak intermolecular H-bond with the amide O-atom from the same amide group of 
an adjacent molecule (N(4)···O(5’) 3.483(2) Å; N(4)-H···O(5’) 170o). This interaction links the 
molecules into extended chains which run parallel to the z-axis and have a graph set motif of 
C(4). The other amide group in the molecule participates in an identical intermolecular 
interaction of necessity because of the centrosymmetric nature of the molecule. The chains 
thereby formed also run parallel to the z-axis but in the opposite direction. The molecules 
themselves bridge adjacent chains, so that the combination of both interactions links the 
molecules into two-dimensional networks which lie parallel to the (100) plane. The cross-linking 
of the chains also builds H-bonded loops involving four molecules and yields the graph set motif 
of R44(26). 
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Fig. 2. ORTEP-Plot [41] of the molecular structure of 10 (arbitrary  numbering of the atoms; 
50% probability ellipsoids). 
 
With the aim of obtaining the 7-membered, monomeric cyclodepsipeptide 9 (Scheme 3), we 
repeated the reaction with varying concentrations of the starting material 6b and different reaction 
times. However, under all conditions 10 was formed as the only product, although in variable 
yield. Thus, the maximum yield of 72% was obtained at a concentration of 20 mM, whereas with 
a concentration of 2 mM the yield dropped to 35%, and at a concentration of 40 mM the yield 
was only 61%. 
 
The rate determining step of the ‘direct amide cyclization’ is believed to be the formation of the 
oxazolone ring (see Scheme 1), a process favored by the precipitation of the corresponding 
ammonium salt. Thus the formation of the lactone is a function of the salt’s solubility in toluene2). 
As a result, N,N-dimethylamides of type 6a should react more easily than N-methyl-N-
                                                  
2) It has been shown previously, that the formation of a 16-membered cyclic depsipeptide, which 
in toluene (heterogeneous conditions) was obtained in 60% yield, does not occur in homogeneous 
solution in DMF [26]. 
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phenylamides like 6b under the conditions of the ‘direct amide cyclization’, because the initially 
formed Me2NH.HCl is less soluble in toluene than Ph(Me)NH.HCl. 
Therefore, we also used 6a as a starting material. The cyclization with HCl gas in toluene at 100o 
gave again the product 10. The lower yield (32%) is mainly caused by purification difficulties 
(see experimental part). 
 
In order to prepare 10 by a specific synthesis, we synthesized the open chain precursor, the linear 
depsipeptide 11, according to standard procedures, starting from the commercially available 
methyl ester 12. After protection of the OH group by benzylation to give 13 and deprotection of 
the carboxyl group, the intermediate 14 was coupled with 5b to yield the diamide 15. The product 
of its acid-catalyzed hydrolysis 16 was coupled with 6b to give 17, which after deprotection gave 
11 in a total yield of 24% (Scheme4).  
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Scheme 4 
 
Crystallization from a mixture of CH2Cl2, i-PrOH, and hexane gave crystals, which were suitable 
for an X-ray crystal-structure determination (Fig. 3). 
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Fig. 3. ORTEP-Plot [41] of the molecular structure of 11 (arbitrary  numbering of the atoms; 
50% probability ellipsoids). 
 
Although the molecule is achiral, the crystal structure is chiral. The absolute structure has not 
been determined and was defined arbitrarily. The amide NH group closest to the OH group forms 
an intramolecular H-bond hydroxy O-atom (N(4)…O(1) 2.709(3) Å; N(4)-H…O(1) 135(3)o). This 
gives rise to a six-membered loop with a graph set motif of S(6), analogous to compound 6b (Fig. 
1). The other amide group forms an intermolecular H-bond with the adjacent amide O-atom from 
a neighboring molecule (N(11)…O(13’’) 2.932(3) Å; N(11)-H…O(13’’) 155(3)o). This interaction 
links the molecules into infinite chains which run parallel to the y-axis and have a graph set motif 
of C(5). The OH group forms an intermolecular H-bond with its adjacent amide O-atom from a 
different neighboring molecule (O(1)…O(3’) 2.655(3) Å; O(1)-H…O(3’) 158(4)o) and thereby also 
links the molecules into infinite chains which run parallel to the y-axis and have a graph set motif 
of C(6). The combination of intermolecular interactions links the molecules into a two-
dimensional network which runs parallel to the yz-plane. 
 
Compound 11 was subjected to cyclization under the standard conditions of the ‘direct amide 
cyclization’. Once more, the 14-membered cyclodepsipeptide 10 was the only product that could 
be  isolated, with the moderate yield of 42%. 
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2.2. Other lactonisation methods. - After all attempts to obtain the 7-membered ring 9 by the 
‘direct amide cyclization’ failed, even after a ten-fold dilution of the reaction mixture, we were 
faced with a number of classical lactonisation options, starting mainly with the corresponding 
hydroxy acid 18, which was obtained easily from either of the amides 6 by hydrolysis in an acidic 
medium. The crystal-structure of 18  is shown in Fig. 4. 
 
The NH group forms an intermolecular H-bond with the O-atom of the hydroxy group of a 
neighboring molecule (N(4)…O(7’’’) 3.086(2) Å; N(4)-H…O(7’’’) 165(2)o). This interaction links 
the molecules into extended chains which run parallel to the y-axis and have a graph set motif of 
C(6). The OH group forms an intermolecular H-bond with C=O of the COOH group from a 
different neighboring molecule (O(7)…O(2’’) 2.746(2) Å; O(7)-H…O(2’’) 170(2)o). This 
interaction also links the molecules into infinite chains which run parallel to the y-axis and have a 
graph set motif of C(9). The OH group of COOH forms an intermolecular H-bond with the amide 
O-atom of a third neighboring molecule (O(1)…O(5’) 2.606(2) Å; O(1)-H…O(5’) 172(2)o). Again, 
this interaction links the molecules into infinite chains which run parallel to the y-axis and have a 
graph set motif of C(7). The combination of all H-bonding interactions links the molecules into 
two-dimensional network which lies parallel to the xy-plane. 
 
The variety of lactonization methods is enormous, and we could try only a few of them. As 
starting point, we used the review by Nicolaou [44] where the classical methods of Yamaguchi 
[45], Corey-Nicolaou [46], and Mukaiyama [47] are mentioned. Unfortunately, none of the above 
reactions yielded the desired product, and the only products obtained were the activated acid 
derivates, namely the Yamaguchi mixed anhydride and the Corey active ester, respectively. Some 
modern variations of these methods [48] were also tried, but they failed to give the desired 
product too. 
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a) 
 
b) 
 
 
Fig. 4. ORTEP-Plots [41] of the molecular structures of a) 18 and b) one of the two symmetry-
independent molecules of 19 (arbitrary  numbering of the atoms; 50% probability ellipsoids). 
 
The most common cyclization methods, using DCC or its water-soluble derivatives and 
analogues, gave as the only product 2-(2-hydroxy-1,1-dimethylethyl)-4,4-dimethyloxazol-5(4H)-
one (19) in 36% yield (Scheme 5). This is the postulated intermediate of the prospected ‘direct 
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amide cyclization’ 6 9. Even after addition of 4-(dimethylamino)pyridine (DMAP) to a mixture 
of 18 and DCC, a procedure known to be suitable for the synthesis of  medium sized lactones 
[49], the reaction path did not change and 19 was isolated as the only product, although in 
moderate yield.  
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Scheme 5 
 
In general, 1,3-oxazol-5(4H)-ones are reactive species; in the case of 19, the gem-dimethyl group 
seems to stabilize it, so that it could be isolated in crystalline form. In the IR spectrum (KBr), 19 
showed a characteristic strong C=O absorption at 1836 cm-1 and in the 13C-NMR spectrum, the 
singlets for C=O and C=N appeared at 182.8 and 166.6 ppm, respectively. The structure of 19 
was established by X-ray crystallography (Fig. 4). 
The asymmetric unit contains two symmetry-independent molecules, whose conformations differ 
only in the orientation of the OH group. The OH group of molecule A forms an intermolecular H-
bond with the N-atom of molecule B (O(7)…N(21’) 2.891(2) Å; O(7)-H…N(21’) 159(3)o). In turn, 
molecule B has an identical interaction with another molecule A. These interactions link the 
molecules into extended  ···A···B···A···B··· chains which run parallel to the y-axis and have a 
graph set motif [42] of C22(12). 
 
As 19 is expected to be the intermediate in the ‘direct amide cyclization’ 6 9, we attempted to 
transform 19 to the depsipeptide in polar, aprotic solvents (AcOEt, MeCN), but all attempts 
failed. After two days of heating 19 under reflux, only the starting material was isolated. Another 
way of converting 19  to  the depsipeptide  9 was the ‘direct amide cyclization’. This reaction 
yielded again only product 10 in excellent yield (86%, Scheme 6). 
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Scheme 6 
 
The next step we took on the way to the synthesis of the 7-membered 9 was to try out some 
reactions involving salts of metals, such as Sb [50], Sn [51], Ag [52], Sc [53] and Ru [54], known 
to catalyze the formation of small and medium sized lactones. Most of these attempts failed in the 
case of 18, and only few led to a definite product, namely once more the dimeric 
cyclodepsipeptide  10 (Scheme 6). Surprisingly, the reaction with I2 in boiling MeCN, which was 
initially used to cyclize terpene-like hydroxy acids [55], gave again the 14-membered ring 10 in 
moderate yield (Scheme 6). Recently, Richard et al. have reported the synthesis of 7-membered 
lactones, containing an amino group in their basic structure, by treatment of the corresponding 
hydroxy esters with NaH in a toluene suspension [56]. Therefore, we treated the ester 20 under 
the same conditions. To our disappointment, this reaction yielded again the dimeric compound 10 
as the sole product. 
 
The discrepancy between the reactions of 6-hydroxy-4-azahexanoic esters [56] and 6 is very 
surprising. One of the possible reasons for the failure of this method in the case of 6 could lie in 
the presence of the amide bond and its rigidity. With the aim of proving this hypothesis, the ester 
analogue of the amide 6, i.e. the diester 22, was synthesized in the same way as compound 11 
(Scheme 7). 
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Scheme 7 
 
Subjecting compound 22 to the reaction conditions described in [56] led to a mixture of products, 
among which the tri- and tetralactones 23 and 24 were isolated as the main products. None of the 
expected 7-membered dilactone could be detected. As an additional product, 2-hydroxyisobutyric 
acid was also obtained. The structures of 23 and 24, i.e. the cyclic tri- and tetramers of 3-
hydroxy-2,2-dimethylpropanoic acid (4) were confirmed by X-ray crystal-structure analyses (Fig. 
5). It turned out that these compounds are already known and the crystal structure of 24 has been 
published previously [57]. They have been prepared by oligomerisation of 3-hydroxy-2,2-
dimethylpropionolactone 25. Therefore, we propose that in the reaction of 22 with NaH, 25 is 
formed by the intramolecular nucleophilic attack of the OH group at the central ester group and 
cleavage of this ester. Then, 25 undergoes the oligomerisation. Apparently, the alternative 
nucleophilic attack at the terminal ester group of 22, which would lead to the 7-membered 
dilactone, cannot compete with the formation of the β-lactone. 
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a) b)  
 
Fig. 5. ORTEP-Plots [41] of the molecular structures of  a) one of the two symmetry-independent 
molecules of 23 and b) 24 (arbitrary  numbering of the atoms; 50% probability ellipsoids). 
 
 
3. Conclusions 
 
In conclusion, our attempts to prepare the 7-membered cyclic depsipeptide 3,3,6,6-tetramethyl-1-
oxa-4-azacycloheptane-2,5-dione (9) using the ‘direct amide cyclization’ starting with 3-hydroxy-
2,2-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-propanamide (6b) failed. The 
only product obtained was the dimeric  14-membered cyclodepsipeptide 10, which was formed in 
a very good yield. Furthermore, the attempts to prepare the monomeric lactone 9 using various 
classical lactonisation procedures failed too, and in almost all cases 10 was obtained as the main 
product in yields of 28-72%. Five different methods for the synthesis of 10 were developed. 
Despite all the variations in reaction conditions and the knowledge of the crystal structures of the 
starting materials and some of the intermediates, there is no convincing explanation for this 
unexpected result and additional experiments are required. 
 
We thank the analytical units of our institute for spectra and analysis, and the  Swiss National 
Science Fondation and F. Hoffmann-La Roche AG, Basel, for financial support. 
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Experimental Part 
 
1. General. Thin-layer chromatography (TLC): Merck TLC aluminium sheets, silica gel 60 F254. 
Prep. TLC: Merck PLC plates (glass), silica gel 60 F254, 2 mm and 40-63 µm. Flash 
chromatography (CC): Uetikon-Chemie ‘Chromatographiegel’ C-560. M.p.: Büchi 540 apparatus, 
uncorrected. IR Spectra: Perkin-Elmer Spectrum one spectrometer; in KBr,  unless otherwise 
stated, absorption bands in cm-1. 1H-NMR (300 MHz) and 13C-NMR (75.5 MHz) spectra: Bruker 
ARX-300 instrument; in CDCl3  at 300 K; TMS as internal standard, unless otherwise stated; δ in 
ppm, coupling constants J in Hz. HSQC and HMBC spectra: Bruker DRX-600 instrument; 1H-
NMR (600 MHz) and 13C-NMR (150 MHz). Mass spectrometry (MS): Finnigan MAT-90 for 
electron impact ionization (EI), Finnigan SSQ-700 for chemical ionization (CI, with NH3) and 
electrospray ionization (ESI, in MeOH + Na), unless otherwise stated. 
 
2. Starting materials. 2,2,N,N-Tetramethyl-N-phenyl-2H-azirin-3-amine (5a) and 2,2,N-
trimethyl-N-phenyl-2H-azirin-3-amine (5b) were prepared according to standard procedures (cf. 
[31] and refs. cited therein). All other products used were commercially available. 
 
3. Coupling with 2H-Azirin-3-amines. 
N-[1-(Dimethylcarbamoyl)-1-methylethyl]-3-hydroxy-2,2-dimethylpropanamide (6a). To a soln. 
of 3-hydroxy-2,2-dimethylpropanoic acid (4; 806 mg, 6.84 mmol) in dry THF (5ml), 5a (1.231 g, 
7.52 mmol) was added dropwise. The mixture was stirred at r.t. for 36 h, the solvent was 
evaporated, and the remaining solid was purified by CC (SiO2, MeOH/CH2Cl2 1:10) and dried in 
h.v. Yield: 1.200 g (76%) of 6a. Pale yellow  crystals. M.p. 126.2-127.4o. 1H-NMR: 1.10, 1.33 
(2s, 2 Me2C); 3.22 (s, Me2N); 3.46 (s, CH2O); 3.90 (br. s,  OH); 6.79 (br. s,  NH). 13C-NMR: 
22.1, 26.3 (2q, 2 Me2C); 41.6 (s, Me2C); 42.4 (q, Me2N); 58.7 (s, Me2C);  70.4 (t, CH2O);  174.1, 
177.2 (2s, 2 CO). CI-MS: 231 (68, [M + 1]+), 186 (100). 
3-Hydroxy-2,2-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]propanamide (6b). 
To a soln. of 4 (806 mg, 6.84 mmol) in dry THF (5ml), 5b (1.309 g, 7.52 mmol) was added 
dropwise. The mixture was stirred at r.t. for 24 h, the solvent was evaporated and the remaining 
solid was purified by CC (SiO2, MeOH/CH2Cl2 1:20) and dried in h.v. Yield: 1.86 g (93%) of 6b. 
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White solid. M.p.102.8-103.3o ([27]: 103.4-104o). 1H-NMR: 1.11, 1.38 (2s, 2 Me2C); 3.28 (s, 
MeN); 3.44 (s, CH2O); 3.90 (br. s,  OH); 6.77 (br. s, NH); 7.25-7.45 (m, 5 arom. H). 13C-NMR: 
22.2, 26.3 (2q, 2 Me2C); 41.6 (s, Me2C); 43.6 (q, MeN); 58.7 (s, Me2C); 70.4 (t, CH2O); 128.2 (d, 
1 arom. CH); 128.4, 129.5 (2d, 4 arom. CH); 144.4 (s, 1 arom. C); 174.1, 177.2 (2s, 2 CO). 
 
4. Cyclizations to 3,3,6,6,10,10,13,13-Octamethyl-1,8-dioxa-4,11-diazacyclotetradecane-
2,5,9,12-tetraone (10). 
4.1. Direct Amide Cyclisations. Procedure A. A suspension of 6b (584 mg, 2 mmol) in  dry 
toluene (100 ml) was heated to 100o, and HCl gas was bubbled through the suspension for 7 min. 
Then, the mixture was let to cool to r.t. while bubbling N2 through it (ca. 20 min). The solvent 
was evaporated, the white residue was washed with 3 × 15 ml of CH2Cl2 and dried in h.v. Yield: 
267 mg (72%) of 10. White powder. M.p. 299.2-300.4o. IR: 3393vs (NH), 2990s, 2977s, 2935m, 
1723vs (C=O), 1673vs (C=O), 1523vs, 1171vs (C-O). 1H-NMR ((D7)DMF): 1.12, 1.40 (2s, 2 
Me2C each ); 4.00 (s, 2 CH2O); 7.64 (s, 2 NH). 13C-NMR ((D7)DMF): 22.1, 24.6 (2q, 2 Me2C 
each); 41.6, 55.4 (2s, 2 Me2C);  71.3 (t, CH2O);  174.3 (s, C=O). 13C-NMR ((D6)DMSO): 20.9, 
23.2 (2q, 2 Me2C each); 40.4, 54.4 (2s, 2 Me2C);  70.1 (t, CH2O);  173.0, 174.3 (s, C=O). CI-MS: 
388 (34, [M + NH4]+), 371 (100, [M + 1]+). ESI-MS: 393 (100, [M + Na]+). Anal. calc. for 
C18H30N2O6 (370.45): C 58.36, H 8.16, N 7.56; found C 57.94, H 8.18, N 7.47. 
Procedure B. A suspension of 6a (230 mg, 1 mmol) in  dry toluene (50 ml) was heated to 100o, 
and HCl gas was bubbled through the suspension for 3 min. Then, the mixture was let to cool to 
r.t. while bubbling N2 through it (ca.20 min). The solvent was evaporated, the white residue was 
washed with 3 × 10 ml of CH2Cl2 and the remaining solid was recrystallized from MeCN to yield  
60 mg (32%) of 10. 
Procedure C. A suspension of 11 (see section 5, 477 mg, 1 mmol) in  dry toluene (50 ml) was 
heated to 100o, and HCl gas was bubbled through the suspension for 3 min. Workup as described 
in Procedure A gave 92 mg (49%) of 10. 
4.2 Other lactonisation methods. 2-[(3-Hydroxy-2,2-dimethyl-propanoyl)amino]-2-methyl-
propanoic acid (18). To a soln. of  6b (2.00 g, 7.35 mmol) in  THF (10 ml), 3N HCl (10 ml) was 
added dropwise at  0o  under constant stirring. After 8 h at r.t., THF was removed i.v. and the H2O 
phase was extracted with  AcOEt (5 × 20 ml). The combined org. fractions were dried (MgSO4) 
and the solvent evaporated. The remaining brownish  crystals were washed twice with 
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Et2O/PrOH 100:1. Yield: 1.312g (92%) of 18. White crystals. M.p.142.3-143.4o ([27]: 142.8-
144.0o). 1H-NMR ((D6)DMSO): 1.00, 1.35 (2s, 2 Me2C); 3.36 (s, CH2O); 5.00 (br. s, OH); 7.52 
(br. s, NH); 12.12 (br. s, COOH). 
Procedure D. A soln. of 18 (205 mg, 1 mmol) and I2  (15 mg, 0.06 mmol)  in dry MeCN (15 ml) 
was heated to reflux for 3 d. After evaporation of the solvent, the residue was washed with  5% 
Na2S2O3 soln. and extracted with AcOEt, and the combined org. fractions were dried (MgSO4). 
Purification by CC yielded 89 mg (49%) of 10 as a white powder. 
Procedure E. A soln. of 18 (103 mg, 0.5 mmol) and Bu2SnO (25 mg, 0.1 mmol)  in dry xylene 
(25 ml) was heated under reflux for 2 d in a  Dean-Stark apparatus (N2 -atmosphere). Then, the 
solvent was evaporated i.v., the solid residue was washed with Et2O (2 × 10 ml) and than with 
warm acetone (5 × 10 ml). The acetone fraction was concentrated to 5 ml, cooled  and filtered to 
yield 36 mg (38%) of 10. 
Ethyl 2-[(3-Hydroxy-2,2-dimethylpropanoyl)amino]-2-methylpropanoate (20). A soln. of 6b (584 
mg, 2 mmol) in a 10% EtOH soln. in toluene (110 ml) was heated to 100o, and HCl gas was 
bubbled through the suspension for 7 min. Then, the mixture was let to cool to r.t. while bubbling 
N2 through it (ca. 20 min). The solvent was evaporated, purification by CC (CH2Cl2/acetone 
100:1) yielded  397 mg (86%) of 20 as colorless oil. 1H-NMR: 1.14 (s, Me2C ); 1.28 (t, 
MeCH2O); 1.43 (s, Me2C ); 3.53 (d, CH2OH); 4.05 (q, MeCH2O); 6.79 (s, NH). 13C-NMR: 15.6 
(q, Me); 22.1, 26.3 (2q, 2 Me2C); 41.6 (s, Me2C);  61.4 (t, CH2O); 69.1 (t, CH2O); 76.8 (s, Me2C); 
174.3, 178.6 (2s, 2 CO). ESI-MS: 254 (100, [M + Na]+). 
Procedure F. To a soln. of 20 (232 mg, 1 mmol)  in dry toluene (5 ml), NaH (40 mg of a 60% 
suspension in mineral oil, 1 mmol) was added slowly at 0o and under constant stirring (N2 -
atmosphere). After 4.5 h at 80o, the mixture was acidified with 0.1 N HCl (~6 ml) to pH 5 and 
extracted with CH2Cl2 and AcOEt. The combined org. fractions were dried (MgSO4) and 
evaporated i.v. The crystalline residue was washed with 
 
CH2Cl2 to yield 52 mg (28%) of 10. 
 
5. Synthesis of 2-Methyl-2-{[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]carbamoyl}-propyl 
2-[(3-Hydroxy-2,2-dimethyl-propanoyl)amino]-2-methylpropanoate (11). 
Methyl 3-Benzyloxy-2,2-dimethylpropanoate (13). To a suspension of  NaH (440 mg of a 60% 
suspension in mineral oil, 11 mmol) in dry THF (15 ml)  methyl 3-hydroxy-2,2-
dimethylpropanoate (1.322 g, 10 mmol) was added dropwise at 0o  and under constant stirring. 
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The reaction was stirred at r.t. for 1 h, then benzyl bromide (1.710 g, 10 mmol) was added. After 
heating under reflux for 3 h, the mixture was cooled, washed with brine (2 × 25ml ), the brine 
fractions were extracted with AcOEt and the combined org. fractions were dried (MgSO4). 
Purification by CC (SiO2 , hexane/Et2O 10:1) yielded 1.05 g (47%) of 13. Colorless oil. IR (film):  
2976m, 2863m, 1736vs (C=O), 1475s, 1454s, 1363m, 1308s, 1226s, 1192s, 1152s (C-O), 1100s 
(C-O), 1029m, 738m, 698m. 1H-NMR: 1.37 (s, Me2C); 3.62 (s, CH2O); 3.84 (s, MeO); 4.68 (s, 
PhCH2); 7.40-7.52 (m, 5 arom. H). 13C-NMR: 22.4 (q, Me2C); 43.6 (t, CH2); 51.7 (s, Me2C); 73.1 
(q, MeO); 76.9 (t, PhCH2); 127.3, 127.6, 128.2 (3d, 5 arom. CH); 138.4 (s, 1 arom. C); 176.8 (s, 
C=O). EI-MS: 222 (28, M+·), 116 (26), 107 (20), 101 (20), 91 (100), 65 (8).  
3-Benzyloxy-2,2-dimethylpropanoic acid (14). To a soln. of of 13 (1.00 g, 4.5 mmol) in EtOH (20 
ml), 8 ml of 2N KOH were added  at 0o . After 1 h stirring at r.t., the org. solvent was evaporated 
i.v., the remaining soln. was  acidified with 1N HCl to pH 1 and extracted with Et2O. The org. 
fractions were dried (MgSO4) and evaporated i.v. The residue was recrystallized from hexane. 
Yield: 830 mg (88%) of 14. White crystals. M.p. 62.1-63.8o. IR:  2975m, 2861m, 1707vs (C=O), 
1454s, 1364m, 1163w, 1100s (C-O), 738m, 698m. 1H-NMR ((D6)DMSO): 1.07 (s, Me2C); 3.42 
(s, CH2O); 4.49 (s, PhCH2); 7.25-7.42 (m, 5 arom. H); 12.21 (s, COOH). 13C-NMR ((D6)DMSO): 
22.2 (q, Me2C); 40.6 (s, Me2C); 72.3 (t, CH2O); 76.7 (PhCH2); 127.2, 127.3, 128.1 (3d, 5 arom. 
CH);  138.4 (s, 1 arom. C); 177.3 (s, COOH).  EI-MS: 208 (7, M+·), 107 (49), 91 (100), 79 (9), 65 
(9). 
3-Benzyloxy-2,2-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]propanamide (15). 
To a soln. of 14 (800 mg, 3.85 mmol)  in  THF (10 ml), a soln. of  5b (670 mg, 3.85 mmol) in 
THF (2 ml) was added dropwise. After 24 h, the solvent was removed i.v. and the residue was 
purified by CC (CH2Cl2/MeOH 40:1). Yield: 1.230 g (84%) of 15. White solid. M.p.105.6-
106.8o. IR: 3339vs (NH), 2992m, 2956m, 2838m, 1644vs (C=O), 1593m, 1253s, 1103s (C-O), 
976w, 753m, 713m, 618w. 1H-NMR: 0.98, 1.31 (2s, 2 Me2C); 3.08 (s, CH2O); 3.14 (s, MeN); 
4.31 (s, PhCH2); 6.96 (s, NH), 7.12-7.27 (m, 10 arom. H). 13C-NMR: 22.8, 26.4 (2q, 2 Me2C); 
41.2 (q, MeN); 42.5, 57.4 (2s, 2 Me2C); 73.3 (t, CH2O); 76.4 (t, PhCH2); 127.4, 127.5, 127.7, 
127.9, 128.3, 129.1 (6d, 10 arom. CH); 137.6, 145.1 (2s,  2 arom. C); 173.2, 175.2 (2s, 2 C=O). 
ESI-MS:  405 (100, [M + Na]+). 
2-[(3-Benzyloxy-2,2-dimethylpropanoyl)amino]-2-methylpropanoic acid  (16). To a soln. of 15 
(1.200 g 3.14 mmol) in THF (5 ml), 3N HCl (5 ml) was added dropwise at 0o. The mixture was 
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left overnight at r.t., the org. solvent was evaporated i.v., and the residue was extracted with 
AcOEt. The combined org. fractions were washed with brine and dried (MgSO4). After 
evaporation, the crystals were washed with Et2O/hexane 2:1. Yield: 818 mg (89%). White 
crystals. M.p.109.4-110.2o. IR:  3355vs (OH), 2989-2863s (br.), 1717vs (C=O), 1620vs (C=O), 
1533vs, 1468s, 1397s, 1257s, 1162s, 1162s, 1092vs, 1012m, 930m, 8289s, 753s, 704m, 693m. 
1H-NMR: 1.17, 1.46 (2s, 2 Me2C); 3.44 (s, CH2O); 4.56 (s, PhCH2); 7.31-7.39 (m, 5 arom. H, 
NH). 13C-NMR:  22.8, 24.8 (2q, 2 Me2C); 42.5, 56.6 (2s, 2 Me2C); 73.6 (t, CH2O); 76.4 (t, 
PhCH2); 127.6, 127.9, 128.4 (3d, 5 arom. CH); 137.2 (s, 1 arom. C); 177.2, 178.0 (2s, 2 C=O). 
CI-MS: 294 (100, [M + 1]+), 295(18). 
2-Methyl-2-{[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]carbamoyl}propyl 2-[(3-
Benzyloxy-2,2-dimethylpropanoyl)amino]-2-methylpropanoate (17). To a soln. of  16 (1.00 g, 
3.41 mmol) in dry THF (15 ml), 1,1’-carbonyldiimidazol (CDI; 552 mg, 3.41 mmol) was added. 
After 2 h  stirring at r.t.,  6b  (934 mg, 3.41 mmol) was added, followed by the dropwise addition 
of a Na-imidazolid suspension (73 mg imidazol, 45 mg of a 60% NaH suspension in mineral oil 
and 3 ml of THF). After stirring overnight, the org. solvent was removed i.v. and the residue was 
purified by CC (CH2Cl2/acetone 60:1). Yield: 1.276g (66%) of 17. White solid. M.p. 114.2-
115.8o. IR: 3353s (NH), 2980m, 2934m, 2873m, 1739vs (C=O), 1702m, 1664vs (br., C=O), 
1594s, 1520s, 1494m, 1454m, 1385m, 1382m, 1150vs (C-O), 1091m, 1023m, 923m, 904m, 738m, 
705m. 1H-NMR: 1.13,
 
1.14 (2s, 2 Me2C); 1.44 (s, 2 Me2C); 3.27 (s, MeN); 3.42 (s, CH2OH); 4.03 
(s, CH2O); 4.57 (s,  PhCH2); 7.04 (s, NH); 7.21-7.41 (m, 10 arom. H, NH). 13C-NMR: 22.3,  22.9, 
24.7, 25.2 (4q, 4 Me2C); 41.4 (q, MeN); 42.5, 42.7, 55.8, 58.3 (4s, 4 Me2C);  70.9 (t, CH2O); 73.5 
(t, CH2O); 76.6 (PhCH2); 127.5, 127.7, 128.0, 128.3, 128.3, 129.3 (6d, 10 arom. H); 137.6,  144.3 
(2s, 2 arom. C); 173.6, 173.7, 174.0, 175.8 (4s, 4 C=O). CI-MS: 590 (100, [M + Na]+). 
 2-Methyl-2-{[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethy]lcarbamoyl}propyl 2-[(3-Hydroxy-
2,2-dimethylpropanoyl)amino]-2-methylpropanoate (11). To a soln. of 17  (1.200 g, 2.11 mmol)  
in dry CH2Cl2 (15 ml), 150 mg of Pd/C were added and the mixture was stirred under an H2 -
atmosphere at r.t. overnight. The suspension was filtered over celite, and evaporated i.v. The 
product was used without further purification. Yield: 901mg (89%) of 11. White crystals. M.p. 
139.2-140.3o. IR: 3358vs (OH), 3281m, 2981m, 2886m, 1746vs (C=O), 1664vs, 1623vs, 1592s, 
1533vs, 1382s, 1264s, 1224m, 1144vs, 1140m, 1062m, 1024w, 781m, 708s. 1H-NMR 
((D6)DMSO): 0.99, 1.04, 1.31, 1.38 (4s, 4 Me2C); 3.20 (s, MeN); 3.34 (d, 3J = 6, CH2O); 3.91 (s, 
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CH2O);  4.97 (t, 3J = 6, OH); 7.16-7.28 (m, 2 arom. H, NH); 7.30-7.40 (m, 3 arom. H); 7.58 (s, 
NH). 13C-NMR ((D6)DMSO): 21.9, 22.1, 24.6, 25.9 (4q, 4 Me2C); 41.6, 42.6, 54.8, 56.4 (4s, 4 
Me2C); 67.5, 69.9 (2t, 2 CH2O); 126.3, 127.0, 128.7 (3d, 5 arom. CH); 137.8 (s, 1 arom. C); 
172.3, 173.6, 173.7, 175.61 (4s, 4 C=O). ESI-MS: 500 (100, [M + Na]+). 
 
6. Formation of 2-(2-Hydroxy-1,1-dimethylethyl)-4,4-dimethyloxazol-5(4H)-one (19). 
Procedure F. A soln. of 18 (103 mg, 0.5 mmol)  and N,N’-dicyclohexylcarbodiimide (DCC; 104 
mg, 0.5 mmol) in AcOEt (10 ml) was stirred overnight at r.t., then filtered, washed with AcOEt, 
and the solvent was evaporated i.v. Recrystallisation of the residue from MeCN yielded 33mg 
(36%) of  19 as white crystals. M.p. 128.1-128.8o. IR:  3327vs (OH), 2928vs, 2850vs, 1836vs, 
1626vs, 1574vs, 1536vs, 1436m, 1311s, 1271m, 1243s, 1088s, 1045m, 892m, 641s. 1H-NMR 
((D6)DMSO): 1.13, 1.30 (2s, 2 Me2C); 3.41 (d, 3J = 6, CH2OH); 4.91 (t, 3J = 6, OH). 13C-NMR 
((D6)DMSO): 21.3, 24.2 (2q, 2 Me2C); 64.9, 67.4 (2s, 2 Me2C); 166.6 (s, C=N); 181.8 (s, C=O). 
CI-MS: 204 (100, [M + NH4]+), 186 (30, [M + 1]+), 174 (10), 158 (6). 
Procedure G. A soln. of 18 (103 mg, 0.5 mmol)  and  1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (86 mg, 0.5 mmol) in AcOEt (10 ml) was stirred overnight at 
r.t., then  washed with brine and extracted with AcOEt. The combined org. fractions were dried 
(MgSO4), the solvent was evaporated i.v., and the residue purified by CC (CH2Cl2/acetone 
150:1). Yield: 26mg (28%) of 19. 
Procedure H. A soln. of 18 (103 mg, 0.5 mmol)  and  4-(dimethylamino)pyridine (DMAP; 66 
mg, 0.5 mmol) in CH2Cl2 (10 ml) was stirred for 15 min at  r.t. Then, DCC (103 mg, 0.5 mmol) 
was added. The mixture was left overnight, then filtered, washed with AcOEt, and the solvent 
was evaporated i.v. Purification  by CC (CH2Cl2/acetone 150:1) yielded 42 mg (45%) of 19. 
 
7. Synthesis and Cyclization of 1-Ethoxycarbonyl-1-methylethyl 3-Hydroxy-2,2-
dimetylpropanoate. 
1-Ethoxycarbonyl-1-methylethyl 3-Benzyloxy-2,2-dimethylpropanoate (21). To a soln. of 14 (1.00 
g, 3.41 mmol) in dry THF (15 ml), CDI (552 mg, 3.41 mmol) was added and the mixture was 
stirred at r.t. for 2 h. Then, methyl 2-hydroxy-2,2-dimethylethanoate (450 mg, 3.41 mmol) was 
added followed by the dropwise addition of 3 ml of  a Na-imidazolid suspension (73 mg 
imidazole, 45 mg of a 60% NaH suspension in mineral oil and 3 ml THF). After stirring 
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overnight, the org. solvent was removed i.v. and the residue purified by CC (CH2Cl2/acetone 
100:1). Yield: 780 mg (48%) of 21. Colorless oil. IR (film): 2983m, 1743vs (C=O), 1471w, 
1383w, 1293m, 1179s (C-O), 1130s (C-O), 1028m, 738w, 698w. 1H-NMR: 1.21 (s + t,  Me2C, 
MeCH2O); 1.52 (s, Me2C); 3.47 (s,  CH2O);  3.76 (q,  MeCH2O); 4.52 (s, PhCH2); 7.25-7.32 (m, 5 
arom. H). 13C-NMR: 13.9 (q, Me); 22.2, 24.3 (2q, 2 Me2C); 43.4 (s, Me2C ); 60.9 (t, MeCH2O); 
73.2 (t, CH2O); 76.7 (t, PhCH2); 77.9 (s, Me2C); 127.2, 127.3,  128.1 (3d, 5 arom. CH); 138.5 (s, 
1 arom. CH); 172.5, 175.1 (2s, 2 C=O). ESI-MS: 345 (100, [M + Na]+). 
1-Ethoxycarbonyl-1-methylethyl 3-Hydroxy-2,2-dimethylpropanoate (22). To a soln. of 19  (900 
mg, 2.61 mmol)  in dry CH2Cl2 (15 ml), 120 mg of Pd/C were added and the mixture was stirred 
under H2-atmosphere at r.t.  overnight. The suspension was filtered over celite, and evaporated 
i.v. The product was used without further purification. Yield: 777 mg (91%) of 22. Colorless oil. 
IR (film): 3528w (br.), 2885m, 2939m, 1743vs (C=O), 1474m, 1296s, 1180m (C-O), 1128s (C-O), 
1053m, 882w, 758w, 670w. 1H-NMR: 1.11 (s, Me2C ); 1.22 (t, MeCH2O); 1.53 (2s, 2 Me2C ); 
3.53 (d, CH2OH); 4.13 (q, MeCH2O).  13C-NMR: 13.8 (q, Me); 21.5, 24.4 (2q, 2 Me2C); 44.3 (s, 
Me2C); 61.3 (t, MeCH2O); 70.0 (t, CH2O); 78.5 (s, Me2C); 172.6, 176.1 (2s, 2 C=O). ESI-MS: 
255 (100, [M + Na]+). 
3,3,7,7,11,11-Hexamethyl-1,5,9-trioxacyclododecane-2,6,10-trione (23) and 3,3,7,7,11,11,15,15-
Octamethyl-1,5,9,13-tetraoxacyclohexadecane-2,6,10,14-tetraone (24). To a soln. of 22  (232 
mg, 1 mmol)  in dry toluene (5 ml), NaH (40 mg of a 60% suspension in mineral oil, 1 mmol) 
was added slowly at 0o and under constant stirring (N2 -atmosphere). After 5 h at 80o, the mixture 
was acidified with 0.1 N HCl (~6 ml) to pH 5 and extracted with CH2Cl2 . The combined org. 
fractions were dried (MgSO4) and evaporated i.v. The crystalline residue was purified by CC 
(CH2Cl2/acetone 200:1) to yield  24 mg  (8%) of 23. M.p. [57]and  38 mg (9.5%) of 24[57]. 
 
8. X-ray Crystal-Structure Determination of 6a, 6b, 10, 11, 18, 19, and  23 (Table and Figs. 1-
5)3). All measurements were made on a Nonius KappaCCD diffractometer [58] using graphite-
                                                  
3) CCDC- 210670-210676 contain supplementary crystallographic data for this paper. These data 
can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or form the 
Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB12 1EZ, U.K. (fax : 
+44-(0)1223-336033; e-mail: deposit@ccdc.cam.ac.uk)) 
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monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 
cooler. The data collection and refinement parameters are given in the Table and views of the 
molecules are shown in Figs. 1-5. Data reductions were performed with HKL Denzo and 
Scalepack [59]. The intensities were corrected for  Lorenz and polarization effects, but not for 
absorption. The structures were solved by direct methods using SIR92 [60], which revealed the 
positions of all non-H atoms. There were two symmetry-independent molecules in the 
asymmetric unit of 6b, 19 and 23. In each case the atomic coordinates of the two molecules were 
tested carefully for a relationship from a higher symmetry space group using the program 
PLATON [61], but none could be found. The non-hydrogen atoms were refined anisotropically.  
Except for 10, the amide and hydroxy H-atoms in the structures were placed in the positions 
indicated by difference electron density maps and their positions were allowed to refine together 
with individual isotropic displacement parameters. All remaining H-atoms in all structures were 
placed in geometrically calculated positions and each was assigned a fixed isotropic displacement 
parameter with a value equal to 1.2Ueq of its parent atom (1.5Ueq for the Me groups of 6a, 11, 19 
and 23).  For 6b, 10 and 18, each structure was refined on F using full-matrix least-squares 
procedures, which minimized the function Σw(|Fo| – |Fc|)2. Refinement of the remaining 
structures was carried out on F2 by minimizing the corresponding function based on F2. 
Corrections for secondary extinction were applied with the exception of 18. In 6b, 10, 11, 18 and 
23, six, two, one, three and three reflections, respectively, were omitted from the final refinement 
of each structure because their observed intensities were much lower than the calculated values as 
a result of being partially obscured by the beam stop. Neutral atom scattering factors for non-H 
atoms were taken form [62a] and the scattering factors for H-atoms were taken from [63]. 
Anomalous dispersion effects were included in Fc [64]; the values for f' and f'' were those of 
[62b]. The values of the mass attenuation coefficients are those of [62c]. All calculations were 
performed using the teXsan crystallographic software package [65] for 6b, 10, and 18 and the 
SHELXL97 program [66] for 6a, 11, 19, and 23, respectively. 
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Table Crystallographic Data of Compounds 6a, 6b, 10, 11, 18, 19 and 23 
 6a 6b 10 
Recrystallized from CDCl3/AcOEt 
/acetone 
toluene/CH2Cl2
 
/AcOEt 
CDCl3/MeOH 
Empirical formula C11H22N2O3 C16H24N2O3 C18H30N2O6 
Formula weight [g mol-1] 230.31 292.38 370.44 
Crystal color, habit yellow, prism colorless, prism colorless, prism 
Crystal dimensions [mm] 0.12 × 0.20 × 0.25 0.18 × 0.20 × 0.25 0.10 × 0.12 × 0.20 
Temp.[K] 160(1) 160(1) 160(1) 
Crystal system monoclinic triclinic monoclinic 
Space group P21/c P
_
1 P21/c 
Z 4 4 2 
Reflections for cell determination 3944 9546 2273 
2θ range for cell determination [°] 4 – 60 2 – 60 4 – 55 
Unit cell parameters a[Å] 
                                 b [Å] 
                                 c [Å] 
                                  α [°] 
                                  β [°] 
                                  γ  [°] 
                                V [Å3] 
8.6612(1) 
10.4339(2) 
14.4276(2) 
90 
100.5340(6) 
90 
1281.85(3) 
8.9268(1) 
11.9930(1) 
16.4091(2) 
99.0727(5) 
92.8174(5) 
108.5531(6) 
1635.33(3) 
9.1635(2) 
9.6501(2) 
10.8786(3) 
90 
103.3648(8) 
90 
935.93(4) 
Dx [g cm-3] 1.193  1.187 1.314  
µ(MoKα) [mm-1] 0.0863  0.0820 0.0981 
Scan type φ and ω φ and ω φ and ω  
2θ (max) [°] 60 60 55 
Total reflections measured 36257 68555 21539 
Symmetry independent reflections 3749 9576 2140  
Reflections with I > 2σ (I) 3038 6579 1713 
Reflections used in refinement 3749 6579 1713 
Parameters refined 160 396 119 
R [onF; I > 2σ(I) reflections] 0.0432 0.0500 0.0412 
wR [onF; I > 2σ(I) reflections] - 0.0496 0.0447 
wR [onF2; all indept. reflections] 0.1204 - - 
Weighting parameter [p]a) - 0.005 0.005 
Weighting parameters [a; b]b) 0.0527; 0.3914 - - 
Goodness of fit 1.046 2.870 2.901 
Secondary extinction coefficient 0.029(5) 2.7(3) × 10-6 3.9(8) × 10-6 
Final ∆ max /σ 0.001 0.0004 0.0004 
∆ρ (max; min) [e Å-3] 0.34; -0.36 0.28; -0.22 0.25; -0.20 
 
 
a) w–1 = σ2(Fo) + (pFo)2 
b) w–1 = σ2(Fo2) + (aP)2 + bP] where P = (Fo2 + 2Fc2)/3 
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11 18 19 23 
CH2Cl2/i-
PrOH/hexane 
toluene/acetone/ i-
PrOH 
MeCN/acetone/ 
CH2Cl2 
CH2Cl2/ acetone 
C25H39N3O6 C9H17NO4 C9H15NO3 C15H24O6 
477.60 203.24 185.22 300.35 
colorless, prism yellow, plate colorless, prism colorless, plate 
0.10 × 0.12 × 0.20 0.02 × 0.15 × 0.17 0.15 × 0.15 × 0.25 0.02 × 0.18 × 0.23 
160(1) 160(1) 160(1) 160(1) 
monoclinic monoclinic monoclinic monoclinic 
P21 P21/n  P21/c ) P21/c  
2 4 8 8 
3173 2004 3721 5976 
4-55 4 – 50 4 – 50 4 – 50 
9.3227(2) 
11.1213(2) 
12.8333(3) 
90 
99.6690(9) 
90 
1311.66(5) 
8.2708(2) 
8.2429(2) 
15.7690(4) 
90 
98.9548(9) 
90 
1061.95(5) 
11.7684(5) 
10.5276(4) 
16.1536(8) 
90 
90.464(2) 
90 
2001.3(2) 
9.8304(1) 
11.9228(2) 
27.7139(5) 
90 
97.1582(6) 
90 
3222.92(9) 
1.209 1.271 1.229 1.238 
0.0861 0.0992 0.0918  0.0948  
φ and ω   ω φ and ω  φ and ω  
55 50 50 50 
32002 14054 30962 51446 
3177 1859 3521 5680 
2118 1330 2425 3981 
3176 1330 3521 5677 
329 139 252 392 
0.0410 0.0411 0.0570 0.0436 
- 0.0379 - - 
0.0965 - 0.1556 0.1120 
- 0.005 - - 
0.0436; 0 - 0.0585; 0.9613 0.0552; 0.1627 
0.995 1.865 1.090 1.037 
0.025(3) - 0.011(2) 0.0036(6) 
0.001 0.0002  0.001  0.001  
0.18; -0.19 0.18; -0.21 0.22; -0.22 0.20; -0.21 
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Chapter 2 
 
14-Membered cyclodepsipeptides with alternating β-hydroxy and α-amino acids by 
cyclodimerization1) 
 
 
 
Abstract 
The cyclodimerization (twinnig) of β-hydroxy acid amides of type 1 under ‘direct amide 
cyclization’ (DAC), conditions is described. Although other coupling methods also gave 
moderate results, best yields were obtained via DAC, reaching 88% for the cyclodimer 10. In all 
cases, when starting with racemic material, only the trans-substituted cyclodepsipeptides were 
isolated. Simple molecular modeling revealed that the formation of the cyclodimer is 
thermodynamically slightly more favorable than that of the cyclomonomer. The proposal that 
cyclodimer formation is preferred because of the presence of intramolecular H-bonds could not 
be confirmed by X-ray crystallography. The influence of substituents, both in the amino acid and 
in the hydroxy acid moieties, was also studied. It is shown, that cyclodimerization was successful 
only when the hydroxy acid moiety is α,α-disubstituted. 
 
 
 
 
 
 
                                                  
1) B. Iliev, A. Linden, R. Kunz, H. Heimgartner, Tetrahedron, submitted. 
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1. Introduction 
 
In a recent paper,1 we reported that amides 1, when subjected to the conditions of the ‘direct 
amide cyclization’ reaction,2-9 yielded only the dimerized product 3. The 14-membered 
cyclodepsipeptide 3 was isolated as the sole product and none of the expected 7-membered 
monomer 2 could be detected (Scheme 1). 
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N
R O
O
NH
O NHO
O
O
O
N
H
O
O X
12 3
HCl gas
 Toluene, 100 oC
R= Me, Ph
 Toluene, 100 oC
HCl gas
 
Scheme  1 
 
In order to explain this unexpected result we investigated some other lactonization methods with 
derivatives of 1, including that described by Richard et al.,10 which, in the case of ethyl 6-
hydroxyhexanoates, had resulted in the formation of 7-membered lactones. Again, in all 
experiments with derivatives of 1, where a defined product could be isolated, we obtained only 
the dimeric product 3.  
 
Cyclic 14-membered depsipeptides with the same ring skeleton as 3 have been known since the 
1960’s, and the dimerization process is not as surprising as it seems at first. Since the discovery, 
isolation and identification of serratamolide (4: R = H, R’ = (CH2)6CH3, Scheme 2) from Serratia 
marcescens in 1961,11 the proof of its antibiotic activity,12 and  its first total synthesis by 
Shemyakin et al.,13 the interest in depsipeptides containing β-hydroxy acids has increased 
significantly, mainly because of their antibiotic properties. The other important biological role of 
the same compound, is its use as a surface-active agent under the name of serrawettin W1,14 and it 
has been patented for the use as a pesticide as well.15 
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The synthetic pathways to serratamolide (4) and its derivatives are numerous, but the approaches 
can be divided into three main groups: classical ring closure of linear precursors, usually by 
lactam bond formation (5 4), ring enlargement (6 7 4), and cyclization by twinning (8 4) 
(Scheme 2). 
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Scheme 2 
 
The main feature of the last-mentioned method is that the cyclization is performed with the 
monomeric linear precursor, and the twinning, or cyclodimerization, takes place during the course 
of the reaction. Some basic theories have been offered as an explanation of this dimerization. One 
of the most popular proposals states that it is mainly due to intermolecular hydrogen bonding 
between carbonyl and amine groups that are  formed during the reaction.16,17 In the case of 4, the 
two planar trans-amide groups  form a trans-annular hydrogen bond (intramolecular) and thus 
favor the formation of a 14-membered ring. That no monomeric product was formed in the 
reaction can probably be explained by the fact that such an intramolecular interaction would not 
be possible within a 7-membered ring. However, the contribution of hydrogen bonding tends to 
be overestimated as some dimerizations also take place in polar solvents, which could interfere 
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with such an intramolecular interaction.17 Another theory proposed by Ovchinnikov et al.18 is that 
the cyclization is preceded by a linear polycondensation, which results in linear dimers and 
oligomers, which, under the conditions of high dilution, may undergo cyclization. The extent of 
the ring closure is determined principally by the most stable conformation of a given linear 
peptide, being close to that of the cyclic product. On the other hand, the formation of trimers 
seems to be statistically unfavorable. 
 
The reason for the preferred dimerization in the case of 1 is most probably a defined 
conformation of the linear precursor and the stability of the transition state. Another reason could 
be the rigidity of the amide bond in 1, although the reactions with an ester analogue of compound 
1 showed that again oligomerization occurred to give tri- and tetrameric structures of the β-
hydroxy acid.1 Therefore, most probably the dimerization is not a result of the amide bond 
rigidity. 
 
In order to further investigate the cyclodimerization of dipeptide analogues of type 1 under the 
conditions  of the ‘direct amide cyclization’ we synthesized some other amide precursors, which 
differ in the substitution in the α-amino acid as well as in the β-hydroxy acid moiety, including 
chiral compounds. Furthermore, we tried to get some information from computer modeling of key 
compounds. 
 
2. Results and discussion 
 
It is known from previous experiments5-7,19,20 that dipeptides of type 1, in which the two methyl 
groups in the amino acid residue are replaced by a cyclopentane ring (i.e. the compounds contain 
1-aminocyclopentane carboxylic acid instead of 1-aminoisobutyric acid (Aib)), react in a very 
similar way to 1. Therefore, our first target was amide 9, which was conveniently prepared by the 
coupling of 3-hydroxy-2,2-dimethylpropanoic acid with N,N-dimethyl-1-azaspiro[2.4]hept-1-en-
2-amine in analogy to Ref. 1 (‘azirine/oxazolone method’; see also Ref. 21). After bubbling HCl 
gas through a solution of 9 in toluene (20 mM) at 100 oC for 4 min, 88% of the corresponding  
14-membered cyclodepsipeptide 10 was obtained (Scheme 3). Similarly, the linear racemic 
dipeptides 11a,b22 carrying two different substituents on the C(α) atom, were also synthesized by 
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the ‘azirine/oxazolone method’. ‘Direct amide cyclization’ of 11b yielded, upon cyclization, 68% 
of the dimeric racemic 12 as the sole product. 
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Scheme 3 
 
This was clearly indicated by the 1H and 13C spectra, which show only one set of signals. The 
structures of 10 and 12 were established by X-ray crystallography (Figure 1). 
The backbones of the two structures are very similar and also resemble the structures of the 
previously  reported tetramethyl analogue 3.1 In the case of 10, the molecule sits about a 
crystallographic centre of inversion. The cyclopentane ring has an envelope conformation with 
the spiro C-atom as the envelope flap. Each amide NH group forms an intermolecular hydrogen 
bond with a lactone carbonyl O-atom of an adjacent molecule. The molecular symmetry results in 
there being two parallel hydrogen bonds running in opposite directions between each molecule. 
These interactions link the molecules into extended double-bridged chains which run parallel to 
the [1 0 0] direction. Taken individually, the repeat unit in the chain generated by one of the 
interactions has a graph set motif24 of C(5). The pair of hydrogen bonds linking two adjacent 
molecules forms a loop with a graph set motif of R22(16). 
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a) 
 
b) 
 
 
Figure 1. ORTEP plots23 of the molecular structures of  a) 10 and b) 12 (50% probability 
ellipsoids, arbitrary numbering of atoms). 
 
In the case of 12, the space group is centrosymmetric and therefore the crystals are racemic. The 
molecule again sits about a crystallographic centre of inversion, so therefore has the (7RS, 7’SR)-
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configuration, i.e.  12 is the trans-isomer. The hydrogen bonding pattern in the crystals of 12 is 
the same as for 10. 
The nature of the cyclodimerization in the case of 11 is remarkable. Starting with a racemic 
precursor 11, one would expect that a mixture of cis- and trans-substituted cyclodimers would be 
obtained, but only the trans-isomer 12 has been formed in 68% yield. 
 
As mentioned before, factors that might influence the cyclization are not only the type, but also 
the number of substituents in the amino acid moiety. Therefore, a cyclization experiment was 
carried out with an analogue of 11, which contains a monosubstituted amino acid. Direct amide 
cyclization was not an option in this case, since the intermediate oxazolone does not form 
smoothly in the case of monosubstituted substrates25. Therefore, we used the base catalyzed 
lactonization described in Ref. 10. The coupling of 3-hydroxy-2,2-dimethylpropanoic acid with 
L-Phe-OtBu.HCl gave the enantiomerically pure  13. When a solution of 13 was heated in toluene 
(200 mM) in the presence of 1 equiv of NaH, the 14-membered cyclic depsipeptide trans-14 was 
obtained as the only isolable product in 44% yield. In order to compare the configurations of the 
two stereogenic centers, the analogous cyclization was performed with a racemic starting 
material, i.e. methyl ester 15 (Scheme 4). Surprisingly, a single cyclodepsipeptide was again 
obtained in 24% yield and was identical with trans-14 in all respects. 
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Scheme 4 
 
The 1H NMR spectrum of the cyclized product obtained from 13  using a shift reagent (Pirkle 
reagent) and HPLC on a chiral adsorbent (Chiracel OD-H, Merck Whelk-O 1) showed the 
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presence of only one compound, which was identical with the product obtained from the 
cyclization of 15. X-ray crystallography of both products confirmed their identical structure and 
proved that the benzyl groups are trans-oriented (Figure 2).  
 
As the precursor 13 was optically active ([α]25D= +44.6, c = 1, CHCl3), an inversion of the 
configuration at one of the stereogenic centers has taken place during the cyclization step. With 
the aim of avoiding this inversion, another cyclization was attempted with the corresponding free 
hydroxy acid 16, which was obtained from the basic hydrolysis of 13. Cyclization of both  rac-16 
and (S)-16 was achieved under neutral conditions using I2 as a catalyst,26 which has previously 
proven to be efficient for the synthesis of depsipeptide 3.1 The product obtained from rac-16 was 
again the racemic trans-14a, while the enantiomerically pure acid (S)-16, obtained by a milder 
hydrolysis of its methyl ester 17, yielded also only one cyclodepsipeptide, namely (S,S)-14 
(Scheme 5). 
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a) 
 
 
b) 
 
 
Figure 2. ORTEP plots23 of the molecular structures of  a) trans-14 and b) molecule A of (S,S)-14 
(50% probability ellipsoids, arbitrary numbering of atoms). 
 
Since the space group of trans-14 is centrosymmetric, the crystals are racemic. The molecule sits 
about a crystallographic centre of inversion, so the two stereogenic centres have inverted 
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configurations, i.e. (7RS, 7’SR). The hydrogen bonding pattern is again analogous to that of 12 
and 10. 
 
Analytical HPLC of both of these compounds on a chiral column (Whelk-O 1 column, 
hexane/EtOH 10:1) clearly shows two different peaks with retention times of 10.8 and 10.9 min, 
respectively. The HPLC diagram of a mixture of the two compounds under the same conditions 
also showed two peaks, proving once more their different structure. Furthermore, it was shown, 
that (S,S)-14 is optically active. For this reason, we expected that it is the cis-isomer with the 
(S,S)-configuration, which was subsequently proven by X-ray crystallography (Figure 2).  
 
In the crystal structure of (S,S)-14, there are two symmetry-independent molecules in the 
asymmetric unit, but the conformations of the two molecules are almost identical.  The space 
group permits the compound in the crystal to be enantiomerically pure, but the absolute 
configuration of the molecule has not been determined.  The enantiomer used in the refinement 
was based on the expected (S)-configuration of each chiral centre in the molecule.  The crystal is 
merohedrally twinned, with twin operator [1 0 0 / 0 -1 0 / 0 0 -1] and the major twin domain has a 
volume fraction of 0.640(1).  Each amide group in molecule A forms an intermolecular hydrogen 
bond with an amide O-atom of an adjacent molecule A.  This results in there being two parallel 
hydrogen bonds running in opposite directions between each molecule.  The interactions link the 
molecules into extended double-bridged ···A···A···A··· chains which run parallel to the [1 0 0] 
direction. Taken individually, the repeat unit in the chain generated by one of the interactions has 
a graph set motif
24
 of C(4).  The pair of hydrogen bonds linking two adjacent molecules forms a 
loop with a graph set motif of R22(18). The molecules of type B are similarly linked into extended 
double-bridged ···B···B···B··· chains which also run parallel to the [1 0 0] direction.  
 
From these results it could be concluded that monosubstituted amino acid blocks in amides of 
type 1 do not prevent the cyclodimerization. Next, the influence of the disubstitution of C(α) of 
the β-hydroxy acid  should be investigated and, therefore, analogous dipeptides with a α-
monosubstituted β-hydroxy acid were synthesized and subjected to cyclization procedures. Being 
readily available, tropic acid (3-hydroxy-2-phenylpropanoic acid) turned out to be an interesting 
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starting material for this study. Thus, amides 18a and 18b were prepared by coupling tropic acid 
with 2,2,N,N-tetramethyl-2H-azirin-3-amine and  2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine, 
respectively, and subjected to the conditions of the ‘direct amide cyclization’. Surprisingly, the 
cyclization failed and only traces of the corresponding 1,3-oxazol-5(4H)-one were identified in 
the crude reaction mixture by IR and NMR spectroscopy. Column chromatography led to no 
identifiable products. Furthermore, the corresponding ethyl ester 19, derived from either of the 
amides 18 by treatment with HCl gas in EtOH, did not yield cyclic products upon treatment with 
NaH. Other lactonization procedures, proven to be successful in the case of amide derivatives,1 
also failed to give the desired cyclic depsipeptide in this case (Scheme 6). 
 
When tropic acid was coupled with L-phenylalanine t-butylester.HCl,  amide 20 was obtained as 
a mixture of two diastereoisomers. Their separation on a Whelk-O 1 preparative HPLC column 
proved to be possible, and we attempted to cyclize them separately, in order to determine the 
stereospecificity of the NaH cyclization. Unfortunately both the racemic and the enantiomerically 
pure substrates failed to give cyclic depsipeptides (Scheme 6). 
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Scheme 6 
 
The reason for the failure of cyclization of  18-20 could be a steric hindrance of the phenyl group 
in the α-position or its electronic effect. To examine this possibility, 3-hydroxy-2-methyl-2-
phenylpropanoic acid was prepared27 and coupled with the corresponding 2H-azirin-3-amines to 
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give 21a,b. The third explanation could be that the cyclization is thermodynamically unfavorable 
when the substrate is monosubstituted in the α-position of the β-hydroxy acid moiety. Therefore, 
α-benzyl-β-hydroxypropanoic acid and  β-hydroxyisobutyric acid were synthesized according to 
known procedures28 and coupled with 2,2,N,N-tetramethyl-2H-azirin-3-amine to give amides 22 
and 23, respectively, as substrates for the cyclization (Scheme 7). 
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Scheme 7 
 
As expected, amide 21b cyclized under DAC conditions to yield the 14-membered 
cyclodepsipeptide 24 in moderate yield. This result suggests that amides of type 18/21 bearing a 
phenyl group at C(α) of the hydroxy acids do cyclize when α,α-disubstituted, i.e. the phenyl 
group in 18 was not the reason for its failure to give cyclic products. Compound 24 was isolated 
as a colorless solid, which showed only one set of signals in the NMR spectra. Therefore it could 
be suggested that only one stereoisomer, as a racemate, has been obtained. Careful crystallization 
from a mixture of toluene/acetonitrile/acetone gave crystals suitable for X-ray crystallography. 
The molecular structure of 24 is depicted in Figure 3, showing that again the trans-isomer has 
been obtained. 
 
Since the space group is centrosymmetric, the compound is racemic.  The molecule sits about a 
crystallographic centre of inversion, so therefore has the (4RS,4'SR)-configuration. Remarkably, 
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the amide groups are not involved in any hydrogen bonds.  Although amide O-atoms in adjacent 
molecules appear to be positioned correctly to accept a hydrogen bond from the amide H-atom, 
the H···O distance of 2.98 Å is much too long for it to be considered a hydrogen bond.  This is 
probably the result of molecular bulk preventing the molecules packing close enough together for 
intermolecular hydrogen bonds to form. 
 
 
 
Figure 3. ORTEP plot23 of the molecular structure of  24 (50% probability ellipsoids, arbitrary 
numbering of atoms). 
 
Amides 22 and 23 failed to cyclize under the DAC reaction conditions, as was the case with 18. 
Upon monitoring the reaction of 18 by IR spectroscopy, the formation of the corresponding 1,3-
oxazol-5(4H)-one 25, which is the expected intermediate in the cyclization reaction, was 
observed (strong absorption at 1820-1830 cm-1),29 and after addition of methanol to the reaction 
mixture,  methyl ester 26 was isolated in 58% yield (Scheme 8). 
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Scheme 8 
 
The formation of a methyl ester and the IR spectra strongly suggest the presence of a 1,3-oxazol-
5(4H)-one as an intermediate. It seems that the oxazolone formation and water elimination in the 
case of 18 are competitive reactions. In order to get an indication of which reaction takes place 
first, a similar set of experiments was carried out with benzyl derivative 22. Upon bubbling HCl 
gas through a solution of 22 in toluene/methanol (20%), the only product obtained was the 
corresponding hydroxy ester 27 (Scheme 9). When the reaction was carried out under the 
conditions described for 18, i.e. oxazolone formation with HCl gas in toluene (monitoring by IR, 
increasing absorption at 1826 cm-1) and addition of methanol after saturation, the dehydrated 
ester 28 and the dehydrated amide 29 were obtained in addition to 27 (Scheme 9). 
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Scheme 9 
 
This result suggests that when the reaction is carried out in the presence of a nucleophile, such as 
methanol, oxazolone 26 is formed first and is immediately  transformed into the corresponding 
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hydroxy ester 27. On the other hand, in the absence of a nucleophile, the intermediate oxazolone 
26 eliminates water, leading to 2-vinyl oxazolones and thus preventing further cyclization. The 
formation of 28 and 29 can be explained by the competitive ring opening of 26 by the 
nucleophiles methanol and N-methylaniline, respectively.  This result is an additional indication 
that the cyclodimerization process occurs via an oxazolone intermediate. 
 
Another variation of the starting materials for the direct amide cyclization (DAC) is the insertion 
of aromatic β-hydroxy acids or β-hydroxycycloalkane carboxylic acids. The first of these 
derivatives, salicylamide 30, was obtained from salicylic acid  by coupling with the 
corresponding  2H-azirin-3-amine (Scheme 10).5,19   
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Scheme 10 
 
Compound 30 was subjected to the DAC conditions. The starting material disappeared quickly 
(TLC), but even after 35 min the only product formed was the corresponding oxazolone 31. After 
its isolation, further exposure to the same reaction conditions did not propagate the reaction 
further, and the oxazolone 31 was recovered. The stability of the oxazolone is in this case 
extremely high, and apparently a ring enlargement reaction is sterically disfavored.  
 
Crystals of 31 suitable for X-ray crystal structure determination were grown from a mixture of 
deuterochloroform and dichloromethane by slow evaporation of the solvent.  The five membered 
heterocycle is planar and the phenyl residue is almost coplanar with the ring.  The hydroxy group 
forms an intramolecular hydrogen bond with the imine N-atom. The interaction can be described 
by the graph set motif24 of S(6) (for crystallographic details see exper. part). 
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Next, the aromatic ring in 30 was replaced by a cycloaliphatic one. The preparation of the 
precursors 33a,b was achieved in three steps according to Scheme 11. The cyclization under the 
standard conditions led to a mixture of two products, the oxazolone 34 and the dehydrated amide 
35, but no cyclodepsipeptide could be detected. 
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Scheme 11 
 
 
3. Computer Modeling 
 
As we were searching for an explanation for the preferred cyclodimerization process of diamides 
of type 1, we carried out some simple quantum mechanical calculations. Especially surprising 
was the discrepancy  with the lower homologue 36, which under the DAC conditions gave the 
cyclic monomer 39 exclusively. Assuming that the reaction proceeds indeed via the oxazolone 
intermediates (37 and 40, respectively), we compared the energies of the corresponding 
monomeric and dimeric ring structures, both in the cases of α-hydroxy acids and β-hydroxy acids 
(Schemes 12 and 13). 
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Scheme 12 
 
AM1 calculations30 with Ampac v.6.5.531 revealed that the transition state required to achieve a 
nucleophilic attack of the oxazolone hydroxy group on the carbonyl C-atom is more favorable in 
the case of 40 than in 37, which is to be expected, having in mind the length of the alkyl chain to 
which the OH group is bound.  Nevertheless, under the DAC conditions, 36 gives 39, whereas 1 
undergoes the twinning process. 
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Direct comparison of the heats of formation (∆H) of 38 and 39, as well as those of  3 and 2, 
reveals that in the first case (Scheme 12) the formation of the dimer 38 is energetically more 
unfavorable than the formation of the monomer 39 (2E39 < E38 ). In the second case (Scheme 13), 
formation of the dimer 3 is energetically more favorable than the formation of the monomer (2E2 
> E3), which suggests that the cause for the different products formed is thermodynamic. This 
crude modeling helps to understand why the dimers of type 3 could be the main products of the 
direct amide cyclization of 1, but it does not explain why they are the only products formed. An 
equilibrium between the monomeric and dimeric forms under the strongly acidic conditions of the 
DAC is to be expected in both cases (between 2 and 3 on the one hand and between 39 and 38 on 
the other). This equilibrium might be shifted almost completely in one direction in the case of 3 
and in the other in the case of 39. 
 
4. Conclusions 
 
Upon investigating the reasons for the cyclodimerization of β-hydroxy acid amides of type 1 
under various conditions, we were able to isolate five different 14-membered cyclodimers of type 
3. Although other coupling methods also gave moderate results, the best yields were obtained via 
the ‘direct amide cyclization’ (DAC), reaching 88% for the cyclodimer 10. It is worth mentioning 
that in all cases, when starting with racemic material, only the trans-substituted 
cyclodepsipeptides were isolated.  
 
The cyclodimerization is most probably a result of the greater thermodynamic stability of the 14-
membered ring compared with the 7-membered one. Another factor which might contribute to the 
cyclodimerization, as suggested in the literature, is H-bond formation, which would be more 
pronounced in the 14-membered ring, although the structures of all cyclodepsipeptides which 
were characterized by X-ray crystallography showed no evidence of intramolecular H-bonding. 
 
Molecular modeling using simple AM1 calculations shows in the case of 1 that the formation of 
the dimeric depsipeptide is indeed thermodynamically favored over the formation of the 
monomer, but it does not explain why the 14-membered ring is the only product formed. A 
mixture of the monomeric and dimeric forms is to be expected. Thus, the reason for the exclusive 
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cyclodimerization of compounds of type 1 remains unclear and further investigation in this area is 
needed. 
 
Variation in the substitution pattern of the starting compounds showed that mono-substitution in 
the amino acid moiety does not prevent twinning (13, 15 and 16 yielded trans-14, although not 
via DAC). Using I2 mediated lactonization allowed for the selective synthesis of both (S,S)-14 
(starting with (S)-16) and trans-14 (starting with rac-16). If, on the other hand, the hydroxy acid 
moiety is monosubstituted (as in 18, 19, 27), although the formation of the intermediate 1,3-
oxazol-5(4H)-one  has been monitored by IR, water elimination occurs and no cyclic products are 
formed. Therefore, the synthesis of β-hydroxy acid containing cyclic depsipeptides via DAC is 
useful only if the starting amides contain α,α-disubstituted acids. 
 
5. Experimental Part 
 
5.1. General.  
 
Thin-layer chromatography (TLC): Merck TLC aluminium sheets, silica gel 60 F254. Prep. TLC: 
Merck PLC plates (glass), silica gel 60 F254, 2 mm and 40-63 µm. Flash chromatography (CC): 
Uetikon-Chemie ‘Chromatographiegel’ C-560. Mp: Büchi 540 apparatus, uncorrected. IR 
Spectra: Perkin-Elmer Spectrum one spectrometer; in KBr,  unless otherwise stated, absorption 
bands in cm-1. 1H NMR (300 MHz) and 13C NMR (75.5 MHz) spectra: Bruker ARX-300 or 
Bruker DRX-600  instrument; 1H NMR (600 MHz) and 13C NMR (150 MHz); in CDCl3  at 300 
K; TMS as internal standard, unless otherwise stated; δ in ppm, coupling constants J in Hz.  Mass 
spectrometry (MS): Finnigan MAT-90 for electron impact ionization (EI), Finnigan SSQ-700 for 
chemical ionization (CI, with NH3) and electrospray ionization (ESI, in MeOH + NaI), unless 
otherwise stated. 
2,2,N,N-Tetramethyl-2H-azirin-3-amine, 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine, 2-benzyl-
2,N-dimethyl-N-phenyl-2H-azirin-3-amine and N,N-dimethyl-1-azaspiro[2.4]hept-1-en-2-amine  
were prepared according to standard procedures (Refs. 5 and 7 and refs. cited therein). 3-
Hydroxy-2-benzylpropanoic acid was prepared by the method of Monteil et al.28 and methyltropic 
acid from hydroptropic aldehyde by hydroxymethylation, followed by oxidation, according to 
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Geffken.27 Hydroxy acids 32 were synthesized by the method of Seebach et al.32 All other 
products used were commercially available. 
 
General procedure 1 (GP1).  
To a solution of a hydroxy acid (2-6 mmol) in  dry THF (5-20 mL), 1.05 equiv of the 
corresponding 2H-azirin-3-amine were added dropwise. The mixture was stirred at rt for 12-36 h, 
the solvent evaporated and the remaining solid purified by column chromatography (CC) over 
silica gel and dried in h.v. 
 
General procedure 2 (GP2). 
According to GP1, the reaction was stirred overnight, the solvent evaporated, the solid residue 
washed with Et2O and recrystallized from AcOEt. 
 
General procedure 3 (GP3). 
To a solution of a hydroxy acid (3 mmol) in dry THF (10 mL) was added the corresponding 
phenylalanine ester hydrochloride (3.0 mmol) and 3-(diethoxyphosphoryloxy)-1,2,3-
benzotriazine-4(3H)-one (DEPBT, 916 mg, 98%, 3.0 mmol). To the cooled mixture were added 
dropwise 12 mmol (1.21 g) Et3N. The mixture was stirred at rt overnight, the solvent was 
partially evaporated, AcOEt was added and the solution was washed with 5% aq KHSO4 and with 
saturated aq NaHCO3 solutions. The combined organic fractions were dried over MgSO4, 
evaporated, purified by CC, and dried in h.v. 
 
General Procedure 4 (GP4). 
To a solution of an ester (2.0 mmol) in 10 mL EtOH was added LiOH.H2O (336 mg, 8 mmol). 
The reaction was stirred overnight at rt, acidified with 6N HCl, the organic solvent was 
evaporated in vacuo  and the residue extracted with AcOEt. The crude acids were used in the next 
reaction step without further purification. 
 
General procedure 5 (GP5). 
A suspension of an amide (1 mmol) in dry toluene (50 mL) was heated to 100 oC, and dry HCl 
gas was bubbled through the suspension for 5-15 min. Then, the mixture was allowed to cool to rt 
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while bubbling N2 through it (ca. 20 min). The solvent was evaporated, the white residue was 
washed with 3 × 15 mL of CH2Cl2 and dried in h.v. 
 
General procedure 6 (GP6). 
According to GP5, after bubbling N2 through the reaction mixture (ca. 20 min) the solvent was 
evaporated, and the residue purified by CC. 
 
General procedure 7 (GP7). 
To a solution of 13 or 15 (1 mmol) in dry toluene (5 mL), NaH (40 mg of a 60% suspension in 
mineral oil, 1 mmol) was added slowly at 0 oC and under constant stirring (N2-atmosphere). After 
6 h at 80 oC, the mixture was acidified with 0.1N HCl (~5 mL) to pH 5 and extracted with CH2Cl2 
The combined organic fractions were dried (MgSO4) and evaporated i.v. The crystalline residue 
was purified by CC (CH2Cl2/acetone 200:1) and dried in h.v. 
 
General procedure 8 (GP8). 
To a solution of a hydroxy acid  (1 mmol )  in acetonitrile (5 mL), I2 (25 mg, 0.1 mmol ) was 
added. After 2 d under reflux, the mixture was cooled and the solvent evaporated. After addition 
of 20 mL of AcOEt and  washing with aq Na2S2O3, the combined organic fractions were dried 
(MgSO4) and evaporated i.v. The crystalline residue was purified by CC. 
 
General Procedure 9 (GP9). 
A suspension of an amide (1 mmol) in a toluene/20% ethanol solution (60 mL) was heated to 
100 oC, and dry HCl gas was bubbled through the suspension for 10 min. Then, the mixture was 
allowed to cool to rt while bubbling N2 through it (ca. 20 min). The solvent was evaporated and 
the oily residue was purified by CC . 
 
General Procedure 10 (GP10). 
A suspension of an amide (0.5 mmol) in dry toluene (25 mL) was heated to 100 oC, and dry HCl 
gas was bubbled through the suspension for 10 min. Then, the mixture was allowed to cool to rt 
while bubbling N2 through it (ca. 20 min). The solvent was removed i.v. and MeOH (15 mL) was 
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added to the residue and stirred at rt for 1 h in the presence of 500 mg SiO2. The silicagel was 
filtered, the solvent was evaporated and the oily residue was purified by CC. 
 
5.2. Preparation of 3-hydroxy-2-methylpropanoic acid. To a solution of methyl 
(R)-3-hydroxy-2-methylpropanoate (1.0 g, 8.38 mmol) in THF/water 75:10 (10 mL) LiOH 
(1.55g, 33.5 mmol) was added at 0 oC. The mixture was stirred overnight, the organic solvent 
evaporated, the residue acidified with 6N HCl to pH 1 and extracted with AcOEt. The colorless 
oil was used in the next reaction without further purification. Yield: 768 mg (88%). Spectroscopic 
data in accordance with previously published data.33 The optical purity has not been determined. 
1H NMR((D6)-DMSO): 1.04 (d, J = 5.9 Hz, CH3); 2.31-2.38 (m, CH); 3.38-3.44, 3.52-3.61 (2m, 
CH2); 4.62 (br s, OH); 11.95 (br s COOH). 
 
5.3. Coupling of β-hydroxy acids with 2H-azirin-3-amines 
  
5.3.1. 3-Hydroxy-2,2-dimethyl-N-[1-(N,N-dimethylcarbamoyl)cyclopentyl]propanamide (9). 
According to GP1, 3-hydroxy-2,2-dimethylpropanoic acid (806 mg, 6.84 mmol) in dry THF (10 
mL),  N,N-dimethyl-1-azaspiro[2.4]hept-1-en-2-amine (1.037 g, 7.52 mmol), 18 h, CC (SiO2, 
acetone/CH2Cl2 1:20). Yield: 1.330 g (76%) of 9. White solid. Mp 180.6-181.9 oC (AcOEt). IR: 
3397vs, 3279s, 2960s, 2873m, 1644vs, 1542vs, 1469m, 1393s, 1309m, 1257m, 1212w, 1164m, 
1119w, 1061s, 1011w, 983w, 911w, 817w, 669m. 1H NMR ((D6)-DMSO): 1.14 (s, Me2C); 1.71 
(m, 2CH2); 1.81-2.00, 2.28-2.48 (2m, 2CH2); 2.99 (s, Me2N); 3.56 (br s, OH); 4.46 (s, CH2O); 
7.42 (br s, NH). 13C NMR ((D6)-DMSO): 22.8 (q, Me2C); 24.2 (t, CH2); 37.2 (t, CH2); 37.7 (q, 
Me2N); 42.8, 66.2 (2s, 2C); 69.1 (t, CH2O); 172.7, 176.9 (2s, 2CO). CI-MS: 257 (21, [M+H]+), 
212.3 (100, [M-NMe2]+). Anal. calcd for C13H24N2O3 (256.35): C 60.91, H 9.44, N 10.93; found: 
C 60.24, H 9.50, N 10.76. 
 
5.3.2. 3-Hydroxy-2,2-dimethyl-N-[1-methyl-1-(N,N-dimethylcarbamoyl)-2-phenylethyl]-
propanamide (11a). According to GP1, 3-hydroxy-2,2-dimethylpropanoic acid (436 mg, 2.00 
mmol) in dry THF (5 mL), 2-benzyl-2,N,N-trimethyl-2H-azirin-3-amine (395 mg, 2.1 mmol), 24 
h, CC (SiO2, acetone/CH2Cl2 1:20). Yield:  538 mg (88%) of 11a. White powder. Mp 92.6-94.9 
oC. 1H NMR ((D6)DMSO): 1.05 (s, Me2C); 1.29 (s, Me); 3.09 (s, Me2N); 3.13-3.38 (m, PhCH2); 
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3.54 (s, CH2O); 4.77 (br s, OH); 6.92 (br s, NH); 7.06-7.36 (m, Ph). 13C NMR ((D6)DMSO): 22.4 
(q, Me2C); 24.8 (q, Me); 37.3 (q, MeN); 41.0 (s, Me2C); 43.8 (t, PhCH2); 70.1 (t, CH2O); 128.3, 
128.8, 129.4 (3d, 5 arom. CH); 136.1 (s, arom. C); 173.1, 175.2 (2s, 2 CO). CI-MS: 307 (100, 
[M+H]+), 262 (25, [M-NMe2]+). 
Recrystallization from DMSO/diethyl ether yielded crystals of 11a, suitable for an X-ray crystal 
structure determination. 
 
5.3.3. 3-Hydroxy-2,2-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)-2-phenyl-
ethyl]propanamide (11b). According to GP1, 3-hydroxy-2,2-dimethylpropanoic acid (436 mg, 
2.00 mmol) in dry THF (5 mL), 2-benzyl-2,N-dimethyl-N-phenyl-2H-azirin-3-amine (525 mg, 
2.1 mmol), 28 h, CC (SiO2, acetone/CH2Cl2 1:30). Yield: 618 mg (84%) of 11b. White powder. 
Mp 62.0-64.2 oC. IR: 3385vs, 3291vs, 3060m, 2941vs, 1701vs, 1634vs, 1591s, 1454s, 1386s, 
1312s, 1238s, 1193m, 1165m, 1111m, 1053s, 886m, 908w, 834w, 772s, 705s. 1H NMR: 0.98, 
1.08 (2s, Me2C); 1.33 (s, Me); 3.29 (s, MeN); 3.41 (m, PhCH2); 3.54 (s, CH2O); 3.77 (br s, OH); 
6.89 (br s, NH); 7.12-4.10 (m, 2Ph). 13C NMR: 22.1 (q, Me2C); 24.1 (q, Me); 41.8 (q, MeN); 43.4 
(s, Me2C); 43.7 (t, PhCH2); 70.4 (t, CH2O); 127.1, 128.3, 128.8, 129.5, 130.1 (5d, 10 arom. CH); 
136.1, 144.2 (2s, 2arom. C); 173.0, 177.1 (2s, 2 CO). CI-MS: 369 (30, [M+H]+), 262 (100, [M-
N(Me)Ph]+), 234.2 (20), 160.1 (18), 134.1(36), 107.1 (26). Anal. calcd for C22H28N2O3  (368.48): 
C 71.71, H 7.66, N 7.60; found: C 71.79, H 7.82, N 7.07. 
 
5.3.4. 3-Hydroxy-2-phenyl-N-[1-methyl-1-(N,N-dimethylcarbamoyl)ethyl]propanamide 
(18a). According to GP2, 3-hydroxy-2-phenylpropanoic acid (tropic acid, 332 mg, 2.00 mmol) in 
dry THF (5 mL), 2,2,N,N-tetramethyl-2H-azirin-3-amine (249 mg, 2.1 mmol), 8 h. Yield: 440 mg 
(79%) of 18a. White powder. Mp 160.8-161.3 oC (AcOEt). IR: 3421m, 3296s, 3060m, 2936m, 
1651vs, 1619vs, 1540s, 1491m, 1454w, 1396s, 1271m, 1219m, 1123s, 1068m, 1051m, 913w, 
750m, 702m. 1H NMR: 1.88, 1.94 (2s, Me2C); 3.28 (s, Me2N); 3.87-4.12 (m, CH2); 4.42 (br t, J = 
6.8Hz, CH); 6.98 (s, NH); 7.50-7.62 (m, Ph). 13C NMR: 24.3, 24. 5 (2q, Me2C); 38.0 (q, Me2N); 
56.9 (s, Me2C); 54.7 (d, CH); 64.9 (t, CH2O); 127.7, 128.2, 129.0 (3d, 5 arom. CH); 136.7 (s, 
arom. C); 171.9, 172.6 (2s, 2CO). 1H NMR ((D6)DMSO): 1.38, 1.32 (2s, Me2C);  2.71 (s, Me2N); 
3.42-3.58, 3.60-3.69, 3.87-3.94 (3m, CH, CH2); 4.78 (t, OH); 7.22-7.36 (m, Ph); 8.31 (s, NH). 13C 
NMR ((D6)DMSO): 25.5, 25.8 (2q, Me2C); 37.0 (q, Me2N); 53.9 (s, Me2C); 55.4 (d, CH); 63.2 (t, 
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CH2O); 126.6, 127.7, 128.0 (3d, 5 arom. CH); 138.1 (s, arom. C); 170.2, 171.7 (2s, 2CO). CI-
MS: 279 (80, [M+H]+), 234 (100, [M-NMe2]+), 206 (22), 157 (18), 104 (8). 
 
5.3.5. 3-Hydroxy-2-phenyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-
propanamide (18b). According to GP2, 3-hydroxy-2-phenylpropanoic acid (tropic acid, 332 mg, 
2.00 mmol) in dry THF (5 mL), 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 
mmol), 9 h. Yield: 578 mg (85%) of 18b. White powder. Mp 128.6-129.9 oC (AcOEt). IR: 3298s, 
3274s, 3055m, 2940m, 1673vs, 16124vs, 1545s, 1488m, 1462w, 1394s, 1270m, 1124s, 1099s, 
1060m, 913m, 745m. 1H NMR: 1.76, 1.89 (2s, Me2C); 3.31 (s, MeN); 3.91-4.19 (m, CH2); 4.36-
4.42 (m, CH); 7.05 (s, NH); 7.41-7.55, 7.60-7.87 (2m, 2Ph). 13C NMR: 24.6, 24. 8 (2q, Me2C); 
41.1 (q, MeN); 57.4 (s, Me2C); 55.0 (d, CH); 67.3 (t, CH2O); 127.6, 127.7, 128.2, 128.5, 128.8, 
129.1 (6d, 10 arom. CH); 136.7, 143.8 (2s, 2arom. C); 173.1, 173.9 (2s, 2CO). ESI-MS:  363 
(100, [M+Na]+). 
 
5.3.6. 3-Hydroxy-2-methyl-2-phenyl-N-[1-methyl-(N,N-dimethylcarbamoyl)ethyl]-
propanamide  (21a). According to GP1,  3-hydroxy-2-methyl-2-phenylpropanoic acid  (360 mg, 
2.00 mmol) in dry THF (5 mL),  2,2,N,N-tetramethyl-2H-azirin-3-amine (249 mg, 2.1 mmol), 36 
h, CC (SiO2, acetone/CH2Cl2 1:10). Yield: 455 mg (78%) of 21a. Colorless crystals. Mp 147.6-
148.4 oC (toluene). IR: 3533s, 3280vs, 3054s, 2928vs, 1708vs, 1622vs, 1526vs, 1394s, 1264s, 
1208s, 1118s, 1050m, 976m, 900w, 770m, 751m, 802m. 1H NMR: 1.50 (s, Me2C); 1.61 (s, Me), 
3.00 (s, Me2N); 3.55-3.70, 4.05-4.19 (2m, CH2O); 4.45 (br s, OH); 7.18-7.41 (m, Ph, NH). 13C-
NMR: 21.4 (q, Me2C); 25.0 (q, Me); 37.7 (q, Me2N); 51.5, 56.4 (2s, 2Me2C); 68.7 (t, CH2O); 
126.5, 126.9, 128.3 (3d, 5 arom. CH); 141.5 (s, arom. C); 172.6, 175.3 (2s, 2CO). CI-MS: 293 
(88, [M+H]+), 248 (100, [M-NMe2]+), 113 (28). Anal. calcd for C16H24N2O3 (292.38): C 65.73, H 
8.27, N 9.58; found: C 65.69, H 8.40, N 9.59. 
 
5.3.7. 3-Hydroxy-2-methyl-2-phenyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)-
ethyl]propanamide (21b). According to GP1,  3-hydroxy-2-methyl-2-phenylpropanoic acid  
(360 mg, 2.00 mmol) in dry THF (5 mL) 2-benzyl-2,N-dimethyl-N-phenyl-2H-azirin-3-amine 
(365 mg, 2.1 mmol), 28 h, CC (SiO2, acetone/CH2Cl2 1:20). Yield: 608 mg (86%) of 21b. White 
solid. Mp 132.1-133.0 oC. IR: 3451s, 3282vs, 3057m, 2992s, 1709s, 1635vs, 1592s, 1445s, 
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1395s, 1262m, 1157m, 1123m, 1092s, 1026s, 921m. 1H NMR: 1.30, 1.38 (2s, Me2C); 1.48 (s, 
Me), 3.22 (s, MeN); 3.55-3.61, 4.00-4.10 (2m, CH2O); 4.63 (br s, OH); 6.61 (br s, NH); 7.18-7.41 
(m, 2Ph). 13C NMR: 21.8 (q, Me2C); 25.7 (q, Me); 41.5 (q, MeN); 52.3, 58.8 (2s, 2Me2C); 69.2 (t, 
CH2O); 126.3, 126.6, 126.9, 127.1, 127.2, 128.1, 128.3, 128.4, 128.6,  129.4 (10d, 10 arom. CH); 
141.6, 144.2 (2s, 2arom. C); 173.7, 176.0 (2s, 2CO). ESI-MS: 731 (48, [2M+Na]+), 377 (100, 
[M+Na]+), 248 (16). 
 
5.3.8. 3-Hydroxy-2-benzyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-
propanamide (22). According to GP2, 3-hydroxy-2-benzylpropanoic acid  (360 mg, 2.00 mmol) 
in dry THF (5 mL), 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), 8 h. Yield: 
560 mg (79%) of 22. White powder. Mp 162.4-163.9 oC. IR: 3409m, 3277s, 3060w, 2932m, 
1630vs, 1592s, 1544s, 1493s, 1395s, 1254m, 1188w, 1092s, 1070m, 769m, 743m, 703s, 617m. 
1H NMR: 1.27, 1.33 (2s, Me2C); 2.38-2.42, 2.61-2.73, 2.88-3.01 (3m, CH2, CH); 3.27 (s, MeN); 
3.66-3.73 (m, OH); 6.18 (br s, NH); 7.11-7.41 (m, 2Ph). 13C NMR:  26.2, 27. 0 (2q, Me2C); 34.3 
(t, CH2); 41.5 (q, MeN); 50.8 (d, CH); 59.0 (s, Me2C); 63.6 (t, CH2O); 126.3, 128.2, 128.3, 128.5, 
129.0, 129.4 (6d, 10 arom. CH); 139.3, 144.4 (2s, 2arom. C ); 173.8, 174.0 (2s, 2CO). ESI-MS: 
377 (100, [M+Na]+). Anal. calcd for C16H24N2O3 (354.45): C 65.73, H 8.27, N 9.58; found: C 
60.24, H 9.50, N 10.76. 
 
5.3.9. 3-Hydroxy-2-methyl-N-[1-methyl-1-(N,N-dimethylcarbamoyl)ethyl]propanamide 
(23). According to GP1, 3-hydroxy-2-methylpropanoic acid  (416 mg, 4.00 mmol) in dry THF (5 
mL),  2,2,N,N-tetramethyl-2H-azirin-3-amine (498 mg, 4.2 mmol), 38 h, CC (SiO2, 
acetone/CH2Cl2 1:20). Yield: 790mg (83%) of 23. Colorless crystals. Mp 118.7-120.0 oC. IR: 
3418s, 1619vs, 1540s, 1397s, 1279m, 1226s, 1124s, 1077m, 1036m. 1H NMR: 1.09 (d, J = 6.1 
Hz, Me); 1.58 (s, Me2C); 2.59 (m, CH); 3.06 (s, Me2N); 3.63 (d, CH2); 4.21 (br s, OH); 7.70 (s, 
NH). 13C NMR: 13.7 (q, Me); 25.5, 25. 6 (2q, Me2C); 37.9 (q, MeN); 56.3 (s, Me2C); 42.3 (d, 
CH); 64.8 (t, CH2O); 173.0, 174.9 (2s, 2CO). ESI-MS: 455 (20, [2M+Na]+), 239 (100, [M+Na]+). 
Anal. calcd for C10H20N2O3 (216.28): C 55.53, H 9.32, N 12.95; found: C 55.74, H 9.71, N 13.12. 
 
5.3.10. 2-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]benzamide (30). 
According to GP1,  salicylic  acid  (276 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N-trimethyl-N-
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phenyl-2H-azirin-3-amine (365 mg, 2.1 mmol), CC (SiO2, acetone/CH2Cl2 1:20). Yield: 565mg 
(92%) of 30. Colorless crystals. Mp 146.1-147.8 oC . IR: 3533s, 3280vs, 3054s, 2928vs, 1708vs, 
1622vs, 1526vs, 1394s, 1264s, 1208s, 1118s, 1050m, 976m, 900w, 770m, 751m, 802m. 1H 
NMR: 1.43 (s, Me2C); 3.22 (s, MeN); 6.68-6.74 (m, 1arom. H); 6.76 (br s, NH); 6.92-7.0 (m, 2H 
arom);7.11-7.28 (m, 4arom. H); 7.31-7.42  (m, 2arom. H); 12.1 (s, OH). 13C NMR: 26.4 (q, 
Me2C); 41.4 (q, MeN); 58.4 (s, Me2C); 119.9 (s, arom. C); 126.6, 126.8, 127.3, 127.9, 128.2, 
128.9, 129.3 (7d, 9 arom. CH); 134.1, 142.2 (2s, 2arom. C); 172.9, 177.5 (2s, 2CO). ESI-MS: 335 
(100, [M+Na]+). 
 
5.3.11. (1R,2S)-2-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-
cyclopentanecarbonamide (33a) According to GP1, (1R,2S)-2-hydroxycyclopentanoic acid 
(32a, 260 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (365 
mg, 2.1 mmol), CC (SiO2, acetone/CH2Cl2 1:10). Yield:  530 mg (86%) of 33a. White powder. 
Mp 153.4-155.0 oC. IR: 3289s,  2943s, 1708vs, 1636vs, 1593s, 1494s, 1390s, 1240s, 1092s, 
1028m, 919m, 732s. 1H NMR: 1.42 (s, Me2C); 1.57-1.68, 1.70-1.77, 1.79-1.96 (3m, 3CH2, CH); 
3.27 (s, MeN); 4.35 (m, CHO);  6.38 (br s, NH); 7.24-7.41 (m, Ph, NH). 13C NMR: 21.9 (t, CH2); 
26.1, 26.4 (2q, Me2C); 26.8, 33.9 (2t, 2CH2); 41.4 (q, MeN); 50.2 (d, CH); 58.6 (s, Me2C); 74.2 
(d, CHO); 128.1, 128.3, 129.4 (3d, 5 arom. CH); 144.2 (s, arom. C); 173.4, 176.1 (2s, 2CO). ESI-
MS: 327 (100, [M+Na]+). 
 
5.3.12. (1R,2S)-2-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-
cyclohexanecarbonamide (33b). According to GP1, (1R,2S)-2-hydroxycyclohexanoic acid (32b, 
288 mg, 2.00 mmol) in dry THF (5 mL),  2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (365 mg, 
2.1 mmol), 12 h, CC (SiO2, acetone/CH2Cl2 1:10).Yield: 566 mg (89%) of 33b.White powder. 
Mp 171.2-172.9 oC. IR: 3290s, 3020m, 2948s, 1711vs, 1635vs, 1599s, 1491s, 1421m, 1391s, 
1239s, 1091s, 1022m, 919m, 731s. 1H NMR: 1.37, 1.42 (2s, Me2C); 1.43-1.52, 1.62-1.74, 1.77-
1.83, 1.86-1.95 (4m, 4CH2, CH); 3.21 (s,  MeN); 3.97 (m, CHO);  6.41 (br s, NH); 7.22-7.41 (m, 
Ph, NH). 13C NMR: 19.2, 24.4, 24.9 (3t, 3CH2); 25.9, 26.1 (2q, Me2C); 31.7 (t, CH2); 41.4 (q, 
MeN); 47.9 (d, CH); 59.4 (s, Me2C); 66.7 (d, CHO); 127.9, 128.2, 129.3 (3d, 5 arom. CH); 142.2 
(s, arom. C); 172.1, 177.4 (2s, 2CO). ESI-MS: 341 (100, [M+Na]+). 
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5.4. Preparation of dipeptide esters 
 
5.4.1. tert-Butyl (S)-2-(3-hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoate (13). 
According to GP3, 3-hydroxy-2,2-dimethylpropanoic acid (654 mg, 3 mmol), L-phenylalanine 
tert-butyl ester hydrochloride (774 mg, 3.0 mmol), CC (SiO2, acetone/CH2Cl2 1:30). Yield: 857 g 
(89%) of 13. Colorless solid. Mp 82.7-84.1 oC. [α]25D  = +44.6 (c = 1, CHCl3). IR: 3265vs, 3006s, 
2982vs, 2867s, 1721vs, 1635vs, 1543vs, 1455s, 1392s, 1315s, 1165vs, 1102m, 963s, 850m. 1H 
NMR: 1.09 (s, Me2C); 1.45 (s, Me3C), 3.00-3.17 (m, PhCH2); 3.42-3.51 (m, CH2O); 3.72 (br s, 
OH); 4.63-4.78 (m, CH); 6.94 (br s,  NH); 7.13-7.36 (m, Ph). 13C NMR: 22.3 (q, Me2C); 27.8 (q, 
Me3C); 37.6 (t, CH2); 43.1 (s, Me2C); 53. (d, CH); 69.9 (t, CH2); 82.3 (s, Me3C); 126.9, 128.3, 
129.3 (3d, 5 arom. CH); 136.1 (s, arom. C); 170.8, 177.1 (2s, 2CO). CI-MS: 322 (88, [M+H]+), 
266 (100, [M- tBu)]+). Anal. calc. for C18H27NO4 (321.42): C 67.26, H 8.47, N 4.36; found: C 
67.04, H 8.66, N 4.20. 
 
5.4.2. Methyl  (RS)-2-(3-hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoate (15). 
According to GP3, 3-hydroxy-2,2-dimethylpropanoic acid (654 mg, 3 mmol), DL-phenylalanine 
methyl ester hydrochloride (639 mg, 3.0 mmol), CC (SiO2, acetone/CH2Cl2 1:30). Yield: 673 g 
(80%) of 15. Pale yellow oil. 1H NMR: 1.03 (s, Me2C); 2.98-3.12 (m, PhCH2); 3.36-3.49 (m, 
CH2O); 3.67 (s, MeO);  4.68-74 (m, CH); 6.50 (br s,  NH); 7.13-7.38 (m, Ph). 13C NMR: 22.2 (q, 
Me2C); 37.6 (t, CH2); 43.0 (s, Me2C); 52.2 (d, CH); 52.9 (q, MeO); 69.5 (t, CH2); 127.0, 128.4, 
129.1 (3d, 5 arom. CH); 135.8 (s, arom. C); 172.2, 177.3 (2s, 2CO). CI-MS: 280 (100, [M+H]+), 
162 (18). Anal. calcd for C15H13NO4 (279.34): C 64.50, H 7.58, N 5.01; found: C 64.15, H 7.73, 
N 4.89. 
 
5.4.3. Methyl  (S)-2-(3-hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoate (17). 
According to GP3, 3-hydroxy-2,2-dimethylpropanoic acid (654 mg, 3 mmol), L-phenylalanine 
methyl ester hydrochloride (639mg, 3.0 mmol), CC (SiO2, acetone/CH2Cl2 1:30). Yield: 720 g 
(86%) of 17. Pale yellow oil. 1H NMR: 1.05 (s, Me2C); 3.00-3.09 (m, PhCH2); 3.38-3.48 (m, 
CH2O); 3.69 (s, MeO);  4.71 (t, J = 6.0 Hz, CH); 6.52 (s, NH); 7.14-7.36 (m, Ph). 13C NMR: 22.3 
(q, Me2C); 37.7 (t, CH2); 43.0 (s, Me2C); 52.1 (d, CH); 53.0 (q, MeO); 69.6 (t, CH2); 127.0, 
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128.4, 129.1 (3d, 5 arom. CH); 135.9 (s, arom. C); 172.3, 177.5 (2s, 2CO). CI-MS: 280 (100, 
[M+H]+), 162 (18). 
 
5.4.4. tert-Butyl (R,S)-2-(3-Hydroxy-2-phenylpropanoylamino)-3-phenylpropanoate (20). 
According to GP3, tropic acid (498 mg, 3 mmol), L-phenylalanine tert-butyl ester hydrochloride 
(774 mg, 3.0 mmol), CC (SiO2, acetone/CH2Cl2 1:30). Yield: 974 mg (88%) of 20. Pale yellow 
crystals. Mp 117.4-119.1 oC. IR: 3426s, 3290s, 3059m, 1738vs, 1658vs, 1635s, 1551m, 1454m, 
1368s, 1223s, 1154vs, 1059m, 1023m, 845m, 740m, 701s. 1H NMR ((D6)DMSO): 1.28, 1.31 (2s, 
Me3C); 2.91-3.10 (m, PhCH2); 3.50-3.62, 3.69-3.80 (2m, CH2O); 4.00-4.16,  4.60-4.78 (2m, 
2CH); 5.81-6.00 (m, OH); 6.73 (d, J = 3.7 Hz,  NH); 6.93-7.27 (m, 2Ph). 13C NMR: 27.8, 27.9 
(2q, Me3C); 37.7 (t, CH2); 53.1, 53.5, 54.3, 54.4 (4d, 2CH); 64.7, 64.8 (t, CH2O); 81.8 (s, Me3C); 
127.7, 128.2, 128.3, 128.4, 129.0, 129.3 (6d, 10 arom. CH); 136.1, 136.8 (2s, 2arom. C); 171.0, 
173.2 (2s, 2 CO). CI-MS: 370 (85, [M+H]+), 313(100, [M – tBu)]+). 
 
5.5. Saponification of dipeptide amides 
 
5.5.1. (RS)-2-(3-Hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoic acid (rac-16). 
According to GP4, from 13 (642 mg, 2.0 mmol). Yield 454 mg (79%) of 13. White solid. Mp 
91.3-94.9 oC. 1H NMR: 0.99, 1.02 (2s, Me2C); 2.96-3.02, 3.08-3.14 (2m, PhCH2); 3.21-3.41 (m, 
CH2O);  4.66-4.78 (m, CH); 6.95 (br s, NH); 6.98-7.18 (m, Ph). 13C NMR: 22.0 (q, Me2C); 37.0 
(t, CH2); 43.3 (s, Me2C); 53.1 (d, CH); 69.3 (t, CH2);  127.0, 128.4, 129.3 (3d, 5 arom. CH); 
135.8 (s, arom. C);  174.0, 178.1 (2s, 2CO). ESI-MS: 288 (100, [M+H]+). 
 
5.5.2. (S)-2-(3-Hydroxy-2,2-dimethylpropanoylamino)-3-phenylpropanoic acid ((S)-16). 
According to GP4, from 17 (558 mg, 2.0 mmol). Yield: 442 mg (79%) of (S)-16. Colorless oil, 
[α]25D = +44.1 (c = 1, CHCl3). IR: 3369vs, 3192s, 2963s, 1723vs, 1643vs, 1529vs, 1455s, 1394m, 
1287m, 1254s, 1179m, 1111w, 1049s, 913w, 699s. 1H NMR: 0.99, 1.01 (2s, Me2C); 2.88-2.94, 
3.02-3.14 (2m, PhCH2); 3.38 (m, CH2O); 4.71-4.83 (m, CH); 6.71 (br s, NH); 6.98-7.18 (m, Ph). 
13C NMR: 21.1 (q, Me2C); 36.1 (t, CH2); 42.4 (s, Me2C); 52.2 (d, CH); 68.5 (t, CH2); 126.1, 
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127.6, 128.4 (3d, 5 arom. CH); 134.9 (s, arom. C);  173.2, 177.2 (2s, 2CO). ESI-MS: 288  (100, 
[M+Na]+). 
 
5.6.Solvolysis of dipeptide amides under DAC conditions 
 
5.6.1. Ethyl 2-(3-hydroxy-2-phenylpropanoylamino)-2-methylpropanoate (19). According to 
GP9, 18 (278 mg, 1 mmol) in  toluene/EtOH 80/20 (60 mL), CC (AcOEt/hexane 1:10). Yield: 
209 mg (76%) of 19. Colorless oil. IR: 3237vs, 3068s, 2980s, 1734vs, 1642vs, 1557s, 1475s, 
1383m, 1288s, 1164s, 1070m, 1037s, 872w, 751m, 699s. 1H NMR: 1.10 (t, J = 6.1 Hz, Me); 1.42 
(s, Me2C); 3.50-3.60, 3.63-3.72 (2m, CH2); 3.91-4.13 (m, CH, CH2); 6.02 (s, OH); 7.11-7.29 (m, 
Ph, NH). 13C NMR:  13.9 (q, Me); 24. 5 (q, Me2C); 54.4 (d, CH); 56.6 (s, Me2C); 61.5 (t, CH2); 
65.1 (t, CH2O); 127.7, 128.3, 129.0 (3d, 5 arom. CH); 136.5 (s, arom. C); 172.8, 174.2 (2s, 2CO). 
ESI-MS: 280 (100, [M+H]+).  
 
5.6.2. Methyl 2-methyl-2-(2-phenylacryloylamino)propanoate (26). According to GP10, 18 
(139 mg, 0.5 mmol) in  toluene (30 mL), CC ( AcOEt/hexane 1:10). Yield: 72 mg (58%) of 26. 
White crystals. Mp 116.8-117.4 oC. IR: 3328m, 3068m, 2960vs, 2861s, 1727vs, 1657s, 1533s, 
1460s, 1382m, 1276vs, 1139s, 1073s, 944w, 731m. 1H NMR: 1.56 (s, Me2C); 3.77 (s, MeO); 
5.60, 6.10 (2s, H2C=); 6.28 (br s, NH); 7.30-7.42 (m, Ph). 13C NMR: 24.6 (q, Me2C); 52.6 (s, 
MeO); 56.7 (s, Me2C); 121.7 (t, H2C=); 127.9, 128.6, 128.9 (3d, 5 arom. CH); 136.8 (s, C=CH2); 
144.7 (s, arom. C); 166.6, 174.7 (2s, 2CO). CI-MS: 265(6, [M+NH4]+), 249 (14), 248 (100, 
[M+H]+). 
 
5.6.3. Methyl  2-(2-benzyl-3-hydroxypropanoylamino)-2-methylpropanoate (27). According 
to GP9, 22 (188 mg, 0.5 mmol) in toluene/MeOH 80/20 (30 mL), CC (AcOEt/hexane 1:10). 
Yield: 81 mg (58%) of 22. Colorless oil. 1H NMR: 1.41, 1.44 (2s, Me2C); 2.59 (m, CH); 2.82 (m, 
CH2); 3.51, (br s, OH); 3.71 (m, MeO, CH2); 6.50 (s, NH); 7.11-7.31 (m, Ph). 13C NMR: 26.3 (q, 
Me2C); 35.2 (t, CH2); 48.4 (s, MeO); 51.1 (d, CH); 55.1 (s, Me2C); 66.0 (t, CH2); 126.6, 128.4, 
128.9 (3d, 5 arom. CH); 138.0 (s, arom. C); 170.9, 172.9 (2s, 2CO). CI-MS: 281 (16), 280 (100, 
[M+H]+). 
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5.7.Attempted cyclization reactions 
 
5.7.1. Direct Amide Cyclisation 
 
5.7.1.1. 8,8,19,19-Tetramethyl-10,21-dioxa-6,17-diazadispiro[4.6.4.6]docosane-7,11,18,22-
tetraone (10). According to GP5,  9 (256 mg, 1 mmol) in  dry toluene (50 mL) for 15 min. Yield:  
186 mg (88%) of 10. White powder. Mp 344.8-346.4 oC (decomp). IR: 3386vs, 3029w, 2989s, 
2936s, 1715vs, 1668vs, 1519vs, 1470m, 1268vs, 1190m, 1126vs, 1012m, 804w, 699s. 1H NMR 
((D7)DMF): 1.00 (s, 2Me2C ); 1.46-1.54 (m, 4CH2); 1.75-1.82, 1.88-1.94 (2m, 4CH2);  3.94 (s, 
2CH2O); 7.69 (s, 2NH). 13C NMR ((D7)DMF): 22.8 (q, 2Me2C ); 24.7, 36.1 (2t, 8CH2);  41.3, 
65.2 (2s, Me2C, 2C);  70.8 (t, 2CH2O); 173.9 174.5 (2s, 4CO). CI-MS: 441 (21), 440 (90, 
[M+Na]+), 423 (100, [M+H]+). Anal. calcd for C22H34N2O6 (422.53): C 62.54, H 8.11, N 6.63; 
found: C 61.89, H 8.07, N 6.56. 
Recrystallization from DMF/toluene/ethyl acetate yielded crystals of 10, suitable for an X-ray 
crystal structure determination. 
 
5.7.1.2. 3,10-Dibenzyl-3,6,6,10,13,13-hexamethyl-1,8-dioxa-4,11-diazacyclotetradecane-
2,5,9,12-tetraone (12). According to GP 5,  11 (368 mg, 1 mmol) in  dry toluene (50 mL), for 15 
min. Yield:  177 mg (34%) of 12. White solid. Mp 288.1-290.5 oC (decomp). IR: 3520m, 3460vs, 
3057w, 2970s, 1744vs, 1660vs, 1527vs, 1483s, 1364s, 1260s, 1236m, 1121vs, 1020w, 719m, 
701s. 1H NMR : 1.11, 1.25, 1.46 (3s, 6Me); 3.28-3.38 (m, 2PhCH2); 4.09 (s, 2CH2O); 7.07 (s, 
2NH); 7.21-7.31 (m, 10 arom. H). 13C-NMR: 21.3, 21.8 (2q, 2Me2C); 28.7 (q, 2Me); 39.7 (s, 
2Me2C); 41.3 (t,  2CH2 ); 58.4 (s, 2C); 70.2 (t, 2CH2O); 126.1, 127.3, 129.6 (3d, 10 arom. CH); 
135.0 (s, 2arom. C); 171.7, 173.2 (2s, 4CO). ESI-MS: 545 (100, [M+Na]+). 
Recrystallization from DMF/benzene/CH2Cl2/hexane/i-PrOH yielded crystals of 12, suitable for 
an X-ray crystal structure determination. 
 
5.7.1.3. 3,6,6,10,13,13-Hexamethyl-3,10-diphenyl-1,8-dioxa-4,11-diazacyclotetradecane-
2,5,9,12-tetraone (24). According to GP6,  21a (292 mg, 1 mmol) in  dry toluene (50 mL), 15 
min, (SiO2, acetone/ CH2Cl2 1:60). Yield: 75 mg (30%) of 24. White solid. Mp 251.6-253.1 oC 
(decomp). IR: 3526m, 3435vs, 3023w, 2987s, 1736vs, 1665vs, 1519vs, 1384s, 1276s, 1142vs, 
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1081w, 998s, 770m, 699s. 1H NMR: 1.30, 1.51, 1.60  (3s, 6Me ); 4.41-4.61 (m, 2CH2O); 7.07 (s, 
2NH); 7.28-7.42 (m, 10 arom. H). 13C-NMR: 22.6, 24.5 (2q, 2Me2C ); 25.7 (q, 2Me); 50.6 (s, 
2Me2C);  56.1 (s, 2C); 70.0 (t, 2CH2O); 126.4, 127.7, 128.9 (3d, 10 arom. CH); 141.0 (s, 2arom. 
C); 172.9 173.5 (2s, 4CO). CI-MS: 513 (32), 512 (100, [M+NH4]+), 495  (28, [M+H]+). 
Recrystallization from toluene/MeCN/acetone yielded crystals of 24, suitable for an X-ray crystal 
structure determination. 
 
5.7.1.4. Reaction of 22 under DAC conditions. A suspension of 22 (188 mg, 0.5 mmol) in  
toluene (30 mL) was heated to 100 oC, and dry HCl gas was bubbled through the suspension for 
20 min (IR monitoring). Then, the mixture was allowed to cool to rt while bubbling N2 through it 
(ca. 20 min), MeOH was added to the solution and stirred at rt for 1 h. The solvent was 
evaporated, the oily residue was purified by CC (AcOEt/hexane 1:10) yielding 27 (13 mg, 9%), 
28 (28 mg, 21%) and 29 (36 mg, 30%). 
 
5.7.1.4.1. Methyl 2-(2-benzylacryloylamino)-2-methylpropanoate (28). Colorless oil. IR: 
3332m, 3069m, 2954vs, 2861s, 1727vs, 1661s, 1537s, 1454s, 1364m, 1282vs, 1241s, 1144s, 
1073s, 1026m, 931w, 731m, 701m. 1H NMR: 1.46, 1.49 (2s, Me2C); 3.61 (s, CH2); 3.71 (s, 
MeO); 5.22, 5.79 (2s, H2C=); 6.32 (br s, NH); 7.14-7.32 (m, Ph). 13C NMR: 24.5 (q, Me2C); 38.5 
(t, CH2); 52.4 (s, MeO); 56.4 (s, Me2C); 119.6 (t, H2C=); 126.4, 128.4, 128.8 (3d, 5 arom. CH); 
138.2 (s, arom. C); 144.4 (s, C=CH2); 167.3, 174.8 (2s, 2CO). CI-MS: 263 (18), 262 (100, 
[M+H]+). 
 
5.7.1.4.2. 2-Benzyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]acrylamide (29). 
White solid. Mp 119.1-121.6 oC. IR: 3282s, 3060w, 2932m, 1634vs, 1598s, 1541s, 1481s, 
1421m, 1390s, 1254m, 1172w, 1090s, 1079m, 769m, 703s. 1H NMR: 1.41 (s, Me2C); 3.20 (s, 
MeN); 3.46 (s, CH2); 5.10, 5.53 (2s, H2C=); 6.18 (br s, NH); 7.09-7.39 (m, 2Ph). 13C NMR: 26.1 
(q, Me2C); 38.4 (t, CH2); 41.3 (q, MeN); 58.1 (s, Me2C); 120.0 (t, H2C=); 126.5, 127.8, 128.1, 
128.6, 129.0, 129.4 (6d, 10 arom. CH); 138.4, 143.4 (2s, 2arom. C); 144.4 (s, C=CH2); 166.5, 
173.1 (2s, 2CO). CI-MS: 237 (52, [M+H]+), 230 (100, [M-N(Me)Ph]+), 108 (18). 
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5.7.1.5. 2-(2-Hydroxyphenyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (31). According to GP6, 30 
(156 mg, 0.5 mmol) in  dry toluene (50 mL), 5 min (SiO2, acetone/CH2Cl2 1:40). Yield: 73 mg 
(74%) of 31. Colorless crystals. Mp. 68.2-69.0 oC. IR: 3079m,  2977s, 1823vs, 1643vs, 1615vs, 
1579s, 1478s, 1320vs, 1251s, 1206s,  1090s, 1016s, 915s, 735s. 1H NMR: 1.55 (s, Me2C); 6.84-
7.08, 7.41-7.49, 7.68-7.73 (3m, 4arom. H). 13C NMR: 24.8 (q, Me2C); 64.5 (s, Me2C); 108.8 (s, 
arom. C); 117.2, 119.3, 128.2, 134.5 (d, 4 arom. CH); 160.0 (s, C=N); 161.8 (s, arom. C); 178.6 
(s, CO). CI-MS: 206 (100, [M+NH4]+). Recrystallization from CDCl3/CH2Cl2 yielded crystals of 
31, suitable for an X-ray crystal structure determination. 
 
5.7.1.6. Reaction of 33a under DAC conditions. According to GP6, 33a  (152 mg, 0.5 mmol) in  
dry toluene (50 mL), 6 min, CC (SiO2, acetone/CH2Cl2 1:10). Yield:  51 mg (34%) of 35a and 30 
mg (28%) of 34a. 
 
5.7.1.6.1. N-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]cyclopent-1-enecarboxamide 
(35a). White solid. Mp 109.6-111.1 oC. 1H NMR: 1.53 (s, Me2C); 1.84-1.95, 2.22-2.26, 2.37-2.44 
(3m, 3 CH2); 3.26 (s,  Me2N); 5.81 (m, CH=);  6.43 (br s, NH); 7.20-7.23, 7.29-7.34 (m, Ph). 13C 
NMR: 23.4 (t, CH2); 26.6 (q, Me2C); 31.0, 31.1, 32.8 (3t, 3CH2); 41.3 (q, MeN); 57.7 (s, Me2C); 
117.9 (s, C=); 127.6, 127.8, 129.1 (d, 5 arom. CH); 139.4 (d, CH=); 144.5 (s, arom. C); 169.0, 
173.1 (2s, 2CO). ESI-MS: 202 (100, [M+Na]+). 
 
5.7.1.6.2. 2-(2-Hydroxycyclopentyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (34a). White solid. 
M.p. 98.0-102.1 oC (decomp). IR: 3080w, 2980m, 1822vs, 1642s, 1597s, 1472m, 1382w, 1216m, 
1095s, 1018m, 916s. 1H NMR: 1.56 (s, Me2C); 1.54-1.75, 1.79-1.98 (2m, 3 CH2, CH); 4.41 (m, 
CHO). 13C NMR: 22.4 (t, CH2); 25.4, 25.8 (2q, Me2C); 27.8, 31.1 (3t, 3CH2); 54.4 (d, CH); 62.3 
(s, Me2C); 76.1 (d, CHO); 162.5 (s, C=N); 173.1 (s, CO). CI-MS: 229 (100, [M+NH4]+). 
 
5.7.1.7. Reaction of 33b under DAC conditions. According to GP6, 33b (158 mg, 0.5 mmol) in  
dry toluene (50 mL), 6 min, CC (SiO2, acetone/CH2Cl2 1:10). Yield:  51 mg (34%) of 35b and 31 
mg (31%) of 34b. 
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5.7.1.7.1. N-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]cyclohex-1-enecarboxamide 
(35b). White crystals. Mp 112.1-113.8 oC. 1H NMR: 1.46 (s, Me2C); 1.52-1.62, 1.84-1.96, 2.01-
2.14 (3m, 4CH2); 3.26 (s, MeN); 5.85 (m, CH=); 6.53 (br s, NH); 7.18-7.20, 7.30-7.36 (m, Ph). 
13C NMR: 21.4, 21.9, 23.8, 25.2 (4t, 4CH2); 26.6 (q, Me2C); 41.3 (q, MeN); 57.6 (s, Me2C); 117.1 
(s, CH=); 127.7, 129.1, 129.3 (3d, 5arom. CH); 133.9 (d, CH=); 144.5 (s, arom. C); 169.6, 173.2 
(2s, 2CO). ESI-MS: 323 (100, [M+Na]+). 
 
5.7.1.7.2. 2-(2-Hydroxycyclohexyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (34b). White solid. Mp 
101.1-105.2 oC (decomp). IR: 3288w, 3017m, 29619m, 1824vs, 1638s, 1595s, 1490m, 1421m, 
1380m, 1092s, 917s. 1H NMR: 1.39, 1.43 (2s, Me2C); 1.44-1.56, 1.64-1.89, 1.90-1.98 (3m, 
4CH2); 4.01 (m, CHO). 13C NMR: 19.8, 24.9, 26.6 (3t, 3CH2); 26.0, 26.1 (q, Me2C); 31.9 (t, 
CH2); 49.0 (d, CH); 64.0 (s, Me2C); 66.9 (d, CHO); 163.1 (s, C=N);  176.8 (s, CO). CI-MS: 215 
(100, [M+NH4]+). 
 
5.7.2. Other cyclizations 
 
5.7.2.1. trans-3,10-Dibenzyl-6,6,13,13-tetramethyl-1,8-dioxa-4,11-diazacyclotetradecane-
2,5,9,12-tetraone (trans-14). According to GP7, 15 (321 mg, 1 mmol) or 13  (279 mg, 1 mmol). 
Yield of  trans-14:  108 mg (44%) (from 13) and 60 mg (24%) (from 15), respectively. Colorless 
crystals. M.p. 232.9-234.6 oC (decomp). [α]25D  = 0 (c = 1, CHCl3). IR: 3374vs, 3024w, 2966m, 
1732vs, 1645vs, 1531s, 1366m, 1282s, 1179s, 1108w, 1001m, 751m, 700m. 1H NMR: 0.90, 0.98 
(2s, Me2C); 3.06 (d, J = 5.8 Hz, CH2); 3.91-3.96 (m, CH2); 4.80-4.84 (m, CH); 5.89 (d, J = 3.9 
Hz, NH); 6.97-6.99 (m, 6arom. H); 7.10-7.25 (m, 4arom. H). 13C NMR: 21.6, 22.7 (2q, Me2C); 
37.6 (t, 2CH2); 42.2 (s, 2C); 52.5 (d, 2CH); 70.9 (t, 2CH2O); 127.2, 128.6, 129.3 (3d, 10 arom. 
CH); 135.7 (s, 2arom. C); 170.0, 174.0 (2s, 4CO). ESI-MS: 517 (100, [M+Na]+), 444 (11). CI-
MS: 513 (30), 512 (100, [M+NH4]+), 496 (12), 495 (30, [M+H]+). Anal. calcd for C28H34N2O6 
(494.59): C 68.00, H 6.93, N 5.66; found: C 67.69, H 7.08, N 5.48. 
Recrystallization from i-PrOH/CH2Cl2/hexane yielded crystals of trans-14, suitable for an X-ray 
crystal structure determination. 
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According to GP8, rac-16  (287 mg, 1 mmol), CC (CH2Cl2/acetone 200:1) yielded  trans-14 as 
white crystals in 25% yield (62 mg). [α]25D  = 0 (c = 1, CHCl3). 
 
5.7.2.2. cis-(S,S)-3,10-Dibenzyl-6,6,13,13-tetramethyl-1,8-dioxa-4,11-diaza-cyclotetradecane-
2,5,9,12-tetraone ((S,S)-14). According to GP8, (S)-16 (1 mmol, 287 mg), CC (CH2Cl2/acetone 
200:1). Yield 54 mg (22%) of (S,S)-14b. Mp 212.1-214.4 oC (decomp). [α]25D  = -26.3 (c = 1, 
CHCl3). 1H NMR: 0.88, 1.08 (2s, 2Me2C); 3.13 (s, 2CH2O); 3.91-4.04, 4.11-4.22 (2m, 2CH2); 
4.83-5.00 (m, 2CH); 5.83 (br s, 2NH); 7.03-7.14, 7.28-7.42 (2m, 2Ph). 13C-NMR: 21.5, 22.7 (2q, 
2Me2C); 37.6 (t, 2CH2); 42.1 (s, 2C); 53.3 (d, 2CH); 71.0 (t, 2CH2); 127.3, 128.7, 129.4 (3d, 10 
arom. CH); 136.1 (s, 2arom. C); 169.7, 174.3 (2s, 4CO). ESI-MS: 517 (100, [M+Na]+), 444 (11). 
Recrystallization from CH2Cl2/sec-BuOH yielded crystals of (S,S)-14, suitable for an X-ray 
crystal structure determination. 
 
5.8. X-Ray crystal structure determination of 10, 11a, 12, trans-14, (S,S)-14, 24 and 31 
 
All measurements were made on a Nonius KappaCCD area-detector diffractometer34 using 
graphite-monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 
700 cooler. The data collection and refinement parameters are given below35 and views of the 
molecules are shown in Figures 1-3. Data reduction was performed with HKL Denzo and 
Scalepack.36 The intensities were corrected for Lorentz and polarization effects, but not for 
absorption. Equivalent reflections were merged. Each structure was solved by direct methods 
using SIR92,37 which revealed the positions of all non-hydrogen atoms. 
In the case of 10, 12, trans-14 and 24, the molecule sits about a crystallographic centre of 
inversion.  
In the case of (S,S)-14, there are two symmetry-independent molecules in the asymmetric unit.  
The atomic coordinates of the two molecules were tested carefully for a relationship from a 
higher symmetry space group using the program PLATON,38 but none could be found.  The 
crystal is merohedrally twinned.  Successful refinement of the structure was achieved using the 
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twin operator [1 0 0 / 0 -1 0 / 0 0 -1] and the major twin domain has a volume fraction of 
0.640(1). 
The non-hydrogen atoms were refined anisotropically.  Any amide or hydroxy H-atoms in the 
structures were placed in the positions indicated by a difference electron density map and their 
positions were allowed to refine together with inividual isotropic displacement parameters.  All 
remaining H-atoms were placed in geometrically calculated positions and refined using a riding 
model where each H-atom was assigned a fixed isotropic displacement parameter with a value 
equal to 1.2Ueq of its parent C-atom (1.5Ueq for the methyl groups). Except for 11a, the 
refinement of each structure was carried out on F2 by using full-matrix least-squares procedures, 
which minimised the function Σw(Fo2 – Fc2)2. The refinement of the structure of 11a was carried 
out on F by minimizing the corresponding function based of F. Corrections for secondary 
extinction were applied.  
 
Neutral atom scattering factors for non-hydrogen atoms were taken from Ref. 39, and the 
scattering factors for H-atoms were taken from Ref. 40. Anomalous dispersion effects were 
included in Fc,41 the values for f ' and f " were those of Ref. 42.  The values of the mass 
attenuation coefficients are those of Ref. 43. All calculations were performed using the 
SHELXL97 program44  with the exception of 11a, where the teXsan crystallographic software 
package45 was used. 
 
Crystal data for 10. C22H34N2O6, M = 422.52, colorless, plate, crystal dimensions 0.05 × 0.12 × 
0.30 mm, triclinic, space group P
_
1, Z = 1, reflections for cell determination 2354, 2θ range for 
cell determination 4 – 55°, a = 6.0630(5) Å, b = 9.5495(6) Å, c = 10.7064(9) Å, α = 66.451(3)°, 
β = 83.228(4)°,  γ  = 71.733(5)°, V = 539.61(7) Å3 , T = 160 K, Dx = 1.300 g cm-3, µ(MoKα) = 
0.0941 mm-1, 2θ (max) = 55°, total reflections measured = 11110, symmetry independent 
reflections = 2457, reflections with I > 2σ (I) = 1919, reflections used in refinement = 2455, 
parameters refined = 143, R(F)  [I > 2σ (I) reflections] = 0.0473, wR(F2)  [all data] = 0.1277 (w = 
[σ 2(Fo2) + (0.0624P)2 + 0.093P]-1 where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.059, 
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secondary extinction coefficient = 0.09(2), final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.30; 
-0.28e Å-3. 
 
Crystal data for 11a. C17H26N2O3, M = 306.40, colorless, prism, crystal dimensions 0.15 × 0.15 
× 0.25 mm, monoclinic, space group P21/n, Z = 4, reflections for cell determination 4110, 2θ 
range for cell determination 4 – 55°, a = 8.1009(1) Å, b = 17.1770(3) Å, c = 12.6459(2) Å, β = 
101.112(1)°, V = 1726.67(5) Å3 , T = 160 K, Dx = 1.179 g cm-3, µ(MoKα) = 0.0806 mm-1, 2θ 
(max) = 55°, total reflections measured = 37684, symmetry independent reflections = 3973, 
reflections used in refinement [I > 2σ (I)] = 2947, parameters refined = 208, R(F) = 0.0469, 
wR(F) = 0.0469 (w = [σ 2(Fo) + (0.005Fo)2]-1, goodness of fit = 2.962, secondary extinction 
coefficient = 3.3(5) × 10-6, final ∆ max /σ = 0.0005, ∆ρ (max; min) = 0.39; -0.27e Å-3. 
 
Crystal data for 12. C30H38N2O6, M = 522.64, colorless, tablet, crystal dimensions 0.05 × 0.10 × 
0.20 mm, monoclinic, space group P21/n, Z = 2, reflections for cell determination 2439, 2θ range 
for cell determination 4 – 50°, a = 6.0109(2) Å, b = 17.3238(5) Å, c = 12.9060(5) Å, β = 
91.855(2) °, V = 1343.22(8) Å3 , T = 160 K, Dx = 1.292 g cm-3, µ(MoKα) = 0.0896 mm-1, 2θ 
(max) = 50°, total reflections measured = 17323, symmetry independent reflections = 2359, 
reflections with I > 2σ (I) = 1731, reflections used in refinement = 2358, parameters refined = 
180, R(F)  [I > 2σ (I) reflections] = 0.0540, wR(F2)  [all data] = 0.1283 (w = [σ 2(Fo2) + 
(0.0395P)2 + 0.6836P]-1 where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.129, secondary 
extinction coefficient = 0.013(2), final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.35; -0.18e Å-3. 
 
Crystal data for trans-14. C28H34N2O6, M = 494.58, colorless, needle, crystal dimensions 0.05 × 
0.05 × 0.25 mm, monoclinic, space group C2/c, Z = 4, reflections for cell determination 2421, 2θ 
range for cell determination 4 – 50°, a = 18.6829(6) Å, b = 14.5471(5) Å, c = 10.0381(3) Å, β = 
104.943(2)°, V = 2635.9(2) Å3 , T = 160 K, Dx = 1.246 g cm-3, µ(MoKα) = 0.0875 mm-1, 2θ (max) 
= 50°, total reflections measured = 18709, symmetry independent reflections = 2333, reflections 
with I > 2σ (I) = 1579, reflections used in refinement = 2333, parameters refined = 170, R(F)  [I > 
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2σ (I) reflections] = 0.0456, wR(F2)  [all data] = 0.1156 (w = [σ 2(Fo2) + (0.041P)2 + 1.0127P]-1 
where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.040, secondary extinction coefficient = 0.0040(7), 
final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.18; -0.17e Å-3. 
 
Crystal data for (S,S)-14. C28H34N2O6, M = 494.58, colorless, prism, crystal dimensions 0.13 × 
0.13 × 0.30 mm, monoclinic, space group P21, Z = 4, reflections for cell determination 7591, 2θ 
range for cell determination 4 – 60°, a = 5.4181(2) Å, b = 35.569(1) Å, c = 13.3108(4) Å,  β = 
90.090(1)°, V = 2565.2(2) Å3 , T = 160 K, Dx = 1.281 g cm-3, µ(MoKα) = 0.0899 mm-1, 2θ (max) 
= 60°, total reflections measured = 52489, symmetry independent reflections = 7611, reflections 
with I > 2σ (I) = 5073, reflections used in refinement = 7606, parameters refined = 675, R(F)  [I > 
2σ (I) reflections] = 0.0446, wR(F2)  [all data] = 0.0899 (w = [σ 2(Fo2) + (0.036P)2]-1 where P = 
(Fo2 + 2Fc2) / 3), goodness of fit = 1.025, secondary extinction coefficient = 0.012(1), final ∆ max 
/σ = 0.001, ∆ρ (max; min) = 0.23; -0.21e Å-3. 
 
Crystal data for 24. C28H34N2O6, M = 494.58, colorless, prism, crystal dimensions 0.22 × 0.25 × 
0.32 mm, triclinic, space group P
_
1, Z = 1, reflections for cell determination 2078, 2θ range for 
cell determination 4 – 50°, a = 5.9467(3) Å, b = 10.1233(5) Å, c = 10.9664(5) Å, α = 73.363(3)°, 
β = 83.818(3)°, γ  = 76.704(3)°, V = 614.97(5) Å3 , T = 160 K, Dx = 1.335 g cm-3, µ(MoKα) = 
0.0938 mm-1, 2θ (max) = 50°, total reflections measured = 8138, symmetry independent 
reflections = 2137, reflections with I > 2σ (I) = 1796, reflections used in refinement = 2136, 
parameters refined = 171, R(F)  [I > 2σ (I) reflections] = 0.0390, wR(F2)  [all data] = 0.1010 (w = 
[σ 2(Fo2) + (0.043P)2 + 0.2587P]1 where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.067, secondary 
extinction coefficient = 0.052(9), final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.18; -0.25e Å-3. 
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Crystal data for 31. C11H11NO3, M = 205.21, colorless, prism, crystal dimensions 0.10 × 0.17 × 
0.30 mm, monoclinic, space group P21/n, Z = 4, reflections for cell determination 2470, 2θ range 
for cell determination 4 – 55°, a = 5.6230(2) Å, b = 8.9884(4) Å, c = 20.2034(8) Å, β = 
93.985(3)°, V = 1018.65(7) Å3 , T = 160 K, Dx = 1.338 g cm-3, µ(MoKα) = 0.0982 mm-1, 2θ (max) 
= 55°, total reflections measured = 21205, symmetry independent reflections = 2333, reflections 
with I > 2σ (I) = 1834, reflections used in refinement = 2331, parameters refined = 143, R(F)  [I > 
2σ (I) reflections] = 0.0517, wR(F2)  [all data] = 0.1359 (w = [σ 2(Fo2) + (0.0581P)2 + 0.2986P]-1 
where P = (Fo2 + 2Fc2) / 3), goodness of fit = 1.107, secondary extinction coefficient = 0.032(6), 
final ∆ max /σ = 0.001, ∆ρ (max; min) = 0.21; -0.22e Å-3. 
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Chapter 3 
 
Reaction of  γ-Hydroxy-N-[1-(dimethylcarbamoyl)ethyl] 
butanamides under the ‘Direct Amide Cyclization’ Conditions 1) 
 
 
The preparation of the title compounds was achieved via the ‘azirine/oxazolone method’ starting 
from the corresponding γ-hydroxy acids. Upon subjecting  the γ-hydroxy-N-[1-
(dimethylcarbamoyl)ethyl]butanamides 4 to the ‘Direct Amide Cyclization’ (DAC) conditions, 
chlorinated acids 11 or imino lactones 12 were obtained as the sole products instead of the 
expected cyclodepsipeptides A or their cyclodimers (Scheme 4). Variation of the substituents in 4 
did not affect the outcome of the reaction and a mechanism for the formation of both products 
from the intermediate oxazolone 13 has been proposed. Under the acidic conditions of the DAC, 
the imino lactones are formed as their HCl salts 12, which, in polar solvents or on silicagel, react 
further to give the chlorinated acids 11. Stabilization of the imino lactones was achieved by 
increasing the substitution in the five membered ring and their structure, in the form of the 
hydrochlorides, was proven independently by X-ray crystallography (Fig. 4). A derivative 15 of 
the imino lactone 12a was prepared by the reaction with the 2H-azirin-3-amine 10a; its structure 
was also established by an X-ray crystal-structure determination (Fig. 3). Furthermore, the 
structures of the ω-chloro acids 11a and 11b were determined by X-ray crystallography (Fig. 2). 
                                                  
1)  B. Iliev, A. Linden, H. Heimgartner, Helv. Chim. Acta, submitted. 
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1. Introduction 
 
Cyclic depsipeptides, i.e. heterodetic cyclopeptides which contain ester (depside) bonds as part of 
their backbone, have been found in many natural products, and show a wide spectrum of 
biological activity [1]. They are therefore sought after as promising lead compounds for drug 
design and discovery. Nature is a rich source of fascinating cyclodepsipeptides, and although the 
significance of incorporating a depside bond is still not clear, it appears to be essential for 
biological activity, since all-amide analogues are often inactive [2]. The depside bond is 
recognized as being more difficult to incorporate into the backbone than the amide bond, 
although macrolactonizations have been studied extensively [2-6], and is therefore usually pre-
formed in the linear precursor prior to the cyclization via amide bond formation to give cyclic 
depsipeptides. 
The most-well-known structures in this class of natural products belong to the ion-selective 
antibiotics, such as valinomycin [7], the closely related enniatin family [8], the actinomycins [9], 
and others. The reduction in the conformational freedom brought about by cyclization often 
results in higher receptor binding affinity. Frequently in these cyclic compounds, extra 
conformational restrictions are also built in, such as D-amino acids, N-alkylated-amino acids or 
α,α-disubstituted amino acids.  
A very efficient method for the incorporation of the latter into depsipeptide rings, the so called 
‘direct amide cyclization’ (DAC), has been developed in our research group in recent years. It has 
been used successfully for the synthesis of 6-, 9-, 12- and 15-membered cyclodepsipeptides from 
α-hydroxy acids [10-12], as well as larger ring systems from α- and β-hydroxy acids [13-15]. 
Therefore, we were interested to investigate reactions of depsipeptides containing β-, γ- and δ-
hydroxy acids and an α-amino acid with the aim of synthesizing 7- to 9-membered analogues. As 
we reported earlier, the cyclization of β-hydroxy acid amides 1, the linear precursors of the 
desired 7-membered rings, yielded only cyclodimers 3 by the dimerization  process [16][17] 
(Scheme 1, Table 1). 
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Scheme 1 
 
Monosubstitution at C(α) of the amino acid moiety (R3=H) did not prevent twinning, although 
the cyclization was carried out under different conditions [17]3). If, however, the hydroxy acid 
moiety in 1 was monosubstituted at C(α), no cyclic depsipeptides were obtained, although the 
formation of the intermediate 1,3-oxazol-5(4H)-one 2 has been monitored by IR spectroscopy. 
Instead, water elimination occurred, to give derivatives of α,β-unsaturated acid amides. 
 
In the present paper, we describe the results of reactions of the higher homologues of 1 containing 
γ-hydroxy acids, which were carried out with the aim of obtaining either 8- or 16-membered 
cyclodepsipeptides. 
 
2. Results and Discussion 
 
The linear amides 4 were synthesized in five steps from the γ,δ-unsaturated aldehydes 5 (Scheme 
2). Reduction gave the pentenols 6, which were acetylated to give 74). The introduction of the 
carboxyl group was achieved by oxidative cleavage of the C=C bond of 7, either with 
                                                  
3) The DAC conditions were not applicable in this case because of the sluggish formation of the 
1,3-oxazol-5(4H)-one intermediate (cf. [18]).  
4) The need for protection of the hydroxy group arises from the fact that attempts to obtain the 
desired γ-hydroxy acids from the corresponding easily available lactones (e.g. 4,4-
dimethyltetrahydropyran-2-one) by alkaline hydrolysis failed. Upon acidification of the sodium 
salt, spontaneous lactonization occurred and only the starting lactone could be isolated. 
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Ru(IV)oxide/NaIO4 [19] or with oxone/acetone [20], although purification proved to be easier in 
the first case, thus leading to 8 in higher yields. The protection of the hydroxy group prevents the 
formation of the lactone under these oxidation conditions [21]. The coupling of 8 with the 
respective amino acid to give 9 was performed by the reaction with 2,2,N,N-tetramethyl- or 
2,2,N-trimethyl-N-phenyl-2H-azirine-3-amine (10a, 10b) and N,N-dimethyl-1-azaspiro[2.4]hept-
1-en-2-amine (10c), respectively, at room temperature (‘azirine/oxazolone method’ [22][23]). 
Deprotection of the hydroxy group by treatment with LiOH in THF/H2O led to the linear 
precursors 4. 
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 4a/11a 4b/11b 4c/11c 4d/11a 4e/11d 4f/11e 
R1 Me H Me Me H Me 
R2 Me H Me Me Ph Ph 
R3 Me Me Me Me Me 
R4 Me Me 
CH2 CH2
CH2CH2
 
Me Me Me 
R5 a) Me Me Me Ph Ph Ph 
  a) R5 only in 4. 
Table 1. Synthesized γ-Hydroxyamides 4 and Chlorinated Acids 11 
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Unexpectedly, the reactions of  4a-c (Table 1) under the conditions of the ‘direct amide 
cyclization’ yielded neither the 8-membered nor the 16-membered cyclodepsipeptides. Instead, 
after chromatographic workup, the chlorinated acids 11a-c were isolated as the sole products 
(Scheme 3). If the N-methyl-N-phenylamide 4d was used instead of the N,N-dimethylamides 4a-
c, the formed product could be isolated after evaporation of the solvent and washing of the 
residue with CH2Cl2. The isolated product was identified as the imino lactone hydrochloride 12a 
(Scheme 3). 
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Scheme 3 
 
At first it seems that R5 is determining the product of the reaction. Indeed, it has been shown that 
in some DAC reactions N,N-dimethyl- and N-methyl-N-phenyl amides behave quite differently 
[15]. Therefore, the cyclization of 4e and 4f was attempted under DAC conditions. Surprisingly, 
in both cases the product was not the imino lactone of type 12, but the chlorinated acid of type 11. 
Therefore, the presence of the PhN residue is not the reason for the different behavior of 4d under 
DAC conditions. 
 
The explanation lies in the purification process. Since N-methylaniline hydrochloride is soluble in 
CH2Cl2 [16][17] and the products of the reaction are not, the crude residue in the case of 4d was 
just washed with CH2Cl2, and thus the imino lactone was isolated as its hydrochloride 12a in pure 
form. On the other hand, Me2NH.HCl is insoluble in CH2Cl2, so that chromatographic workup 
was necessary in the case of 4a-c, which led to the formation of the corresponding chloro acids 
11.  In the case of 4e,f, due to the presence of the Ph substituent in the hydroxy acid moiety, the 
product of the reaction was soluble in CH2Cl2 and no precipitate was formed. For this reason, 
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chromatographic purification was required which yoelded chlorinated acids 11 as the sole product 
(Scheme 3).  
 
It is worth mentioning, that the 1H-NMR spectrum of 12a in (D6)DMSO changes with time. After 
just half an hour at room temperature, the appearance of signals at 1.00, 1.31, 2.09, 3.59 and 8.05 
ppm was observed, which grew stronger with time, while the signals at 1.15, 1.56, 3.13 and 4.56 
ppm diminish (Fig. 1). 
 
 
Fig. 1. Dynamic 1H-NMR spectrum of 12a in (D6)DMSO: a) Spectrum of 12a, b) Spectrum of 11a 
 
The new signals were sharp and well defined, indicating the formation of a single compound, 
rather than decomposition. After ca. 12 h at room temperature, the ratio of both compounds was 
roughly 1:1, while after 3 d only traces of the starting compound 12a could be observed. The 
spectrum of the newly formed substance coincides with the spectrum of 11a. The same process 
was also observable in the 13C NMR spectrum, the isomerization proceeding in a variety of polar 
Chapter 3  
 113 
solvents such as DMF and acetone. In the latter, the ratio between 12a and 11a reached 1:1 in 
about a week and then remained constant. Flash chromatography of a mixture of 11a and 12a 
allowed the isolation of analytical amounts of 12a. Finally, the instability of 12a in solution was 
proven in a control experiment in which a mixture of 12a and 11a in CH2Cl2 containing 10% of 
MeOH was stirred at room temperature. After 14 h, only the chlorinated acid 11a was isolated. 
Apparently, under the DAC reaction conditions, the initially formed product is the imino lactone 
hydrochloride 12a, which, in polar solvents, undergoes an isomerization to give 11a (Scheme 4). 
 
Cl
O
N
H
OH
O
OH
O
N
H
N
O
Ph
O
N
HO
OO
N+
OH
O
H
N
+
O
O
OH
H
N+
O
O
OH
H
DMSO, DMF
or  Acetone
4d A
11a
Cl-
Cl - 12a
Cl-
13a)
b)
b)
a)HCl gas
Toluene
100o
 
Scheme 4 
 
A reaction mechanism for the formation of 11a and 12a is shown in Scheme 4. Treatment of 4d 
with HCl gas leads to the corresponding 1,3-oxazol-5(4H)-one 13. When no external nucleophiles 
are present, the OH group acts as a nucleophile and attacks one of the two electrophilic centres in 
the ring. If the attack occurs at the C=O group (pathway a), the 8-membered cyclodepsipeptide A 
would be formed. On the other hand, the OH attack at the C=N group (pathway b), would lead to 
the opening of the oxazolone ring yielding the imino lactone hydrochloride 12a. The latter can be 
isolated if no chromatographic workup is necessary. In a polar solvent, the chloride ion 
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apparently attacks the methylene group adjacent to the O-atom, which leads to the open chain ω-
chloro acid 11a5). 
Due to its instability in solution, no crystals of 12a suitable for an X-ray crystal structure 
determination could be obtained, but the structures of the chlorinated acids 11a  and 11b were 
confirmed by X-ray crystallography (Fig. 2)6).  
 
The OH group in 11a forms an intermolecular H-bond with the amide O-atom of a neighboring 
molecule, thereby linking the molecules into extended chains which run parallel to the [0 1 0] 
direction and can be described by a graph set motif [25] of C(7).  The amide group forms an 
intermolecular H-bond with the carboxylate carbonyl O-atom of a different neighboring 
molecule, thus also linking the molecules into extended chains.  These chains run parallel to the 
[1 0 0] direction and can be described by a graph set motif of C(5). The combination of both 
interactions generates a two-dimensional network, which lies parallel to the (0 0 1) plane. 
 
In the case of 11b, there are two symmetry-independent molecules in the asymmetric unit.  The 
most significant difference between the independent molecules is in the orientation of the Cl-
atom. Furthermore, each of the two symmetry-independent molecules is disordered over the Cl-
(CH2)3- section of the molecule. Two positions were defined for these atoms in each molecule, 
except for the Cl-substituted C-atom, which is common to both conformations. 
                                                  
5) We expect that in the presence of a better nucleophile a competition with the attack of Cl- 
should be possible, which would lead to a mixture of products, but all reactions in the presence of  
CsI, Bu4NI and PhSNa, respectively, led to the formation of 11 exclusively.  
6) The structure of 11c has also been proven by an X-ray crystal-structure determination. The 
quality of the crystals and, subsequently, the results of the structure determination were poor, 
although unambiguous.  The results are not reported here, but have been deposited at the CCDC 
(see footnote 6). 
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a) 
 
 
b) 
 
Fig. 2. ORTEP Plots [24] of the molecular structures of  a) 11a  and b) one of the disordered 
conformations of one of the two symmetry-independent molecules of 11b  (arbitrary numbering of 
the atoms; 50% probability ellipsoids) 
 
The major conformation is present in approximately 65% and 80% of molecules A and B, 
respectively. Except for the orientations of the Cl-atoms, the major conformation of molecule A 
is almost identical to that of the minor conformation of molecule B and vice-versa. The OH group 
of each molecule in 11b forms an intermolecular hydrogen bond with the amide O-atom of an 
adjacent molecule of the same type.  These interactions link the molecules into infinite extended 
chains composed entirely of molecules of type A or entirely of type B.  These chains run in the [1 
0 1] direction and can be described by a graph set motif of C(7).  The amide group of each 
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molecule forms an intermolecular H-bond with the carbonyl O-atom of the carboxyl group of an 
adjacent symmetry-independent molecule.  These interactions link the molecules into extended 
···A···B···A···B··· chains which run in the [0 0 1] direction and can be described by a binary graph 
set motif of C22(10). The combination of all H-bonding interactions links the molecules into 
extended two-dimensional networks which lie parallel to the (0 1 0) plane. 
 
In order to isolate the crucial intermediate 12a, extraction with aq. Na2CO3 solution [26] and 
deprotection by treatment with polyvinylpyridine were attempted, but neither procedure gave 
satisfying results. Although esterification of 12a with CH2N2 yielded the corresponding crude 
methyl ester hydrochloride 14a  (Scheme 5), the product was also not stable in polar solvents and 
isomerized partially to the corresponding chloro ester. 
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Scheme 5 
 
Finally, the reaction of 12a with 2H-azirin-3-amine 10b yielded the diamide 15, which was stable 
in solution and whose structure was confirmed by X-ray crystallography (Fig. 3). This is the first 
direct proof of the tetrahydrofuran-2-imine structure. 
 
The central amide group (N(4)H) of 15 has a weak intramolecular H-bonding interaction with the 
imine N-atom (N(7)), which results in a five-membered loop that can be described by a graph set 
motif  [25] of S(5). 
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Fig. 3. ORTEP Plot [24] of the molecular structure of 15 (arbitrary numbering of the atoms; 50% 
probability ellipsoids) 
When the hydroxy-protected amide 9d was subjected to the DAC conditions, the corresponding 
protected 1,3-oxazol-5(4H)-one 16a (Scheme 6) was isolated in good yield, which indicated that 
an oxazolone, i.e. 13 in Scheme 4, is most probably the first intermediate from which the imino 
lactones 12 and the chloro acids 11 are formed. Therefore, we decided to prepare 9g-i with 
different protecting groups, which could potentially allow the deprotection and isolation of  the 
oxazolone with a free hydroxy group as a precursor for the cyclization to give A. 
 
We planned to prepare 9g-i analogously to 9d (Scheme 2). The benzyl, (benzyloxy)methyl (Bom) 
and Fmoc protecting group could be introduced before the oxidative clevage of the double bond 
and yield the protected acids of type 8, which could then be reacted with 2H-azirin-3-amine 10b 
to give the protected diamides 9. Because of the instability of the protecting group under the 
oxidation conditions, direct protection of the hydroxy amide 4d was preferred (Scheme 6). 
Unfortunately, the deprotection failed in all cases. 
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Scheme 6 
 
Since the DAC method failed to give cyclic depsipeptides, we attempted to synthesize the 
hydroxy esters of type 17 from amides 4 and to subject them to the NaH cyclization procedure, 
described earlier [16][17]. Unexpectedly, treatment of 4d and 4e with HCl gas in toluene 
containing 20% EtOH as an external nucleophile did not yield the desired esters 17, but gave as 
the main products the imino lactone esters 14 in moderate yields together with the corresponding 
ω-chloro esters 18 (Scheme 7). 
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Scheme 7 
Further experiments with 4d in the presence of MeOH showed that the ester could also be formed 
directly from the imino lactone 12a, either under DAC conditions or by treatment with CH2N2 
(Schemes 5 and 7). 
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If instead of the hydroxy amides 4, the protected alcohols 9d or 9f were subjected to the DAC 
conditions in the presence of MeOH, the unprotected linear esters 17 were formed (Scheme 8). 
We believe that again oxazolones are the intermediates and since the OH group in 9 is protected, 
it is to be expected that protected oxazolones of type 16 (Scheme 6) are the intermediates. 
Nucleophilic addition of MeOH to the oxazolone, followed by ring opening, leads to the ester 
group in 17. The deacetylation could be explained by trans-esterification, via formation of 
AcOMe, which is a common reaction under acidic conditions.  
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Scheme 8 
 
The esters 17 were subjected to the conditions of the NaH-catalyzed cyclization, i.e. they were 
treated with NaH in toluene at 80o [16][27], but no cyclic products were obtained. As in previous 
studies [16][17], the rigidity of the amide bond was suggested as the reason for the failure. 
Therefore, the aminoketone 19 was synthesized, as depicted in Scheme 9, and subjected to the 
same reaction conditions. Again, no cyclic products could be identified in the mixture. 
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Scheme 9 
 
If indeed the formation of the cyclic products 12 and 14 occurs via the attack of the OH group at 
the imminium C-atom of the oxazolone 12 (see Scheme 4, path b), α-substitution in the hydroxy 
diamide 4 might present sufficient steric hindrance in order to direct the nucleophilic attack onto 
Synthesis of Cyclic Depsipeptides under Direct Amide Cyclization Conditions 
 120 
the ester group (Scheme 4, path a). Therefore, the amides 4g and 4h were prepared, analogously 
to Scheme 2. Treatment of amides 4g and 4h with HCl gas in toluene at 100o (DAC conditions) 
yielded imino lactones as sole products (Scheme 10).  
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Scheme 10 
 
Unlike their analogues 12a-c, compounds 12g,h are stable in solution. The higher substitution of 
the ring apparently stabilizes it, i.e. the gem-dimethyl effect (Thorpe-Ingold effect [28]) makes 
the ring opening thermodynamically unfavorable. Thanks to their stability in solution, crystals 
suitable for an X-ray crystal structure determination could be grown for both hydrochlorides 12g 
and 12h (Fig. 4).  
 
Since the space group of 12g is centrosymmetric, the compound in the crystal is racemic. The OH 
group forms a H-bond with a neighboring chloride ion, while the imminium group forms a H-
bond with a different chloride ion.  Thus, each chloride ion accepts two H-bonds. These 
interactions link two cations and two anions in a cyclic manner into a tetrameric unit and can be 
described by a graph set motif [25] of R24(14). 
 
Similar H-bonding interactions occur in 12h, but this time the interactions link the ions into 
extended chains, which run parallel to the [1 0 0] direction and can be described by a graph set 
motif of C12(7). 
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a)   
 
 
b) 
 
Fig. 4. ORTEP Plots [24] of the molecular structures of a) 12g and b) 12h (arbitrary numbering 
of the atoms; 50% probability ellipsoids) 
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3. Conclusions 
 
When γ-hydroxy diamides 4 were subjected to the DAC reaction conditions, neither the 8-
membered nor the 16 membered depsipeptides were formed. Depending on the work-up 
procedure, either the chlorinated acids 11 or the imino lactone hydrochlorides 12 with a carboxyl 
group were obtained as the sole products in good yields. Both products are formed via the 
intermediate oxazolones by an attack of the OH group at the iminium C-atom, instead of at the 
carbonyl group of the oxazolone (Scheme 4). This attack leads to the five-membered ring, instead 
of the desired eight-membered ring. The former are obviously more stable than the latter. 
Compounds 12, with α-H atoms next to the carbonyl group, are unstable in solution and 
isomerize to the corresponding ω-chloro acids 11. Increased substitution of the imino lactone 
stabilizes the five membered ring and prevents isomerization. A few other cyclization methods 
were also tried, but they all failed to give cyclic depsipeptides. 
 
Experimental Part 
 
1. General. See [16]. 
 
2. Starting Materials. 2,2,N,N-Tetramethyl-2H-azirin-3-amine (10a), 2,2,N-trimethyl-N-phenyl-
2H-azirin-3-amine (10b), and N,N-dimethyl-1-azaspiro[2.4]hept-1-en-2-amine (10c)  were 
prepared according to standard procedures (cf. [16] and refs. cited therein). 2,2-Dimethylpent-4-
enal (5a) was prepared from isobutyraldehyde according to Noack et al. [29], 2-phenylpent-4-en-
1-ol (6c) was obtained from 2-phenylpropanal by following the method of  Iqbal et al. [30], and 
2-methyl-2-phenylpent-4-enal (5d) was synthesized from 2-phenylpropanal analogously to 5a. 
All spectra were in accordance with literature data [31]. 2,2,3-Trimethylpent-4-enal (5e) and 
2,2,3,3-tetramethylpent-4-enal (5f) were prepared according to Brannock et al. [32] from crotyl 
bromide and 1-bromo-3-methylbut-2-ene, respectively. 1-Bromo-4-hydroxy-3,3-dimethylbutan-
2-one (23) was synthesized according to  Mihelcic et al. [33]. All other products used were 
commercially available. 
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3. Preparation of Pent-4-enyl Acetates. General Procedure 1 (GP 1). To a soln. of the 
corresponding pent-4-enal 5 (5 mmol) in MeOH (20 ml) at 0o, NaBH4 (760 mg, 20 mmol) was 
added in small portions within 20 min, then the mixture was allowed to warm to r.t. and was 
stirred for a total of 1 h. The solvent was evaporated i.v. and the residue dissolved in H2O. 
Extraction with Et2O (5 × 30 ml), drying (MgSO4) and evaporation i.v. yielded the pent-4-en-1-
ols 6, which were acetylated without further purification. For this purpose, 6 (5 mmol) was 
dissolved in Et2O (50 ml) and pyridine (0.81 ml, 10 mmol) was added. The mixture was heated to 
reflux and a soln. of Ac2O (0.41 ml, 5.5 mmol) in Et2O (10 ml) was added dropwise within 20 
min. The mixture was stirred under reflux for another 1.5 h, cooled, the salt was filtered off, the 
org. layer washed with 10% aq. CuSO4 soln. and brine, dried (MgSO4), evaporated i.v. and 
purified by column chromatography (CC, SiO2) to yield the desired pent-4-enyl acetates 7. 
3.1. 2,2-Dimethylpent-4-enyl Acetate (7a). According to GP 1 from 2,2-dimethylpent-4-enal (5a, 
560 mg, 5 mmol), CC (hexane/Et2O 10:1). Yield: 593 mg, 79% of 7a as a colorless oil. All 
spectra were in accordance with literature data [34]. 
3.2. 2-Phenylpent-4-enyl Acetate (7c). To a soln. of 2-phenylpent-4-en-1-ol (6c, 5 mmol, 810 mg) 
in Et2O (50 ml), pyridine (0.81 ml, 10 mmol) was added, the mixture was heated to reflux and 
then a soln. of Ac2O (0.71 ml, 5.5 mmol) in  Et2O (10ml) was added dropwise over 20 min. The 
reaction was stirred under reflux for another 1.5 h, cooled, the pyridinium acetate filtered off, the 
org. layer washed with 10% aq. CuSO4 soln. and brine, dried (MgSO4), evaporated i.v. and 
purified by  CC (hexane/Et2O 15:1) to  yield 860 mg  (84%) of 7c. Colorless oil. 1H-NMR: 1.98 
(s, MeCO); 2.24-2.41 (m, CH2); 2.91-3.06 (m, PhCH); 4.11-4.26 (m, CH2O); 4.92-5.09 (m, 
CH2=CH); 5.62-5.83 (m, CH2=CH); 7.12-7.39 (m, 5 arom. H). 13C-NMR: 20.8 (q, Me); 36.8 (t, 
CH2); 44.4 (d, CH); 67.6 (t, CH2O); 116.6 (t, CH2=CH); 126.7, 127.4, 128.3 (3d, 5 arom. CH), 
135.6 (d, CH2=CH); 141.3 (s, arom. C); 170.8 (s, C=O). ESI-MS: 205 (100, [M + H]+). 
3.3. 2-Methyl-2-phenylpent-4-enyl Acetate (7d). According to GP 1 from 2-methyl-2-phenylpent-
4-enal (5d, 870 mg, 5 mmol), CC (hexane/Et2O 20:1). Yield: 785 mg (72%) of 7d. Colorless oil. 
IR: 3075s, 2962vs, 2860vs, 1745vs, 1636s, 1482s, 1432s, 1386s, 1334s, 1188s, 1076s, 1029s, 
912m. 1H-NMR: 1.35 (s, Me); 2.05 (s, MeCO); 2.31-2.59 (m, CH2); 4.13-4.28 (m,  CH2O); 4.87-
5.11 (m, CH2=CH); 5.45-5.59 (m, CH2=CH); 7.14-7.44 (m, 5 arom. H). 13C-NMR: 20.7, 22.5 (2q, 
2 Me); 41.0 (s, C); 43.4 (t, CH2); 71.4 (t, CH2O); 117.8 (t, CH2=CH); 126.1, 127.7, 128.1 (3d, 5 
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arom. CH); 133.3 (d, CH2=CH); 144.3 (s, arom. C); 170.9 (s, C=O). ESI-MS: 219 (100, [M + 
H]+). 
3.4. 2,2,3-Trimethylpent-4-enyl Acetate (7e). According to GP 1, from 2,2,3-trimethylpent-4-enal 
(5e, 5 mmol, 630 mg), CC (hexane/Et2O 10:1). Yield: 604 mg (71%) of 7e. Colorless oil. IR: 
3077w, 2973vs, 2879s, 1744vs, 1637m, 1473m, 1377s, 1036s, 914m. 1H-NMR: 0.86, 0.90 (2s, 
Me2C); 0.98 (d, J = 4.5, Me); 1.98 (s, MeCO); 2.11-2,23 (m, MeCH); 3.36 (s, CH2O); 4.90-5.04 
(m, CH2=CH); 5.74-5.92 (m, CH2=CH). 13C-NMR: 14.6, 20.8, 21.6 (3q, Me, Me2C, MeCO); 36.5 
(s, Me2C), 40.9 (d, MeCH); 70.4 (t, CH2O); 114.1 (t, CH2=CH); 141.5 (d, CH2=CH); 171.8 (s, 
C=O). ESI-MS: 193 (100, [M + H]+). 
3.5. 2,2,3,3-Tetramethylpent-4-enyl Acetate (7f). According to GP 1, from 2,2,3,3-
tetramethylpent-4-enal (5f, 5 mmol, 700 mg), CC (hexane/Et2O 10:1). Yield: 717 mg (78%) of 7f. 
Colorless oil. IR: 3072m, 2964vs, 2909s, 1746vs, 1635m, 1473m, 1414m, 1380s, 1315s, 1040s, 
913s. 1H-NMR: 0.88, 0.99 (2s, 2 Me2C); 2.02 (s, MeCO); 3.90 (s, CH2O); 4.89-5.00 (m, 
CH2=CH); 5.87-5.96 (m, CH2=CH). 13C-NMR: 20.5 (q, Me2C); 21.0 (q, MeCO); 22.6 (q, Me2C); 
38.3, 40.8 (2s, 2 Me2C); 70.6 (t, CH2O); 112.0 (t, CH2=CH); 145.3 (d, CH2=CH); 171.3 (s, C=O). 
ESI-MS: 207 (100, [M + H]+). 
 
4. 4-Acetoxybutanoic Acids 8. General Procedure 2 (GP 2). To a soln. of pent-4-enyl acetates 7 
(5 mmol) in MeCN/CCl4/H2O  2:2:3  (70 ml), NaIO4 (2.28 g, 20 mmol) was added under stirring. 
After 10 min, a catalytic amount of RuO2.H2O was added and the mixture stirred vigorously at r.t. 
for 4-12 h. Filtration of the white residue over celite, washing with CH2Cl2, extraction of the 
collected mother liquor with CH2Cl2, drying (MgSO4), evaporation i.v. and purification by CC  
yielded  8  as colorless oils. 
4.1. 4-Acetoxy-3,3-dimethylbutanoic Acid (8a). According to GP 2 from 7a (5 mmol, 780 mg), 6 
h, CC (CH2Cl2/MeOH 20:1). Yield: 625mg (73%) of 8a. Colorless oil. IR: 3284 s (br), 2969s, 
1739vs, 1709vs, 1475w, 1379s, 1243s, 1041s, 926w. 1H-NMR: 0.98 (s, Me2C); 1.98 (s,  MeCO); 
2.28 (s, CH2); 3.88 (s, CH2O); 9.83 (br. s, COOH). 13C-NMR: 20.6 (q, Me); 24.9 (q, Me2C); 33.5 
(s, Me2C), 42.8 (t, CH2); 71.6 (t, CH2O); 171.1 (s, C=O); 177.7 (s, COOH). ESI-MS: 197 (100, 
[M + Na]+). 
4.2. 4-Acetoxy-3-phenylbutanoic Acid (8c). According to GP 2, 7c (5 mmol, 1.020 g), 4 h, CC 
(CH2Cl2/acetone 20:1). Yield: 678 mg (61%) of 8c. Colorless oil. 1H-NMR: 1.99 (s, MeCO); 
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2.61-2.88 (m, CH2); 3.42-3.58 (m, PhCH); 4.09-4.36 (m, CH2O); 7.13-7.38 (m, 5 arom. H.); 10.63 
(br. s, COOH). 13C-NMR: 20.6 (q, MeCO); 37.1 (t, CH2), 40.7 (d, CH); 67.3 (t, CH2O); 127.2, 
127.5, 128.6 (3d, 5 arom. CH); 139.8 (s, arom. C); 170.7 (s, C=O); 177.3 (s, COOH). ESI-MS: 
245 (100, [M + Na]+). 
4.3. 4-Acetoxy-3-methyl-3-phenylbutanoic Acid (8d). According to GP 2 from 7d (5 mmol, 1090 
mg), 6 h, CC (CH2Cl2/MeOH 20:1). Yield: 861mg (73%) of 8d. Colorless oil. 1H-NMR: 1.31 (s, 
Me); 2.01 (s, MeCO); 2.28-2.36 (m, CH2); 4.18-4.45 (m, CH2O); 7.08-7.38 (m, 5 arom. H). 13C-
NMR: 20.9 (q, MeCO); 26.6 (q, Me); 31.1 (s, Me2C); 45.7 (d, CH); 69.3 (t, CH2O); 127.3, 127.6, 
128.9 (3d, 5 arom. CH); 141.2 (s, arom. C); 171.4 (s, C=O); 176.1 (s, COOH). ESI-MS: 259 
(100, [M + Na]+). 
4.4. 4-Acetoxy-2,3,3-trimethylbutanoic Acid (8e). According to GP 2 from  7e (5 mmol, 850 mg ), 
6 h, CC (CH2Cl2/MeOH 20:1). Yield: 771mg (82%) of 8e. Colorless oil. IR: 3466 br. s, 2976s, 
1738vs, 1710vs, 1467w, 1390s, 1245s, 1041s, 925w. 1H-NMR: 0.95, 0.99 (2s, Me2C); 1.18 (d, J = 
4.7,  MeCH); 2.00 (s, MeCO); 2.48 (q, J = 4.7, MeCH); 3.89 (s, CH2O); 10.11 (br. s, COOH). 
13C-NMR: 15.6, 20.6 (2q, 2 Me); 21.8, 22.1 (2q, Me2C); 38.7 (s, Me2C); 45.1 (d, CH); 70.8 (t, 
CH2O); 171.0 (s, C=O); 181.3 (s, COOH). ESI-MS: 211 (100, [M + Na]+). 
4.5. 4-Acetoxy-2,2,3,3-tetramethylbutanoic Acid (8f). According to GP 2 from 7f (5 mmol, 920 
mg), 4 h, CC (CH2Cl2/MeOH 20:1). Yield: 524 mg (52%) of 8f. IR: 3290s (br), 2972s, 1743vs, 
1477m, 1377m, 1248s, 1214w, 1040s, 1021w, 926w. 1H-NMR: 0.99, 1.19 (2s, 2 Me2C); 2.03 (s, 
MeCO); 3.99 (s, CH2O); 9.63 (br. s, COOH). 13C-NMR: 20.6 (q, MeCO); 21.1, 21.4 (2s, 2 
Me2C); 38.3, 46.9 (2s, 2 Me2C); 70.1 (t, CH2O); 171.1 (s, C=O); 183.3 (s, COOH). CI-MS: 203 
(38, [M + H]+), 143 (100, [M - MeCO]+). 
 
5. Coupling of 8 with 2H-Azirin-3-amines 10. General Procedure 3 (GP 3). Acids 8 were taken 
up in dry THF (20 ml) and the corresponding aminoazirine 10 was added dropwise. The mixture 
was stirred overnight at r.t., the solvent evaporated i.v. and the residue purified by CC to yield 
acetoxy diamides  9. 
5.1. 3-[1-Methyl-1-(N,N-dimethylcarbamoyl)ethylcarbamoyl]-2,2-dimethylpropyl Acetate (9a). 
According to GP 3 from  8a (348 mg, 2 mmol) in dry THF (20 ml) and 10a (235 mg, 2.1 mmol), 
CC (CH2Cl2/MeOH 30:1). Yield: 509 mg (89%) of 9a. White powder. M.p. 99.1-99.2o. 1H-NMR: 
0.98, 1.52 (2s, 2 Me2C); 2.05 (s, MeCO); 2.10 (s, CH2); 3.08 (br. s, Me2N); 3.98 (s, CH2O); 7.12 
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(s, NH). 13C-NMR: 20.9 (q, MeCO); 24.5, 24.7 (2q, 2 Me2C); 34.1 (s, Me2C); 38.2 (q, Me2N); 
45.5 (t, CH2); 56.8 (s, Me2C); 71.8 (t, CH2O); 169.4, 171.2, 173.2 (3s, 3 C=O). ESI-MS: 309 
(100, [M + Na]+]). 
5.2. 3-[1-(N,N-Dimethylcarbamoyl)cyclopentylcarbamoyl]-2,2-dimethylpropyl Acetate (9c). 
According to GP 3 from  8a (348 mg, 2 mmol) in dry THF (20 ml) and 10c (290 mg, 2.1 mmol), 
CC (CH2Cl2/MeOH 20:1). Yield: 549 mg (88%) of 9c. White powder. M.p. 139.0-140.2o. 1H-
NMR: 1.02 (s, Me2C); 1.66-1.78, 1.83-1.93 (2m, 4 CH2); 2.07 (s, MeCO); 2.18-2.26 (m, CH2); 
2.98 (br. s, Me2N); 3.96 (s, CH2O); 6.41 (br. s, NH). 13C-NMR: 21.0 (q, MeCO); 22.4 (t, CH2); 
24.6 (q, Me2C); 34.3 (t, CH2); 35.7 (s, Me2C); 38.2 (q, Me2N); 44.3 (t, CH2); 66.8 (s, Me2C); 71.9 
(t, CH2O); 169.8, 171.4, 172.5 (3s, 3 C=O). CI-MS: 313 (40, [M + H]+), 268 (100, [M - NMe2]+), 
5.3. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2,2-dimethylpropyl Acetate 
(9d). According to GP 3 from 8a (348 mg,  2 mmol) in dry THF (20 ml) and 10b (365 mg, 2.1 
mmol), CC (CH2Cl2/MeOH 40:1). Yield: 584 mg (84%) of 9d. White powder. M.p. 94.1-95.8o. 
1H-NMR: 0.99, 1.48 (2s, 2 Me2C); 2.03 (s, MeCO); 2.12 (s, CH2); 3.26 (s, MeN); 3.91 (s, CH2O); 
6.38 (s, NH); 7.21-7.43 (m, 5 arom. H). 13C-NMR: 20.9 (q, MeCO); 24.4, 26.0 (2q, 2 Me2C); 34.0 
(s, Me2C); 41.5 (q, MeN); 46.0 (t, CH2); 58.3 (s, Me2C); 71.7 (t, CH2O); 127.9, 128.2, 129.3 
(3d,5 arom. CH); 144.5 (s, arom. C); 169.6, 171.2, 173.4 (3s, 3 C=O). ESI-MS: 371 (100, [M + 
Na]+]). 
5.4. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2-phenylpropyl Acetate (9e). 
According  to GP 3 from 8c (444 mg, 2 mmol) in dry THF (20 ml) and 10b (365 mg, 2.1 mmol), 
CC (CH2Cl2/MeOH 50:1). Yield: 689 mg (87%) of 9e. White powder. M.p. 133.3-134.2o. 1H-
NMR: 1.32, 1.38 (2s, Me2C); 2.09 (s, MeCO); 2.18-2.25, 2.43-2.50 (2m, CH2); 3.20-3.26 (m, 
MeN, CH); 3.72-3.77 (m, CH2O); 5.97 (s, NH); 7.17-7.36 (m, 10 arom. H). 13C-NMR: 21.1 (q, 
MeCO); 26.1, 26.2 (2q, Me2C); 40.9 (t, CH2); 41.3 (q, MeN); 44.5 (d, CH); 58.1 (s, Me2C); 67.0 
(t, CH2O); 126.9, 127.5, 127.9, 128.6, 129.3 (5d, 5 arom. CH); 141.8, 144.4 (2s, 2 arom. C); 
169.9, 171.0, 173.0 (3s, 3 C=O). ESI-MS: 419 (100, [M + Na]+). 
5.5. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2-methyl-2-phenylpropyl 
Acetate (9f). According to GP 3 from 8d (472 mg, 2 mmol) in dry THF (20 ml) and 10b (365 mg, 
2.1 mmol), CC (CH2Cl2/MeOH 50:1). Yield: 689 mg (84%) of 9f. White powder. M.p. 135.1-
136.6o. 1H-NMR: 1.08, 1.16, 1.36 (3s, Me, Me2C); 2.08 (s, MeCO); 2.11-2.17 (m, CH2); 3.16 (s, 
MeN); 4.21 (s, CH2O); 5.64 (s, NH); 7.09-7.41 (m, 10 arom. H). 13C-NMR: 20.8 (q, MeCO); 
Chapter 3  
 127 
22.4, 26.1, 26.6 (3q, Me, Me2C); 30.8 (s, Me2C); 41.1 (q, MeN); 46.3 (t, CH2); 57.4 (s, Me2C); 
71.1 (t, CH2O); 126.1, 127.6, 127.9, 128.5, 128.9, 129.3 (6d, 10 arom. CH); 143.6, 144.8 (2s, 2 
arom. C); 168.9, 170.8, 172.9 (3s, 3 C=O).  CI-MS: 411 (42, [M + H]+), 304 (100, [M – 
Me(Ph)N]+), 175 (21). 
5.6. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2,2-dimethylbutyl Acetate 
(9g). According to GP 3 from 8e (372 mg, 2 mmol) in dry THF (20 ml) and 10b (365 mg, 2.1 
mmol), CC (CH2Cl2/MeOH 50:1). Yield: 637 mg (88%) of 9g. White powder. M.p. 139.6-140.9o. 
1H-NMR: 0.99, 1.00 (2s, Me2C); 1.05 (d, J = 3.9,  MeCH); 1.40, 1.41 (2s, Me2C); 2.05-2.12 (m, 
MeCO, CH); 3.19 (s, MeN); 3.86 (q, CH2O); 6.66 (s, NH); 7.14-7.46 (m, 5 arom. H). 13C-NMR: 
12.2 (q, Me); 20.8 (q, MeCO); 21.6, 22.4, 24.8, 25.0 (4q, 2 Me2C); 35.9 (s, Me2C); 41.4 (q, 
MeN); 46.4 (d, CH); 58.5 (s, Me2C); 71.3 (t, CH2O); 128.0, 128.4, 129.3 (3d, 5 arom. CH); 144.1 
(s, arom. C); 170.9, 172.7, 173.7 (3s, 3 C=O). ESI-MS: 385 (100, [M + Na]+). 
5.7. 3-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl]-2,2,3-trimethylbutyl Acetate 
(9h). According to GP 3 from 8f (404 mg, 2 mmol) in dry THF (20 ml) and 10b (365 mg, 2.1 
mmol), CC (CH2Cl2/MeOH 50:1). Yield: 684 mg (91%) of 9h. White powder. M.p. 119.9-120.9o. 
1H-NMR: 0.93, 1.11, 1.47 (3s, 3 Me2C); 2.04 (s, MeCO); 3.26 (s, MeN); 3.98 (s, CH2O); 7.04 (s, 
NH); 7.18-7.41 (m, 5 arom. H). 13C-NMR: 21.0, 21.7, 24.9 (3q, 3 Me2C); 38.6 (s, Me2C); 41.7 (q, 
MeN); 47.2, 58.8 (2s, 2 Me2C); 70.7 (t, CH2O); 128.3, 128.6, 129.5 (3d, 5 arom. CH); 144.1 (s, 
arom. C); 171.1, 174.3, 176.9 (3s, 3 C=O). ESI-MS: 415 (20, [M + K]+), 399 (100, [M + Na]+), 
377 (60, [M + H]+). Anal. calc. for C21H32N2O4 (376.50): C 66.99, H 8.57, N 7.44; found: C 
66.35, H 8.28, N 7.15. 
 
6. Deprotection of 9 to give Hydroxydiamides 4. General Procedure 4 (GP 4).  The amides 9 
were treated with 4 equiv. of LiOH in THF/H2O 2:1 at r.t. for 4-12 h. Evaporation of the solvent 
i.v., extraction of the residue with CH2Cl2, drying (MgSO4), evaporation i.v. and washing with 
Et2O yielded the hydroxydiamides 4 as white powders, which were used without further 
purification. 
6.1. 4-Hydroxy-3,3-dimethyl-N-[1-methyl-1-(N,N-dimethylcarbamoyl)ethyl]butanamide (4a). 
According to GP 4 from 9a (858 mg, 3 mmol), 4 h. Yield: 677 mg (93%) of 4a. White powder. 
M.p. 138.6-139.9o. 1H-NMR: 0.99, 1.64 (2s, Me2C); 2.14 (s, CH2); 3.12 (br. s, Me2N); 3.91 (s, 
CH2O); 7.02 (s, NH). 13C-NMR: 24.6, 24.8 (2q, 2 Me2C); 34.6 (s, Me2C); 38.8 (q, Me2N); 45.4 (t, 
Synthesis of Cyclic Depsipeptides under Direct Amide Cyclization Conditions 
 128 
CH2); 56.8 (s, Me2C); 71.3 (t, CH2O); 171.4, 173.0 (2s, 2 C=O). CI-MS: 244 (32, [M + H]+]), 201 
(100, [M - Me2N]+]). 
6.2. 4-Hydroxy-N-[1-methyl-1-(N,N-dimethylcarbamoyl)ethyl]butanamide (4b). A soln. of 
sodium 4-hydroxy-butanate (1.0 g, 7.9 mmol) in H2O (10 ml) was acidified with 3N HCl. 
Extraction with AcOEt (5 × 30 ml), drying (MgSO4), evaporation of the solvent i.v. yielded 520 
mg (63%) of 4-hydroxybutanoci acid as a viscous fluid, which was used without further 
purification. All spectra were in accordance with the data in [35]. 4-Hydroxybutanoic acid (600 
mg, 5.77 mmol) was dissolved in dry THF (20 ml) and 10a (711 mg, 6.35 mmol, 1.1 equiv.)  was 
added dropwise. The mixture was stirred overnight at r.t., the solvent evaporated i.v. and the 
residue purified by CC (CH2Cl2/MeOH 10:1). Yield: 1134 mg (90%) of 4b. White solid. M.p. 
124.6-125.3o. 1H-NMR: 1.48 (s, Me2C); 1.73-1.82 (m, CH2); 2.08 (t, J = 6.2, CH2); 3.26 (s, 
Me2N); 3.65 (t, J = 6.2, CH2O); 6.38 (s, NH); 7.24-7.32 (m, 5 arom. H). 13C-NMR: 24.4 (t, CH2); 
26.0 (q, Me2C); 41.5 (q, Me2N); 46.0 (t, CH2); 58.3 (s, Me2C); 71.7 (t, CH2O); 127.9, 128.2, 
129.3 (3d, 5 arom. CH); 144.5 (s, arom. C); 171.2, 173.4 (2s, 2 C=O). CI-MS: 279 (85, [M + 
H]+), 172 (100, [M - Me2N]+). 
6.3. 4-Hydroxy-3,3-dimethyl-N-[1-(N,N-dimethylcarbamoyl)cyclopentyl]butanamide (4c). 
According to GP 4 from 9c (936 mg, 3 mmol), 6 h. Yield: 738 mg (91%) of 4c. White powder. 
M.p. 138.4-139.9o. 1H-NMR: 0.99 (s, Me2C); 1.62-1.76, 1.84-2.02 (2m, 4 CH2); 2.21-2.39 (m, 
CH2); 3.03 (br. s, Me2N); 3.38 (s, CH2O); 6.61 (br. s, NH). 13C-NMR: 24.4 (t, CH2); 25.2 (q, 
Me2C); 35.7 (s, Me2C); 37.3 (t, CH2); 37.9 (q, Me2N); 46.4 (t, CH2); 66.6 (s, C); 71.9 (t, CH2O); 
172.2, 172.7 (2s, 2 C=O). ESI-MS: 309 (10, [M + K]+), 293 (100, [M + Na]+). 
6.4. 4-Hydroxy-3,3-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl) 
ethyl]butanamide (4d). According to GP 4, from 9d (1044 mg, 3 mmol), 6 h. Yield: 845 mg 
(92%) of 4d. White powder. M.p. 138.4-139.9o. 1H-NMR: 0.92, 1.44 (2s, 2 Me2C); 2.13 (s, CH2); 
3.22 (s, MeN); 3.91 (s, CH2O); 6.32 (s, NH); 7.16-7.41 (m, 5 arom. H). 13C-NMR: 25.2, 26.0 (2q, 
2 Me2C); 35.6 (s, Me2C); 41.3 (q, MeN); 47.2 (t, CH2); 58.2 (s, Me2C); 71.4 (t, CH2O); 127.9, 
128.2, 129.2 (3d, 5 arom. CH); 144.3 (s, arom. C); 171.6, 173.1 (2s, 2 C=O).  ESI-MS: 345 (20, 
[M + K]+), 329 (100, [M + Na]+). Anal. calc. for C17H26N2O3 (306.41): C 66.64, H 8.55, N 9.14; 
found: C 66.36, H 8.49, N 8.97. 
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6.5. 4-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-3-phenyl 
butanamide (4e). According to GP 4, from 9e (1188 mg, 3 mmol), 8 h. Yield: 934 mg (88%) of 
4e. White powder. M.p. 129.0-129.9o. 1H-NMR: 1.28, 1.35 (2s, Me2C); 2.11-2.21, 2.34-2.46 (2m, 
CH2); 3.17 (br. s, MeN, CH); 3.64-3.79 (m, CH2O); 5.96 (s, NH); 7.10-7.41 (m, 10 arom. H). 13C-
NMR: 26.1, 26.2 (2q, Me2C); 40.9 (q, MeN); 41.2 (t, CH2); 44.5 (d, CH); 58.2 (s, Me2C); 67.1 (t, 
CH2O); 126.8, 127.5, 127.9, 128.6, 129.3 (5d, 10 arom. CH); 141.7, 144.4 (2s, 2 arom. C); 171.1, 
173.0 (2s, 2 C=O). CI-MS (i-butane): 355 (100, [M + H]+). 
6.6. 4-Hydroxy-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-3-methyl-3-
phenylbutanamide (4f). According to GP 4 from 9f (820 mg, 2 mmol), 12 h. Yield: 587 mg 
(90%) of 4f. White powder. M.p. 121.9-123.3o. 1H-NMR: 1.22, 1.23, 1.24 (3s, Me, Me2C); 2.11-
2.19, 2.31-2.38 (2m, CH2); 3.15 (s, MeN); 3.51-3.59, 3.83-3.89 (2m, CH2O); 5.84 (s, NH); 7.11-
7.43 (m, 10 arom. H). 13C-NMR: 23.6, 26.1, 26.2 (3q, Me, Me2C); 41.4 (q, Me2N); 42.7 (s, 
Me2C); 47.4 (t, CH2); 58.1 (s, Me2C); 70.6 (t, CH2O); 126.1, 126.5, 127.8, 128.5, 129.3 (5d, 10 
arom. CH); 144.5, 145.5 (2s, 2 arom. C); 170.9, 173.0 (2s, 2 C=O). CI-MS (i-butane): 327 (80, 
[M + H]+), 221 (100, [M - Ph(Me)N]+). 
6.7. 4-Hydroxy-2,3,3-trimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl) 
ethyl]butanamide (4g). According to GP 4 from 9g (724 mg, 2 mmol), 4 h. Yield: 576 mg (90%) 
of 4g. White powder. M.p. 124.2-126.3o. 1H-NMR: 1.00 (s, Me2C); 1.09 (d, J = 4.6, MeCH); 
1.40, 1.42 (2s, Me2C); 2.08 (q, J = 4.6, CH); 3.18 (s, MeN); 3.51-3.59 (m, CH2O); 6.96 (s, NH); 
7.12-7.42 (m, 5 arom. H). 13C-NMR: 12.7 (q, Me); 23.4, 24.2, 25.0 (3q, 3 Me2C); 37.6 (s, Me2C); 
41.7 (q, MeN); 49.9 (d, CH); 58.9 (s, Me2C); 69.3 (t, CH2O); 128.4, 128.6, 129.5 (3d, 5 arom. 
CH); 143.9 (s, arom. C); 173.8, 175.6 (2s, 2 C=O). ESI-MS: 343 (100, [M + Na]+). 
6.8. 4-Hydroxy-2,2,3,3-tetramethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-
butanamide (4h). According to GP 4, from 9h (752 mg, 2 mmol), 4 h. Yield: 608 mg (91%) of 
9h. White powder. M.p. 129.9-131.3o. 1H-NMR: 0.88, 1.15, 1.46 (3s, 3 Me2C); 3.29 (s, MeN); 
3.44 (s, CH2O); 6.48 (s, NH); 7.23-7.42 (m, 5 arom. H). 13C-NMR: 21.5, 21.9, 24.6 (3q, 3 Me2C); 
39.6 (s, Me2C); 41.6 (q, MeN); 47.6, 58.9 (2s, 2 Me2C); 70.7 (t, CH2O); 128.2, 128.4, 129.4 (3d, 
5 arom. CH); 143.9 (s, arom. C); 173.9, 177.8 (2s, 2 C=O). ESI-MS: 357 (100, [M + Na]+). 
 
7. Attempted Direct Amide Cyclizations of Amides 4. General Procedure 5 (GP 5). A suspension 
of 4 (0.5 mmol) in dry toluene (50 ml) was heated to 100o and HCl gas was bubbled through the 
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suspension for 4-6 min. Then, the mixture was allowed to cool to r.t. while bubbling N2 through it 
(ca. 20 min). The solvent was evaporated, the white residue was washed with CH2Cl2 (3 × 15 ml) 
and dried in h.v. to yield imino lactone hydrochlorides 12 as white powders.  
General Procedure 6 (GP 6).  A suspension of 4 was treated as in GP 5. The solvent was 
evaporated, and the oily residue was purified by CC to yield the ω-chloro acids 11. 
7.1. 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoic Acid Hydrochloride 
(12a). According to GP 5 from 4d (153 mg, 0.5 mmol). Yield: 101 mg (84%). M.p. 158.3-159.1o. 
IR: 3431w, 2938s, 2804s, 1735vs, 1678vs, 1529s, 1414m, 1319m, 1194s, 1166s, 1003m, 946m, 
754m. 1H-NMR ((D6)DMSO): 1.15, 1.56 (2s, 2 Me2C); 3.13 (s, CH2); 4.56 (s, CH2O); 13.2 (br. s, 
COOH). 13C-NMR ((D6)DMSO): 23.5, 24.1 (2q, 2 Me2C); 38.0, 60.1 (s, Me2C); 88.0 (t, CH2O); 
162.0 (C=N); 180.2 (s, C=O). CI-MS: 200 (100, [M - Cl]+).  
7.2. 2-[(3,4,4-Trimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoic Acid Hydrochloride 
(12g). According to GP 5 from 4g (160 mg, 0. 5mmol). Yield: 78 mg (73%). M.p. 152.4-153.6o. 
IR: 3386w, 2986s, 2776s, 1739vs, 1671vs, 1514m, 1478s, 1240m, 1178s, 1165s, 997s, 773m. 1H-
NMR ((D6)DMSO): 1.08 (d, J = 4.9, Me); 1.21, 1.48 (2s, 2 Me2C); 2.18 (q, J = 4.9, CH); 4.42 (s, 
CH2O); 10.0 (br. s, COOH). 13C-NMR ((D6)DMSO): 12.0 (q, Me); 21.1, 22.2 (2q, 2 Me2C); 36.5 
(s, Me2C); 46.1 (d, CH); 58.2 (s, Me2C); 87.2 (t, CH2O); 163.1 (C=N); 178.0 (s, C=O). CI-MS (i-
butane): 214 (100, [M - Cl]+), 108 (25). Anal. calc. for C11H20NO3Cl (249.74): C 52.90, H 8.07, N 
5.61; found C 50.55, H 7.87, N 5.25. 
7.3. 2-[(3,3,4,4-Tetramethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoic Acid 
Hydrochloride (12h). According to GP 5  from 4h (167 mg, 0.5 mmol). Yield: 79 mg (78%), 
M.p. 157.0-157.6o. IR: 3390w, 3024s, 2938s, 2778s, 1738vs, 1669vs, 1476s, 1400s, 1313m, 
1178s, 998m, 880m, 772m. 1H-NMR ((D6)DMSO): 0.97, 1.26, 1.56 (3s, 3 Me2C); 4.58 (s, CH2O); 
12.9 (br. s,  COOH). 13C-NMR ((D6)DMSO):  21.6, 22.5, 26.1 (3q, 3 Me2C); 42.8, 46.6, 60.7 (3s, 
3 Me2C); 86.8 (t, CH2O); 168.1 (C=N); 183.2 (s, C=O). ESI-MS: 228 (100, [M + Na]+). 
7.4. 2-(4-Chloro-3,3-dimethylbutanoylamino)-2-methylpropanoic Acid (11a). According to GP 6  
from 4a (122 mg, 0.5 mmol) or from  4d (153 mg, 0.5 mmol), CC (CH2Cl2/acetone 10:1). Yield: 
57 mg (48%) of 11a from 4a and 62 mg (52%) from 4d. White powder. M.p. 116.1-117.3o. IR: 
3356vs, 2981s, 2605m, 1717vs, 1620vs, 1548vs, 1473s, 1393s, 1294m, 1221s, 1158s, 1023m, 
895m, 791s. 1H-NMR ((D6)DMSO): 1.00, 1.31 (2s, 2 Me2C); 2.09 (s, CH2); 3.59 (s, CH2Cl); 7.12 
(br. s, NH); 12.9 (br. s, COOH). 13C-NMR ((D6)DMSO): 24.9, 25.8 (2q, 2 Me2C); 36.6 (s, Me2C); 
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44.9 (t, CH2); 55.3 (t, CH2Cl); 60.3 (s, Me2C); 172.1, 181.1 (2s, 2 C=O). ESI-MS: 260 (32, 
[M(37Cl) + Na]+), 258 (100, [M(35Cl) + Na]+). 
7.5. 2-(4-Chlorobutanoylamino)-2-methylpropanoic Acid (11b). According to GP 6 from 4b (140 
mg, 0.5 mmol), CC (CH2Cl2/acetone 10:1). Yield: 62 mg (66%) of 11b. White solid. M.p. 111.9-
113.1o. IR: 3318vs, 2988s, 1721vs, 1623s, 156s, 1467s, 1399m, 1230m, 1166s, 1050w, 945w, 
787m. 1H-NMR: 1.57 (s, Me2C); 2.07-2.13 (m, CH2); 2.37 (t, J = 6.1, CH2); 3.61 (t, J = 6.1, 
CH2Cl); 7.29 (br. s, NH). 13C-NMR : 24.7 (q, Me2C); 33.9 (t, CH2); 44.4 (t, CH); 55.6 (t, CH2Cl); 
59.6 (s, Me2C); 171.8, 176.6 (2s, 2 C=O). CI-MS: 210 (10, [M(37Cl) + NH4]+), 208 (25, [M(35Cl) 
+ NH4]+), 172 (100, [M - Cl]+). 
7.6. 1-[(4-Chloro-3,3-dimethylbutyl-1-oxo)amino]cyclopentanecarboxylic Acid (11c). According 
to GP 6 from 4c (135 mg, 0.5 mmol), CC (CH2Cl2:acetone 10:1). Yield: 69 mg (53%) of 11c. 
White powder. M.p. 113.2-114.7o. 1H-NMR: 1.02, 1.09 (2s, Me2C); 1.71-1.76, 1.94-2.02 (2m, 4 
CH2); 3.22 (m, CH2); 3.63 (m, CH2Cl); 7.47 (br. s, NH). 13C-NMR: 24.8 (t, CH2); 25.3 (q, Me2C); 
36.3 (q, Me2C); 37.5, 44.7 (2t, 2 CH2); 55.0 (t, CH2Cl); 66.1 (s, Me2C); 171.7, 176.4 (2s, 2 C=O). 
CI-MS: 264 (28, [M(37Cl) + H]+), 262 (72, [M(35Cl) + H]+), 226 (100, [M - Cl]+). 
7.7 2-(4-Chloro-3-phenylbutanoylamino)-2-methylpropanoic Acid (11d). According to GP 6  
from 4e (184 mg, 0.5 mmol), CC (CH2Cl2/acetone 20:1). Yield: 51 mg (43%) of 11d. White 
powder. M.p. 119.6-121.8o (decomp). IR: 3320vs, 2928s, 1722vs, 1626vs, 1606s, 1557s, 1496s, 
1442s, 1315s, 1260m, 1170s, 1079m, 752s, 696s. 1H-NMR: 1.36, 1.39 (2s, Me2C); 2.53-2.60, 
2.70-2.78 (m, CH2); 3.48-3.52 (m, PhCH); 3.85-3.91 (m, CH2Cl);  7.24-7.32 (m, 5 arom. H); 7.45 
(br. s, NH); 12.3 (br. s, COOH). 13C-NMR: 24.8, 25.3 (2q, 2 Me2C); 40.2 (t, CH2); 45.3 (d, CH); 
55.3 (t, CH2Cl); 59.6 (s, Me2C); 127.6, 128.7, 129.0 (3d, 5 arom. CH); 142.3 (s, arom. C); 171.1, 
179.1 (2s, 2 C=O). CI-MS: 286 (15, [M(37Cl) + H]+), 284 (39, [M(35Cl) + H]+), 248 (100, [M - 
Cl]+). 
 
8. Synthesis of dipeptide esters. General Procedure 7 (GP 7).  A suspension of 4 (0.5 mmol) in a 
mixture of dry toluene (50 ml) and alcohol (5 ml) was heated to reflux and HCl gas was bubbled 
through the suspension for 6 min. Then, the mixture was allowed to cool to r.t. while bubbling N2 
through it (ca. 20 min). The solvent was evaporated, and the oily residue was purified by CC to 
yield the products as colorless oils. 
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General Procedure 8 (GP 8). To solid  12a (117 mg, 0.5 mmol), a 0.5 M soln. of CH2N2 in Et2O 
(1 ml, 0.5 mmol) was added dropwise at 0o. After the disappearance of the yellow color, another 
1 ml of CH2N2 was added, the mixture allowed to warm up to r.t., stirred for 15 min, filtered, and 
the solvent evaporated  i.v. The white solid 14a was used without further purification. 
8.1. Methyl 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoate (14a). 
Accordig to GP 7 from 4d (153 mg, 0.5 mmol), 5 ml of MeOH, CC (CH2Cl2/acetone 20:1). 
Yield: 50 mg (43%) of 14a. White solid. M.p. 88.6-89.8o. IR: 2961s, 2876m, 1736vs, 1706vs, 
1567s, 1360m, 1271s, 1143s, 101m, 919m, 731s. 1H-NMR ((D6)DMSO): 1.05, 1.28 (2s, 2 Me2C); 
2.24 (s, CH2); 3.56 (s, MeO); 3.83 (s, CH2O). 13C-NMR ((D6)DMSO): 23.6, 25.8 (2q, Me2C); 
36.6 (s, Me2C); 42.4 (t, CH2); 50.1 (q, MeO); 58.9 (s, Me2C); 80.3 (t, CH2O); 162.2 (s, C=N); 
175.3 (s, C=O). CI-MS: 231 (100, [M + NH4]+). 
An experiment according to GP 8 yielded 113 mg (98%) of 14a  as a white solid. 
8.2. Ethyl 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methylpropanoate (14b). 
According to GP 7 from 4d (153 mg, 0.5 mmol), 5 ml of EtOH, after CC (CH2Cl2/acetone 20:1). 
Yield: 49 mg (43%) of 14b and 51 mg of ethyl 2-(4-chloro-3,3-dimethylbutanoylamino)-2-
methylpropanoate 18b (38%) as colorless oils. 
14b: IR: 2965vs, 2893s, 1714vs, 1697vs, 1468s, 1380s, 1273s, 1166s, 1035m, 911m, 731s. 1H-
NMR: 1.11 (s, Me2C); 1.21 (t, J = 7.1, MeCH2); 1.43 (s, Me2C); 2.33 (s, CH2); 3.82 (s, CH2O); 
4.18 (q, J = 7.1, MeCH2). 13C-NMR: 14.3 (q, Me); 25.1, 26.6 (2q, Me2C); 37.1 (s, Me2C); 44.5 (t, 
CH2); 60.4 (t, MeCH2); 60.5 (s, Me2C); 81.9 (t, CH2O); 163.7 (s, C=N); 176.5 (s, C=O). ESI-MS: 
477 (15, [2M + Na]+), 250 (100, [M + Na]+), 228 (12, [M + H]+). 
18b: 1H-NMR: 1.05 (s, Me2C); 1.16 (t, J = 7.2, MeCH2); 1.27 (s, Me2C); 2.24 (s, CH2); 3.81 (s, 
CH2Cl); 4.02 (q, J = 7.2, MeCH2); 6.02 (br. s, NH). 13C-NMR: 14.2 (q, Me); 24.7, 25.8 (2q, 2 
Me2C); 35.8 (s, Me2C); 38.4 (t, CH2); 54.9 (t, CH2O); 61.3 (t, MeCH2); 65.6 (s, Me2C); 170.4, 
172.6 (2s, 2 C=O). ESI-MS: 288 (31), 286 (100, [M + Na]+). 
8.3. Methyl 2-Methyl-2-[(4-methyl-4-phenyltetrahydrofuran-2-yliden)amino]propanoate (14c). 
According to GP 7 from 4f (168 mg, 0.5 mmol), 5 ml of MeOH, CC (CH2Cl2/acetone 25:1). 
Yield:  77 mg (56%) of 14c. Colorless oil. 1H-NMR: 1.45, 1.46, 1.49 (3s, Me, Me2C) ; 2.73-2.79, 
2.97-3.02 2 (2m, CH2); 3.68 (s, MeO); 4.31 (s, CH2O); 7.16-7.36 (m, 5 arom. H). 13C-NMR: 26.1, 
26.7, 27.1 (3q, Me, Me2C); 43.0 (t, CH2); 44.6 (s, Me2C); 51.3 (q, MeO); 60.1 (s, Me2C); 80.9 (t, 
Chapter 3  
 133 
CH2O); 127.3, 126.8, 128.7 (3d, 5 arom. CH); 144.5 (s, arom. C); 163.0 (s, C=N); 176.7 (s, 
C=O). CI-MS: 276 (100, [M + H]+), 108 (22). 
8.4. Ethyl 1-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]cyclopentanecarboxylate (14d). 
According to GP 7 from 4c (135 mg, 0.5 mmol), 5 ml of EtOH, CC (CH2Cl2/acetone 20:1). 
Yield: 71 mg (28%) of 14d and 45 mg (31%) of ethyl 1-(4-chloro-3,3-
dimethylbutanoylamino)cyclopentanecarboxylate (18d) as colorless oils. 
14d: 1H-NMR: 1.12 (s, Me2C); 1.21 (t, J = 7.0, MeCH2); 1.81-1.94 (m, 4 CH2); 2.41 (s, CH2); 
3.89 (s, CH2O); 4.14 (q, J = 7.0, MeCH2). 13C-NMR: 14.3 (q, Me); 25.1 (q, Me2C); 37.3, 37.6, 
38.4, 39.1 (4t, 4 CH2); 44.2 (s, Me2C); 44.9, 47.1 (2t, 2 CH2); 60.6 (s, Me2C); 82.2 (t, CH2O); 
162.4 (s, C=N); 174.9 (s, C=O). CI-MS: 254 (100, [M + H]+), 200 (18, [M - Et]+), 158 (36). 
18d: 1H-NMR: 1.09 (s, Me2C); 1.20 (t, J = 6.9, MeCH2); 1.74-1.82, 1.84-1.94 (2m, 4 CH2, Me2C); 
2.16 (s, CH2); 3.56 (s, CH2O); 4.16 (q, J = 6.9, MeCH2); 6.02 (br. s, NH). 13C-NMR: 14.2 (q, 
Me);  24.7, 25.8 (2q, 2 Me2C); 35.8 (s, Me2C); 37.4, 37.7, 38.4, 39.1 (4t, 4 CH2); 44.2 (t, CH2); 
54.9 (t, CH2O); 61.3 (t, MeCH2); 65.6 (s, Me2C); 170.4, 172.6 (2s, 2 C=O). CI-MS: 292 (34, 
[M(37Cl) + H]+), 290 (100, [M(35Cl) + H]+), 254 (28). 
8.5. Methyl 2-(4-Hydroxy-3,3-dimethylbutanoylamino)-2-methylpropanoate (17a). According to 
GP 7 from 9d (174 mg, 0.5 mmol), 5 ml of MeOH, CC (CH2Cl2/acetone 20:1). Yield: 56 mg 
(48%) of 17a. Colorless oil. 1H-NMR: 0.98, 1.43 (2s, 2 Me2C); 2.11 (s, CH2); 3.29 (s, CH2O); 
3.78 (s, MeO); 6.25 (s, NH). 13C-NMR: 24.6, 25.2 (2q, 2 Me2C); 35.7 (s, Me2C); 46.9 (t, CH2); 
52.5 (q, MeO); 56.4 (s, Me2C); 71.2 (t, CH2O); 171.9, 174.9 (2s, 2 C=O). ESI-MS: 254 (100, [M 
+ Na]+). 
8.6. Methyl 2-(4-Hydroxy-3-methyl-3-phenylbutyrylamino)-2-methylpropanoate (17b). According 
to GP G from 9f (205 mg, 0.5 mmol) with 5 ml MeOH, CC (CH2Cl2/acetone 20:1). Yield 57 mg 
(38%) of 17b. Colorless oil. 1H-NMR: 1.38 (s, Me2C); 1.39 (s, Me); 2.47-2.51, 2.66-3.70 (2m, 
CH2); 3.65-3.69, 3.89-3.92 (2m, CH2O); 3.68 (s, MeO); 6.25 (s,  NH); 7.19-7.42 (m, 5 arom. H). 
13C-NMR: 23.3, 24.5, 24.6 (3q, 3 Me); 43.0 (t, CH2); 46.5 (s, C); 52.3 (q, MeO); 56.1 (s, C); 70.3 
(t, CH2O); 126.0, 126.4, 128.4 (3d, 5 arom. CH); 145.4 (s, arom. C); 171.2, 174.7 (2s, 2 C=O). 
CI-MS (i-butane): 294 (100, [M + H]+). 
 
9. Protection of Hydroxy Amide 4d. 9.1. 4-Benzyloxy-3,3-dimethyl-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]butanamide (9g). To a soln. of 4d (1 mmol, 306 mg) in  dry THF (20 ml), 
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NaH (44 mg, 1.1 mmol, 60% suspension in mineral oil) was added at 0o. After 1 h at r.t., 
benzylbromide (171 mg, 1 mmol) was added and the mixture heated to reflux for 3 h. Washing 
with brine, extraction with Et2O, drying (MgSO4) and evaporation i.v. yielded a colorless oil, 
which was purified by CC (CH2Cl2/acetone 40:1). Yield: 329 mg (73%) of  9g. Colorless oil. 1H-
NMR: 0.99, 1.36 (2s, 2 Me2C); 2.18 (s, CH2); 3.12 (s, CH2O); 3.22 (s, MeN); 4.43 (s, PhCH2); 
5.91 (br. s, NH); 7.12-7.43 (m, 10 arom. H). 13C-NMR: 25.4, 26.7 (2q, 2 Me2C); 34.8 (s, Me2C); 
41.3 (q, MeN); 46.3 (t, CH2); 57.7 (s, Me2C); 73.1 (t, CH2O); 78.5 (t, PhCH2); 127.4, 127.6, 
127.7, 127.8, 128.3, 129.2 (6d, 10 arom. CH); 138.4, 145.0 (2s, 2 arom. C); 170.6, 173.2 (2s, 2 
C=O). CI-MS (i-butane): 397 (100, [M + H]+). 
9.2. {2,2-Dimethyl-3-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl] 
propyl}[(9H-fluoren-9-yl)methyl] Carbonate (9h). To a  soln. of 4d (306 mg, 1 mmol) in CH2Cl2 
(20 ml), pyridine (3 ml) and FmocCl (284 mg, 1.1 mmol) were added. The mixture was stirred at 
r.t. for 3 h, diluted with CH2Cl2 (30 ml), washed with a 10% CuSO4 soln. and brine, the org. 
fractions were dried (MgSO4) and evaporated i.v. and purified by CC (CH2Cl2/acetone 30:1). 
Yiled: 450 mg (88%) of 9h. White powder. M.p. 108.9-110.6o. IR: 3320vs, 2966s, 1745vs, 
1678vs, 1650vs, 1599s, 1532s, 1441s, 1386s, 1316m, 1154m, 964m, 909s, 758m. 1H-NMR: 0.99, 
1.39 (2s, 2 Me2C); 1.86 (s, CH2); 3.19 (s, MeN); 3.92 (s, CH2O); 1.15 (t, J = 5.8, CH2CH); 4.36 
(d, J = 5.8, CH2CH); 6.12 (s, NH); 7.09-7.32, 7.50-7.80 (2m, 13 arom. H). 13C-NMR: 24.5, 25.5 
(2q, 2 Me2C); 34.2 (s, Me2C); 41.3 (q, MeN); 45.3 (t, CH2); 58.0 (s, Me2C); 69.7 (t, CH2O); 75.1 
(t, CH2CH); 119.9 (d, CH); 125.0, 127.0, 127.7, 127.8, 127.9, 129.1 (6d, 13 arom. CH); 141.2, 
143.3, 144.5 (3s, 5 arom. C); 155.2 (s, NC(O)O); 169.4, 173.1 (2s, 2 C=O). ESI-MS: 551 (100, 
[M + Na]+). 
9.3. 4-(Benzyloxy)methoxy-3,3-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)-
ethyl]butanamide (9i). To a soln. of 4d (306 mg, 1 mmol) in CH2Cl2 (20 ml) was added (i-
Pr)2NEt (142 mg, 1.1 mmol) and benzyloxymethylchloride (BomCl, 156 mg, 1 mmol). The 
mixture was stirred at r.t. for 12 h, diluted with CH2Cl2 (30 ml), washed with NH4Cl soln. and 
brine, dried (MgSO4), evaporated  i.v. and purified by CC (CH2Cl2/acetone 40:1). Yield:  375 mg 
(88%) 9i. Colorless oil. 1H-NMR: 0.99, 1.42 (2s, 2 Me2C); 1.84 (s, CH2); 3.22 (s, MeN); 3.32 (s, 
CH2); 4.51, 4.68 (2s, CH2); 5.94 (br. s,  NH); 7.08-7.42 (m, 10 arom. H). 13C-NMR: 25.0, 26.3 
(2q, 2 Me2C); 34.5 (s, Me2C); 41.2 (q, MeN); 45.9 (t, CH2); 57.8 (s, Me2C); 69.3, 76.2, 94.8 (3t, 3 
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CH2); 127.6, 127.7, 127.8, 128.3, 129.0, 129.2 (6d, 10 arom. CH); 137.6, 144.6 (2s, 2 arom. C); 
170.2, 173.1 (2s, 2 C=O). CI-MS: 427 (16, [M + H]+), 320 (100, [M – Ph(Me)N]+), 108 (16). 
 
10. Synthesis of 1,3-Oxazol-5(4H)-ones. 10.1. 3-(4,4-Dimethyl-1,3-oxazol-5(4H)-on-2-yl)-2,2-
dimethylpropyl Acetate  (16a). According to GP 6 from 9d (153 mg, 0.5 mmol), 4 min HCl gas, 
CC (CH2Cl2/acetone 40:1). Yield: 123 mg (51%) of 16a. White solid.  M.p. 99.5-101.7o. 
Recovered starting material: 33 mg (21%). IR: 3385m, 2976s, 2937s, 1820vs, 1739vs, 1672vs, 
1525m, 1474s, 1379s, 1240vs, 1072s, 1041s, 966s, 897m. 1H-NMR: 1.05, 1.36 (2s, 2 Me2C); 2.04 
(s, MeCO); 2.42 (s, CH2); 3.92 (s, CH2O), 7.21-7.34 (m, 5 arom. H). 13C-NMR: 20.8 (q, MeCO); 
24.4, 24.6 (2q, 2 Me2C); 34.3 (s, Me2C); 38.0 (t, CH2); 65.3 (s, Me2C); 71.6 (t, CH2O); 161.9 (s, 
C=N); 170.9, 181.4 (2s, 2 C=O). ESI-MS: 541 (100, [2(M + H2O) + Na]+), 371  (25), 282 (70, [M 
+ H2O + Na]+). 
10.2. 2-(3-Benzyloxy-2,2-dimethylpropyl)-4,4-dimethyl-1,3-oxazol-5(4H)-one (16b). According to 
GP 6, from 9g (198 mg, 0.5 mmol), 4 min HCl gas, CC (CH2Cl2/acetone 50:1). Yield:  49 mg 
(34%) of 16b. White powder. M.p. 104.2-106.0o. Recovered starting material: 124 mg (31%). IR: 
2951s, 1894s, 2565w,1822vs, 1723vs, 1612vs, 1534vs, 1458s, 1265s, 1101s, 1058m, 1040m, 
911m. 1H-NMR: 1.01, 1.38 (2s, 2 Me2C); 2.48 (s, CH2); 3.14 (s, CH2O); 4.56 (s, PhCH2); 7.21-
7.34 (m, 5 arom. H). 13C-NMR: 24.5, 24.9 (2q, 2 Me2C); 35.4 (s, Me2C); 38.3 (t, CH2); 65.2 (s, 
Me2C); 73.3 (t, CH2O); 78.6 (t, PhCH2); 127.5, 128.1, 128.3 (3d, 5 arom. CH); 138.5 (s, arom. 
C); 162.5 (s, C=N); 182.1 (s, C=O). CI-MS (i-butane): 290 (18, [M + H]+), 200 (100, [M - Bn]+). 
10.3. [3-(4,4-Dimethyl-1,3-oxazol-5(4H)-on-2-yl)-2,2-dimethylpropyl][(9H-fluoren-9-yl)methyl] 
Carbonate (16c).  According to GP 6 from 9h (169 mg, 0.33 mmol), 4 min HCl gas, CC 
(CH2Cl2/acetone 80:1). Yield: 64 mg (46%) of 16c. White powder. M.p. 93.8-95.2o. Recovered 
starting material: 66 mg (39%). IR: 3320s, 2966s, 1821vs, 1745vs, 1678vs, 1650vs, 1599s, 1532s, 
1441s, 1386m, 1316m, 1156m, 909s. 1H-NMR: 1.01, 1.34 (2s, 2 Me2C); 2.32 (s, CH2); 3.87 (s, 
CH2O); 4.12 (t, J = 6.0, CH2CH); 4.38 (d, J = 6.0, CH2CH); 7.18-7.37, 7.53-7.81 (2m, 8 arom. 
H). 13C-NMR: 24.3, 24.8 (2q, 2 Me2C); 34.5 (s, Me2C); 37.9, 46.7 (2t, 2 CH2); 65.1 (s, Me2C); 
65.9 (t, CH2O); 69.8 (t, CH2CH); 119.9 (d, CH);  125.0, 126.8, 127.1, 127.7 (4d, 8 arom. CH); 
141.2, 143.3 (2s, 2 arom. C); 155.0 (s, NC(O)O); 161.6 (s, C=N); 181.1 (s, C=O). CI-MS: 422 
(16, [M + H]+), 200 (100, [M - Fmoc]+), 179 (44). 
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10.4. 2-[3-(Benzyloxy)methoxy-2,2-dimethylpropyl]-4,4-dimethyl-1,3-oxazol-5(4H)-one  (16d). 
According to GP 6 from 9i (143 mg, 0.33 mmol), 5 min HCl gas, CC (CH2Cl2/acetone 60:1). 
Yield: 42 mg (36%). White solid. M.p. 104.1-105.8o. Recovered starting material: 52 mg (35%). 
1H-NMR: 0.97, 1.36 (2s, 2 Me2C); 2.42, 3.36, 4.59, 4.73 (4s, 4 CH2); 7.14-7.43 (m, 5 arom. H). 
13C-NMR: 24.4, 24.7 (2q, 2 Me2C); 34.9 (s, Me2C); 45.5 (t, CH2); 56.8 (s, Me2C); 69.3, 76.1, 94.8 
(3t, 3 CH2); 127.7, 128.3, 129.5 (3d, 5 arom. CH); 137.6 (s, arom. C); 162.4 (s, C=N); 172.6 (s, 
C=O). CI-MS (i-butane): 320 (100, [M + H]+). 
10.5. 2,2-Dimethyl-3-(4-oxo-3-oxa-1-azaspiro[4.4]non-1-en-2-yl)propyl Acetate (16e). 
According to GP 6 from 9c (156 mg, 0.5 mmol), 5 min HCl gas, CC (CH2Cl2/acetone 30:1). 
Yield:  45 mg (34%) of 16e. White solid. M.p. 101.1-103.1o. Recovered starting material: 33 mg 
(21%). IR: 3385w, 2976s, 2937s, 1820vs, 1739vs, 1672vs, 1474m, 1379s, 1240s, 1072s, 1041s, 
966m. 1H-NMR: 1.01 (s, Me2C); 1.73-2.04 (m, MeCO, 4 CH2); 2.42 (s, CH2); 3.90 (s, CH2O). 
13C-NMR: 20.8 (q, MeCO); 24.5 (q, Me2C); 25.8 (t, 2 CH2); 34.3 (s, Me2C); 38.0, 38.2 (2t, 3 
CH2); 71.6 (t, CH2O); 73.9 (s, spiro-C); 161.8 (s, C=N); 170.9, 182.1 (2s, 2 C=O). ESI-MS: 593 
(100, [2M + H2O + Na]+), 324 (58, [M + H2O + K]+), 308 (64, [M + H2O + Na]+), 286 (90, [M + 
H2O + H]+). 
 
11. 2-[(4,4-Dimethyltetrahydrofuran-2-yliden)amino]-2-methyl-N-[1-methyl-1-(N-methyl-N-
phenylcarbamoyl)ethyl]propanamide (15). To solid 12a (100 mg, 0.42 mmol) a soln. of 10b (110 
mg, 3 mmol, 1.5 equiv.) in CH2Cl2 (5 ml) was added under vigorous stirring. The solvent was 
immediately removed i.v. and the suspension left at r.t. overnight. CC (CH2Cl2/acetone 20:1) 
yielded  102 mg (64%) of 15. White powder. M.p. 142.1-143.3o. IR: 3364vs, 2976s, 2937s, 
1708vs, 1666vs, 1645vs, 1493s, 1380s, 1223m, 1111m, 1014s, 781m, 710s. 1H-NMR: 1.08, 1.42, 
1.50 (3s, 3 Me2C); 2.26 (s, CH2); 3.21 (s, MeN); 3.89 (s, CH2O); 7.06-7.29 (m, 5 arom. H); 8.07 
(br. s, NH). 13C-NMR: 23.8, 24.9, 26.1 (3q, 3 Me2C); 36.5 (s, Me2C); 41.0 (q, MeN); 45.2 (t, 
CH2); 57.3, 60.6 (2q, 2 Me2C); 81.5 (t, CH2O); 127.3, 128.1, 129.4 (3d, 5 arom. CH); 144.8 (s, 
arom. C); 161.5 (s, C=N); 173.6, 176.3 (2s, 2 C=O). ESI-MS: 369 (100, [M + Na]+). 
 
12. Methyl 2-(4-Hydroxy-3,3-dimethyl-2-oxobutylamino)-2-methylpropanoate (19). To a soln. of 
1-bromo-4-hydroxy-3,3-dimethylbutan-2-one (390 mg, 2 mmol) in Et3N (5 ml),  methyl 1-amino-
2-methylpropanoate hydrochloride (456 mg, 3 mmol) was added. The mixture was heated under 
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reflux overnight, cooled, diluted with CH2Cl2 (150 ml) and washed with a 10% CuSO4 soln. and 
brine. Drying (MgSO4), evaporation of the solvent and CC (CH2Cl2/acetone 30:1) yielded 195 
mg (42%) of 19. Yellow oil. IR: 2973m, 2884m, 1725vs, 1660vs, 1528m, 1471s, 1364s, 1192s, 
1046m. 1H-NMR: 1.12, 1.46 (2s, 2 Me2C); 3.50, 3.54 (2s, 2 CH2); 3.71 (s, MeO); 6.74 (br. s, 
NH). 13C-NMR: 21.1, 25.1 (2q, 2 Me2C); 48.4 (s, Me2C); 49.9 (t, CH2); 51.9 (q, MeO); 58.2 (s, 
Me2C); 69.4 (t, CH2O); 176.4, 212.6 (2s, 2 C=O). CI-MS (i-butane): 232 (70, [M + H]+), 146 
(100), 128 (40). 
 
13.  X-ray Crystal-Structure Determination of 11a, 11b, 12g, 12h and 15 (Table and Figs. 2-4)6). 
All measurements were made on a Nonius KappaCCD area-detector diffractometer [36] using 
graphite-monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 
700 cooler. The data collection and refinement parameters are given in the Table and views of the 
molecules are shown in Figs. 2-4. Data reduction was performed with HKL Denzo and Scalepack 
[37]. The intensities were corrected for  Lorenz and polarization effects, and in the cases of 11a, 
12g  and 12h, an absorption correction based on the multi-scan method [38] was applied. Each 
structure was solved by direct methods using SIR92 [39], which revealed the positions of all non-
H atoms. The non-H atoms were refined anisotropically.  
In the case of 11b, there are two independent molecules in the asymmetric unit.  The atomic 
coordinates of the two molecules were tested carefully for a relationship from a higher symmetry 
space group using the program PLATON  [40] but none could be found.  Each molecule is 
disordered over two conformations. Two positions were defined for each atom of the Cl-(CH2)3- 
section of each molecule, except for the Cl-substituted C-atom, which is common to both 
conformations.  Bond length restraints were applied to all bonds involving disordered atoms so as 
to maintain reasonable geometry. The best results were obtained with relative site occupation 
factors of 0.65:0.35 and 0.80:0.20 for the disordered components of molecules A and B, 
respectively. 
                                                  
6)
 CCDC- 286035 - 286040 contain supplementary crystallographic data for this paper. These data 
can be obtained free of charge form the Cambridge Crystallographic Data Centre, via 
http://www.ccdc.cam.ac.uk/data_request/cif 
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The hydroxy and ammonium H-atoms in 12g and 12h, as well as the amide H-atom in 15 and the 
amide and hydroxy H-atoms in 11a and 11b were placed in the positions indicated by  difference 
electron density maps and their positions were allowed to refine together with individual isotropic 
displacement parameters. All remaining H-atoms in all structures were placed in geometrically 
calculated positions and each was assigned a fixed isotropic displacement parameter with a value 
equal to 1.2Ueq of its parent atom (1.5Ueq for the Me groups). The refinement of each structure 
was carried out on F2 using full-matrix least-squares procedures, which minimized the function 
Σw(Fo2 – Fc2)2. Corrections for secondary extinction were applied, except in the cases of 11a and 
11b. Neutral atom scattering factors for non-H atoms were taken form [41] and the scattering 
factors for H-atoms were taken from [42]. Anomalous dispersion effects were included in Fc [43]; 
the values for f' and f'' were those of [44]. The values of the mass attenuation coefficients are 
those of [45]. All calculations were performed using the SHELXL97 program [46]  
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Table 2. Crystallographic Data of Compounds 11a, 11b, 12g, 12h and 15 
 
 
 11a 11b 
   
Crystallized from toluene/CH2Cl2/MeCN/acetone xylene/AcOEt/MeOH 
Empirical formula C10H18ClNO3 C8H14ClNO3 
Formula weight [g mol-1] 235.71 207.66 
Crystal color, habit colorless, prism colorless, plate 
Crystal dimensions [mm] 0.07 × 0.17 × 0.25 0.02 × 0.15 × 0.20 
Temp. [K] 160(1) 160(1) 
Crystal system monoclinic triclinic 
Space group P21/c   P
_
1   
Z 4 4 
Reflections for cell determination 18016 4764 
2θ range for cell determination [°] 4 – 60 4 – 55 
Unit cell parameters  a [Å] 
                                  b [Å] 
                                  c [Å] 
                                  α [°] 
                                  β [°] 
                                  γ  [°] 
                                 V [Å3] 
5.8846(1) 
10.5564(2) 
19.0140(4) 
90 
91.887(1) 
90 
1180.51(4) 
9.5502(2) 
10.3588(2) 
11.3586(3) 
92.417(1) 
90.584(1) 
109.313(1) 
1059.16(4) 
Dx [g cm-3] 1.326 1.302 
µ(MoKα) [mm-1] 0.312 0.338 
Scan type φ and ω φ and ω 
2θ (max) [° 60 55 
Transmission factors (min; max) 0.887; 0.979 - 
Total reflections measured 32539 26265 
Symmetry independent reflections 3448 4824 
Reflections with I > 2σ (I) 2459 3464 
Reflections used in refinement 3448 4822 
Parameters refined; restraints 148; 0 309; 10 
R [on F; I > 2σ(I) reflections] 0.0443 0.0667 
wR [on F2; all indept. reflections] 0.1158 0.2011 
Weighting parameters [a; b]a) 0.0546; 0.3536 0.0996; 0.8346 
Goodness of fit 1.046 1.069 
Secondary extinction coefficient - - 
Final ∆ max /σ 0.001 0.001 
∆ρ (max; min) [e Å-3] 0.26; -0.32 0.92; -0.89 
a) w–1 = σ2(Fo2) + (aP)2 + bP] where P = (Fo2 + 2Fc2)/3 
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12g  12h 15 
   CH2Cl2/acetone/i-PrOH CH2Cl2/i-PrOH/acetone CH2Cl2/Et2O/hexane 
C11H20ClNO3 C12H22ClNO3 C21H31N3O3 
249.74 263.76 373.49 
colorless, prism colorless, prism colorless, tablet 
0.13 × 0.20 × 0.25 0.18 × 0.20 × 0.25 0.12 × 0.15 × 0.30 
160(1) 160(1) 160(1) 
triclinic monoclinic monoclinic 
P
_
1   P21/n   P21/n   
2 4 4 
13668 49886 4258 
4 – 55 4 – 60 4 – 52 
8.1623(3) 
8.8802(2) 
9.0067(3) 
86.145(2) 
88.338(2) 
79.602(2) 
640.56(4) 
7.0504(1) 
15.0693(2) 
13.0955(2) 
90 
90.7171(8) 
90 
1391.22(3) 
10.1674(3) 
19.4044(7) 
11.5235(4) 
90 
112.515(2) 
90 
2100.2(1) 
1.295 1.259 1.181 
0.291 0.272 0.0794 
φ and ω φ and ω ω 
55 60 52 
0.855; 0.968 0.864; 0.957 - 
15813 37833 37791 
2932 4054 4135 
2535 3375 3006 
2931 4052 4134 
159; 0 169; 0 256; 0 
0.0330 0.0370 0.0472 
0.0833 0.0960 0.1132 
0.0355; 0.2522 0.033; 0.7281 0.0406; 0.6032 
1.055 1.055 1.048 
0.019(5) 0.009(2) 0.015(2) 
0.001 0.001 0.001 
0.30; -0.25 0.28; -0.23 0.18; -0.19 
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Chapter 4 
 
Transformation of 5-Hydroxy- into 5-Chloropentanoylamino Derivatives under 
‘Direct Amide Cyclization’ Conditions 1) 
 
 
 
 
The application of the ‘direct amide cyclization’ conditions on the δ-hydroxy acid containing 
linear diamide 11 is described (Scheme 3). Instead of the cyclization to the expected 9-membered 
cyclodepsipeptide, only the chloro acid 12 was obtained. Its formation could be explained by 
consecutive formation of the 1,3-oxazol-5(4H)-one 16 and the 6-membered imino lactone 17 as 
intermediates (Scheme 4). The spontaneous isomerization of the latter gave 12 in a good yield. 
 
                                                  
1)  B. Iliev. S. Verma, A. Linden, H. Heimgartner, Helv. Chim. Acta, submitted. 
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1. Introduction 
 
Cyclic depsipeptides are a class of biologically active secondary metabolites, which contain not 
only amide bonds as part of their ring structure, but also other bonds, usually lactone bonds. Their 
biological activity is diverse, being based mainly on their capability to transport selectively metal 
ions through cell membranes, and they are sought after as potential anticancer, antiviral, 
antibiotic and anti-inflammatory drugs [1]. 
One of the many methods known for their synthesis is the direct amide cyclization [2]: a 
suspension of an amide of type A in toluene is treated with dry HCl gas. Cyclization by 
elimination of the corresponding ammonium chloride leads to the intermediate 1,3-oxazol-5(4H)-
one of type B. In the absence of other nucleophiles, B undergoes a ring enlargement via 
intramolecular nucleophilic attack of the hydroxy group at the carbonyl C-atom of the 
neighboring lactone group, to give the cyclodepsipeptide C  (Scheme 1). 
 
N
H
O
N
O
R
OH
O
N
+
O
H
OH
N
H
OO
OCl
-
R = Me, Ph
-HCl
A B C
-R(Me)NH2Cl-
+
 
Scheme 1 
 
This method has been used successfully for the synthesis of 6-, 9-, 12- and 15-membered [3] and 
larger ring systems [4]. For example, α-hydroxy acid derivatives of type 1 (n = 1) under the 
‘direct amide cyclization’ conditions led to morpholinediones of type 3 [5] (Scheme 2). Recently, 
we have shown that diamides of type A, which contain  β-hydroxy acids, i.e. 1 (n = 2), under 
these reaction conditions did not give the expected 7-membered cyclodepsipeptides, and only 
their dimers, the 14-membered rings 4 were isolated in good yields [6][7] (Scheme 2). Treatment 
of γ-hydroxy acid derivatives (1, n = 3) with HCl gas in toluene yielded no cyclodepsipeptides at 
all. Instead, the only products isolated were the hydrochlorides of imino lactones 5, which are 
unstable in solution and isomerize in polar solvents or on silicagel to give the chlorinated acids 6 
[8] (Scheme 2). 
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In all cases so far, the formation of the intermediate oxazolone 2 was proven chemically or by IR 
spectroscopy. The results show that there is a relationship between the number of C-atoms 
between the OH and CONH groups and the type of product formed. Therefore, it was of interest 
to subject δ-hydroxy acid amides 1 (n = 4) to the conditions of the ‘direct amide cyclization’, 
which could yield either a 9- or 18-membered cyclodepsipeptide on the one hand, or a 6-
membered imino lactone on the other. The result of a first example is shown below. 
 
2. Results and Discussion 
 
Since the previously used standard methods for syntheses of β- and γ-hydroxy acids [8] were not 
applicable to their δ-hydroxy analogues, we used the method of Goto et al. [9]: 3,3-dimethyl-γ-
butyrolactone 7 was treated with NaOH and Ac2O, which led to the O-protected 5-acetoxy-3,3-
dimethylpentanoic acid (8) in moderate yield (Scheme 3). 
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The reaction of the acid 8 with 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine (9) [10] yielded the 
protected diamide 10. After deprotection  with LiOH, 11 was subjected to the ‘direct amide 
cyclization’ (DAC) conditions (HCl gas, toluene, 100o). Trituration of the crude product with 
CH2Cl2, a procedure that has allowed the isolation of the imino lactone hydrochlorides 5 without 
isomerization to the corresponding chlorinated acids [8], yielded in the present case the chloro 
acid 12 directly as the only product in good yield. Recrystallization from MeCN gave crystals 
which were suitable for an X-ray crystal structure determination (Fig. 1). 
 
Fig. 1. ORTEP Plot [11] of the molecular structure of 12 (arbitrary numbering of the atoms; 50% 
probability ellipsoids) 
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Although the compound is achiral, it has crystallized in a polar space group and the absolute 
structure has been determined unambiguously. The OH group forms an intermolecular H-bond 
with the amide O-atom of a neighboring molecule, thereby linking the molecules into extended 
chains, which run parallel to the [0 1 0] direction and can be described by a graph set motif [12] 
of C(7). The amide group forms an intermolecular H-bond with the carboxylate carbonyl O-atom 
of a different neighboring molecule. This interaction links the molecules into extended chains, 
which run parallel to the [1 0 0] direction and can be descdibed by a graph set motif of C(5). The 
combination of both interactions generates a two-dimensional framework that lies parallel to the 
(0 0 1) plane (Fig. 2). 
 
Fig. 2. Molecular packing of 12, showing the H-bonding interactions 
 
In our earlier studies, the ring size has a controlling influence over which of the possible products 
is formed from compounds of type 1 under the DAC conditions. With β-hydroxy acids (n = 2, 
Scheme 2) 14-membered rings 4 (cyclodimers) are preferred over 7-membered ones, while the 
formation of 5-membered imino lactones 5 is preferred over the corresponding 8-membered 
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cyclodepsipeptides in the case of γ-hydroxy acids (n = 3). Therefore, the expected product in the 
case where 1 contains a δ-hydroxy acid was either a 6-membered imino lactone analogous to 5, or 
a 9-membered cyclodepsipeptide. As the 9-membered cyclodepsipeptide 13 has already been 
synthesized via DAC from the linear precursor  14 [3][13] (Scheme 4), the formation of 12 was a 
surprise. 
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Scheme 4 
 
The formation of 12 proceeds most probably through the intermediate 1,3-oxazolone derivative 
16 and the 6-membered imino lactone 17, which apparently is unstable under these conditions 
and, by analogy with 5, isomerizes spontaneously to give the chloro acid 12. 
 
3. Conclusions 
 
The DAC conditions were applied to the linear precursor 11, which contains a δ-hydroxy acid. 
Surprisingly, no cyclic depsipeptide was formed under these conditions. Thus, the dependence of 
the result of the DAC reaction on whether an α-, β-, γ-, or δ-hydroxy acid diamide is used has 
been confirmed. The general use of the ‘direct amide cyclization’ for the synthesis of cyclic 
depsipeptides is apparently limited to linear precursors which contain α-hydroxy acid amides. 
The use of β-hydroxy acid precursors is also possible for the formation of larger rings [4], but can 
lead to cyclodimers or side products as well. 
 
Synthesis of Cyclic Depsipeptides under Direct Amide Cyclization Conditions 
150 
Experimental Part 
 
1. General. See [8]. 
 
2. Starting materials. 2,2,N-Trimethyl-N-phenyl-2H-azirin-3-amine (9) was prepared according 
to standard procedures (cf. [8] and refs. cited therein). Butyrolactone 7 was prepared by a known 
method [14]. 
 
3. 5-Acetoxy-3,3-dimethylpentanoic acid (8). To a soln. of 7 (20 mmol, 2560 mg) in MeOH (10 
ml) was added 2N NaOH (11 ml) at 0o. The mixture was stirred at r.t. for 2 h, the solvent 
evaporated i.v. and the remaining H2O was distilled azeotropically with benzene (3 x 10 ml). The 
white residue was dried overnight under h.v.  and then Ac2O (10 ml) was added. After 14 h at 80o, 
the mixture was cooled, the solvent evaporated and the oily residue extracted with AcOEt (5 x 30 
ml). Drying (MgSO4) and CC on SiO2 with CH2Cl2/MeOH 20:1 yielded 1201 mg (32%) of 9. 
Recovered starting material: 980 mg (37%).  IR: 3288s (br), 2971s, 1738vs, 1711vs, 1471w, 
1378s, 1356m, 1244s, 1094s, 1040s, 925w. 1H-NMR: 0.97 (s, Me2C); 1.59-1.71 (m, CH2); 1.99 
(s, MeCO); 2.21 (s, CH2); 4.01 (br. s, CH2O); 10.41 (br. s, COOH). 13C-NMR: 20.7 (q, MeCO); 
27.2 (q, Me2C);  32.0 (s, Me2C), 37.6, 43.9 (2t, 2 CH2); 66.6 (t, CH2O); 171.1 (s, C=O); 177.3 (s, 
COOH). ESI-MS: 211 (100, [M + Na]+). 
 
4. 4-[1-Methyl-1-(N-methyl-N-phenylcarbamoyl)ethylcarbamoyl)-3,3-dimethylbutyl Acetate (10). 
To a soln. of  8 (376 mg,  2 mmol) in dry THF (20 ml), 9 (365 mg, 2.1 mmol) was added. The 
mixture was stirred at r.t. overnight and the solvent evaporated i.v.  CC with CH2Cl2/MeOH 40:1 
yielded 622 mg (86%) of 10. White powder. M.p. 98.1-99.4o. 1H-NMR: 0.97, 1.41 (2s, 2 Me2C); 
1.62 (t, J = 7.1, CH2 ); 1.99 (s, MeCO); 2.08 (s, CH2); 3.19 (s, MeN); 3.1 (t, J = 7.1, CH2O); 6.55 
(s, NH); 7.20-7.39 (m, 5 arom. H). 13C-NMR: 20.8 (q, MeCO); 26.3, 27.0 (2q, 2 Me2C); 33.0 (s, 
Me2C); 41.3 (t, CH2); 42.3 (q, MeN); 48.2 (t, CH2); 58.1 (s, Me2C); 68.7 (t, CH2O); 127.8, 128.0, 
129.3 (3d, 5 arom. CH); 144.6 (s, arom. C); 169.8, 171.6, 173.2 (3s, 3 C=O). ESI-MS: 385 (100, 
[M + Na]+]). 
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5. 5-Hydroxy-3,3-dimethyl-N-[1-methyl-1-(N-methyl-N-phenylcarbamoyl)ethyl]-pentanamide 
(11). A soln. of 9 (362 mg, 1 mmol) in THF/H2O 2:1 (20 ml) was treated with 4 equiv. of LiOH 
at r.t. for 4 h. Evaporation of the solvent i.v., extraction of the residue with CH2Cl2, drying 
(MgSO4), evaporation i.v. and washing with Et2O yielded the hydroxydiamide 11, which was 
used without further purification. Yield:  298 mg (93%) of 11. White solid. M.p. 128.4-126.0o. 
1H-NMR: 0.99, 1.46 (2s, 2 Me2C); 1.60 (t, J = 7.1, CH2); 2.00 (s, CH2); 3.17 (s, MeN); 3.18 (t, J 
= 7.1, CH2O); 6.51 (s, NH); 7.18-7.36 (m, 5 arom. H). 13C-NMR: 26.4, 28.8 (2q, 2 Me2C); 32.8 
(s, Me2C); 41.4 (t, CH2); 42.4 (q, MeN); 48.2 (t, CH2); 58.2 (s, Me2C); 69.7 (t, CH2O); 127.8, 
128.0, 129.3 (3d, 5 arom. CH); 144.5 (s, arom. C); 171.7, 173.3 (2s, 2 C=O). ESI-MS: 343 (100, 
[M + Na]+). 
 
6. 2-(5-Chloro-3,3-dimethylpentanoylamino)-2-methylpropanoic Acid (12). A suspension of 11 
(80 mg, 0.25 mmol) in dry toluene (30 ml) was heated to 100o and HCl gas was bubbled through 
the suspension for 4-6 min. Then, the mixture was allowed to cool to r.t. while bubbling N2 
through it (ca. 20 min). The solvent was evaporated, the white residue was washed with CH2Cl2 
(3 x 15 ml) and dried in h.v. Yield: 36 mg (59%) of 12. M.p. 118.9-121.0o. IR: 3320vs, 2980s, 
1722vs, 1620s, 1561s, 1466s, 1428s, 1389m, 1246m, 1232m, 1166s, 1092m, 1051w, 945w. 1H-
NMR ((D6)DMSO): 0.97, 1.33 (2s, 2 Me2C); 1.68-1.79 (m, CH2); 1.97 (s, CH2); 3.60-3.69 (m, 
CH2Cl); 7.82 (br. s, NH); 11.81 (br. s, COOH). 13C-NMR ((D6)DMSO): 24.8, 27.2 (q, Me2C); 
33.4, 42.5 (t, CH2); 54.6 (t, CH2Cl); 55.7 (s, Me2C); 169.9, 175.4 (2s, 2 C=O). ESI-MS: 274 (25, 
[M(37Cl) + Na]+), 272 (100, [M(35Cl) + Na]+), 214 (10, [M - Cl]+). 
 
7. X-Ray Crystal-Structure Determination of 12 (Table and Figs. 1,2).1) All measurements were 
made on a Nonius KappaCCD area-detector diffractometer [15] using graphite-monochromated 
MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 cooler. The data 
collection and refinement parameters are given in the Table and views of the molecules are 
shown in Figs. 1 and 2. Data reduction was performed with HKL Denzo and Scalepack [16]. The 
                                                  
1) CCDC- 286116 contains supplementary crystallographic data for this paper. These data can be 
obtained free of charge form the Cambridge Crystallographic Data Centre, via 
http://www.ccdc.cam.ac.uk/data_request/cif 
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intensities were corrected for Lorentz and polarization effects, and an absorption correction based 
on the multi-scan method [17] was applied.  Equivalent reflections, other than Friedel pairs, were 
merged. The structure was solved by direct methods using SIR92 [18], which revealed the 
positions of all non-H-atoms.  The non-H-atoms were refined anisotropically.  The hydroxy and 
amide H-atoms were placed in the positions indicated by a difference electron density map and 
their positions were allowed to refine together with individual isotropic displacement parameters.  
All remaining H-atoms were placed in geometrically calculated positions and refined using a 
riding model where each H-atom was assigned a fixed isotropic displacement parameter with a 
value equal to 1.2Ueq of its parent C-atom (1.5Ueq for the methyl groups).  Refinement of the 
structure was carried out on F2 using full-matrix least-squares procedures, which minimised the 
function Σw(Fo2 – Fc2)2.  A correction for secondary extinction was applied. Refinement of the 
absolute structure parameter [19][20] yielded a value of 0.01(6), which confirms that the refined 
model represents the true absolute structure. Neutral atom scattering factors for non-H atoms 
were taken form [21] and the scattering factors for H-atoms were taken from [22]. Anomalous 
dispersion effects were included in Fc [23]; the values for f' and f'' were those of [24]. The values 
of the mass attenuation coefficients are those of [25]. All calculations were performed using for 
the SHELXL97 program [26]. 
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Table.  Crystallographic Data of 12 
 12 
  
Crystallized from CH3CN 
Empirical formula C11H20ClNO3 
Formula weight [g mol-1] 249.74 
Crystal color, habit colorless, plate 
Crystal dimensions [mm] 0.02 × 0.20 × 0.25 
Temp. [K] 160(1) 
Crystal system monoclinic 
Space group P21   
Z 2 
Reflections for cell determination 45269 
2θ range for cell determination [°] 4 – 55 
Unit cell parameters  a [Å] 
                                  b [Å] 
                                  c [Å] 
                                  β [°] 
                                 V [Å3] 
6.1314(3) 
10.4871(5) 
10.4750(5) 
104.760(2) 
651.32(5) 
Dx [g cm-3] 1.273 
µ(MoKα) [mm-1]  0.286 
Scan type  φ and ω 
2θ (max) [°]  55 
Transmission factors (min; max) 0.864; 0.996 
Total reflections measured 13304 
Symmetry independent reflections  2950 
Reflections with I > 2σ (I) 2548 
Reflections used in refinement 2950 
Parameters refined; restraints 159; 1 
R [on F; I > 2σ(I) reflections] 0.0372 
wR [on F2; all indept. reflections] 0.0814 
Weighting parameters [a; b]a) 0.0314; 0.1588 
Goodness of fit 1.044 
Secondary extinction coefficient 0.035(5) 
Final ∆ max /σ 0.001 
∆ρ (max; min) [e Å-3]  0.19; -0.16 
 
a) w–1 = σ2(Fo2) + (aP)2 + bP] where P = (Fo2 + 2Fc2)/3 
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